The domains in CBP that are involved in CREB binding and transcriptional activation are highly related to the adenoviral entity1_term-associated cellular protein p300 (refs 2, 3), and to two hypothetical proteins from Caenorhabditis elegans, entity2_term and K03H1.10 (refs 4 and 5, respectively), whose functions are unknown.
E1A
R10E11.1
0
The domains in CBP that are involved in CREB binding and transcriptional activation are highly related to the adenoviral E1A-associated cellular protein entity1_term (refs 2, 3), and to two hypothetical proteins from Caenorhabditis elegans, entity2_term and K03H1.10 (refs 4 and 5, respectively), whose functions are unknown.
p300
R10E11.1
0
The domains in CBP that are involved in CREB binding and transcriptional activation are highly related to the adenoviral E1A-associated cellular protein p300 (refs 2, 3), and to two hypothetical proteins from Caenorhabditis elegans, entity1_term and entity2_term (refs 4 and 5, respectively), whose functions are unknown.
R10E11.1
K03H1.10
0
The domains in CBP that are involved in entity1_term binding and transcriptional activation are highly related to the adenoviral entity2_term-associated cellular protein p300 (refs 2, 3), and to two hypothetical proteins from Caenorhabditis elegans, R10E11.1 and K03H1.10 (refs 4 and 5, respectively), whose functions are unknown.
CREB
E1A
0
The domains in CBP that are involved in entity1_term binding and transcriptional activation are highly related to the adenoviral E1A-associated cellular protein entity2_term (refs 2, 3), and to two hypothetical proteins from Caenorhabditis elegans, R10E11.1 and K03H1.10 (refs 4 and 5, respectively), whose functions are unknown.
CREB
p300
0
The domains in CBP that are involved in entity1_term binding and transcriptional activation are highly related to the adenoviral E1A-associated cellular protein p300 (refs 2, 3), and to two hypothetical proteins from Caenorhabditis elegans, R10E11.1 and entity2_term (refs 4 and 5, respectively), whose functions are unknown.
CREB
K03H1.10
0
The domains in CBP that are involved in CREB binding and transcriptional activation are highly related to the adenoviral entity1_term-associated cellular protein p300 (refs 2, 3), and to two hypothetical proteins from Caenorhabditis elegans, R10E11.1 and entity2_term (refs 4 and 5, respectively), whose functions are unknown.
E1A
K03H1.10
0
The domains in CBP that are involved in CREB binding and transcriptional activation are highly related to the adenoviral E1A-associated cellular protein entity1_term (refs 2, 3), and to two hypothetical proteins from Caenorhabditis elegans, R10E11.1 and entity2_term (refs 4 and 5, respectively), whose functions are unknown.
p300
K03H1.10
0
Inhibition of actin polymerization by a synthetic dodecapeptide patterned on the sequence around the entity1_term-binding site of entity2_term.
actin
cofilin
1
Inhibition of entity1_term polymerization by a synthetic dodecapeptide patterned on the sequence around the actin-binding site of entity2_term.
actin
cofilin
0
Inhibition of entity1_term polymerization by a synthetic dodecapeptide patterned on the sequence around the entity2_term-binding site of cofilin.
actin
actin
0
To approach the problem, we have constructed a carp genomic library and isolated 28 nonoverlapping clones containing sequences of different entity1_term (MHC) isoforms along with a clone containing carp entity2_term sequences.
myosin heavy chain
actin
0
To approach the problem, we have constructed a carp genomic library and isolated 28 nonoverlapping clones containing sequences of different myosin heavy chain (entity1_term) isoforms along with a clone containing carp entity2_term sequences.
MHC
actin
0
To approach the problem, we have constructed a carp genomic library and isolated 28 nonoverlapping clones containing sequences of different entity1_term (entity2_term) isoforms along with a clone containing carp actin sequences.
myosin heavy chain
MHC
0
Using the known three-dimensional structure of the homologous entity1_term-binding domain of entity2_term, these results have enabled us to determine the likely orientation of the utrophin actin-binding domain with respect to the actin filament.
actin
fimbrin
1
Using the known three-dimensional structure of the homologous actin-binding domain of fimbrin, these results have enabled us to determine the likely orientation of the entity1_term actin-binding domain with respect to the entity2_term filament.
utrophin
actin
1
Using the known three-dimensional structure of the homologous actin-binding domain of fimbrin, these results have enabled us to determine the likely orientation of the entity1_term entity2_term-binding domain with respect to the actin filament.
utrophin
actin
1
Using the known three-dimensional structure of the homologous actin-binding domain of entity1_term, these results have enabled us to determine the likely orientation of the entity2_term actin-binding domain with respect to the actin filament.
fimbrin
utrophin
1
Using the known three-dimensional structure of the homologous entity1_term-binding domain of fimbrin, these results have enabled us to determine the likely orientation of the utrophin entity2_term-binding domain with respect to the actin filament.
actin
actin
0
Using the known three-dimensional structure of the homologous actin-binding domain of fimbrin, these results have enabled us to determine the likely orientation of the utrophin entity1_term-binding domain with respect to the entity2_term filament.
actin
actin
0
Using the known three-dimensional structure of the homologous actin-binding domain of entity1_term, these results have enabled us to determine the likely orientation of the utrophin entity2_term-binding domain with respect to the actin filament.
fimbrin
actin
0
Using the known three-dimensional structure of the homologous entity1_term-binding domain of fimbrin, these results have enabled us to determine the likely orientation of the entity2_term actin-binding domain with respect to the actin filament.
actin
utrophin
0
Using the known three-dimensional structure of the homologous entity1_term-binding domain of fimbrin, these results have enabled us to determine the likely orientation of the utrophin actin-binding domain with respect to the entity2_term filament.
actin
actin
0
Using the known three-dimensional structure of the homologous actin-binding domain of entity1_term, these results have enabled us to determine the likely orientation of the utrophin actin-binding domain with respect to the entity2_term filament.
fimbrin
actin
0
Disruption of the entity1_term gene, which is homologous to entity2_term/RVS161 and which is also required for correct actin localization, also blocks endocytosis.
RVS167
END6
1
Disruption of the entity1_term gene, which is homologous to END6/entity2_term and which is also required for correct actin localization, also blocks endocytosis.
RVS167
RVS161
1
Disruption of the entity1_term gene, which is homologous to END6/RVS161 and which is also required for correct entity2_term localization, also blocks endocytosis.
RVS167
actin
1
Disruption of the RVS167 gene, which is homologous to END6/entity1_term and which is also required for correct entity2_term localization, also blocks endocytosis.
RVS161
actin
0
Disruption of the RVS167 gene, which is homologous to entity1_term/RVS161 and which is also required for correct entity2_term localization, also blocks endocytosis.
END6
actin
0
Disruption of the RVS167 gene, which is homologous to entity1_term/entity2_term and which is also required for correct actin localization, also blocks endocytosis.
END6
RVS161
0
The very much lower affinity of entity1_term for modified entity2_term explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled actin in the presence of profilin and the apparently weak inhibition by profilin of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled actin.
profilin
actin
1
Reinvestigation of the inhibition of entity1_term polymerization by entity2_term.
actin
profilin
1
The very much lower affinity of profilin for modified entity1_term explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled entity2_term in the presence of profilin and the apparently weak inhibition by profilin of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled actin.
actin
actin
0
The very much lower affinity of profilin for modified actin explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled entity1_term in the presence of entity2_term and the apparently weak inhibition by profilin of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled actin.
actin
profilin
0
The very much lower affinity of profilin for modified actin explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled entity1_term in the presence of profilin and the apparently weak inhibition by profilin of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled entity2_term.
actin
actin
0
The very much lower affinity of entity1_term for modified actin explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled entity2_term in the presence of profilin and the apparently weak inhibition by profilin of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled actin.
profilin
actin
0
The very much lower affinity of profilin for modified actin explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled entity1_term in the presence of profilin and the apparently weak inhibition by entity2_term of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled actin.
actin
profilin
0
The very much lower affinity of profilin for modified entity1_term explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled actin in the presence of entity2_term and the apparently weak inhibition by profilin of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled actin.
actin
profilin
0
The very much lower affinity of profilin for modified entity1_term explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled actin in the presence of profilin and the apparently weak inhibition by profilin of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled entity2_term.
actin
actin
0
The very much lower affinity of profilin for modified entity1_term explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled actin in the presence of profilin and the apparently weak inhibition by entity2_term of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled actin.
actin
profilin
0
The very much lower affinity of profilin for modified actin explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled actin in the presence of entity1_term and the apparently weak inhibition by profilin of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled entity2_term.
profilin
actin
0
The very much lower affinity of entity1_term for modified actin explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled actin in the presence of entity2_term and the apparently weak inhibition by profilin of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled actin.
profilin
profilin
0
The very much lower affinity of profilin for modified actin explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled actin in the presence of entity1_term and the apparently weak inhibition by entity2_term of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled actin.
profilin
profilin
0
The very much lower affinity of entity1_term for modified actin explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled actin in the presence of profilin and the apparently weak inhibition by profilin of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled entity2_term.
profilin
actin
0
The very much lower affinity of profilin for modified actin explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled actin in the presence of profilin and the apparently weak inhibition by entity1_term of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled entity2_term.
profilin
actin
0
The very much lower affinity of entity1_term for modified actin explains the anomalous critical concentrations curves obtained for 5-10% pyrenyl-labeled actin in the presence of profilin and the apparently weak inhibition by entity2_term of the rate of filament elongation when polymerization is quantified by the increase in fluorescence of pyrenyl-labeled actin.
profilin
profilin
0
Herpes simplex virus type 1 (HSV-1) encodes a entity1_term that consists of three polypeptides encoded by the entity2_term, UL8, and UL52 genes (Crute, J.J., Tsurumi, T., Zhu, L., Weller, S.K., Olivo, P.D., Challberg, M.D., Mocarski, E.S., and Lehman, I.R.
helicase-primase
UL5
1
Herpes simplex virus type 1 (HSV-1) encodes a entity1_term that consists of three polypeptides encoded by the UL5, UL8, and entity2_term genes (Crute, J.J., Tsurumi, T., Zhu, L., Weller, S.K., Olivo, P.D., Challberg, M.D., Mocarski, E.S., and Lehman, I.R.
helicase-primase
UL52
1
Herpes simplex virus type 1 (HSV-1) encodes a entity1_term that consists of three polypeptides encoded by the UL5, entity2_term, and UL52 genes (Crute, J.J., Tsurumi, T., Zhu, L., Weller, S.K., Olivo, P.D., Challberg, M.D., Mocarski, E.S., and Lehman, I.R.
helicase-primase
UL8
1
Herpes simplex virus type 1 (HSV-1) encodes a helicase-primase that consists of three polypeptides encoded by the entity1_term, UL8, and entity2_term genes (Crute, J.J., Tsurumi, T., Zhu, L., Weller, S.K., Olivo, P.D., Challberg, M.D., Mocarski, E.S., and Lehman, I.R.
UL5
UL52
0
Herpes simplex virus type 1 (HSV-1) encodes a helicase-primase that consists of three polypeptides encoded by the UL5, entity1_term, and entity2_term genes (Crute, J.J., Tsurumi, T., Zhu, L., Weller, S.K., Olivo, P.D., Challberg, M.D., Mocarski, E.S., and Lehman, I.R.
UL8
UL52
0
Herpes simplex virus type 1 (HSV-1) encodes a helicase-primase that consists of three polypeptides encoded by the entity1_term, entity2_term, and UL52 genes (Crute, J.J., Tsurumi, T., Zhu, L., Weller, S.K., Olivo, P.D., Challberg, M.D., Mocarski, E.S., and Lehman, I.R.
UL5
UL8
0
The C-terminal of TRADD comprises the "death domain" that is responsible for association of entity1_term and other death domain-containing proteins such as FADD and entity2_term.
TNFR1
RIP
1
The C-terminal of TRADD comprises the "death domain" that is responsible for association of entity1_term and other death domain-containing proteins such as entity2_term and RIP.
TNFR1
FADD
1
The C-terminal of entity1_term comprises the "death domain" that is responsible for association of TNFR1 and other death domain-containing proteins such as FADD and entity2_term.
TRADD
RIP
0
The C-terminal of TRADD comprises the "death domain" that is responsible for association of TNFR1 and other death domain-containing proteins such as entity1_term and entity2_term.
FADD
RIP
0
The C-terminal of entity1_term comprises the "death domain" that is responsible for association of entity2_term and other death domain-containing proteins such as FADD and RIP.
TRADD
TNFR1
0
The C-terminal of entity1_term comprises the "death domain" that is responsible for association of TNFR1 and other death domain-containing proteins such as entity2_term and RIP.
TRADD
FADD
0
In infected cells, C protein was detected exclusively in the cytoplasm as granular fluorescence, which coincided very well with the distribution of nucleocapsid protein NP and entity1_term entity2_term, which were also detected with specific antisera.
phosphoprotein
P
1
In infected cells, entity1_term was detected exclusively in the cytoplasm as granular fluorescence, which coincided very well with the distribution of nucleocapsid protein entity2_term and phosphoprotein P, which were also detected with specific antisera.
C protein
NP
1
In infected cells, entity1_term was detected exclusively in the cytoplasm as granular fluorescence, which coincided very well with the distribution of nucleocapsid protein NP and phosphoprotein entity2_term, which were also detected with specific antisera.
C protein
P
1
In infected cells, C protein was detected exclusively in the cytoplasm as granular fluorescence, which coincided very well with the distribution of entity1_term entity2_term and phosphoprotein P, which were also detected with specific antisera.
nucleocapsid protein
NP
1
In infected cells, C protein was detected exclusively in the cytoplasm as granular fluorescence, which coincided very well with the distribution of entity1_term NP and entity2_term P, which were also detected with specific antisera.
nucleocapsid protein
phosphoprotein
0
In infected cells, C protein was detected exclusively in the cytoplasm as granular fluorescence, which coincided very well with the distribution of nucleocapsid protein entity1_term and entity2_term P, which were also detected with specific antisera.
NP
phosphoprotein
0
In infected cells, entity1_term was detected exclusively in the cytoplasm as granular fluorescence, which coincided very well with the distribution of nucleocapsid protein NP and entity2_term P, which were also detected with specific antisera.
C protein
phosphoprotein
0
In infected cells, C protein was detected exclusively in the cytoplasm as granular fluorescence, which coincided very well with the distribution of entity1_term NP and phosphoprotein entity2_term, which were also detected with specific antisera.
nucleocapsid protein
P
0
In infected cells, C protein was detected exclusively in the cytoplasm as granular fluorescence, which coincided very well with the distribution of nucleocapsid protein entity1_term and phosphoprotein entity2_term, which were also detected with specific antisera.
NP
P
0
In infected cells, entity1_term was detected exclusively in the cytoplasm as granular fluorescence, which coincided very well with the distribution of entity2_term NP and phosphoprotein P, which were also detected with specific antisera.
C protein
nucleocapsid protein
0
The structure of Ykt6pN differed entirely from that of syntaxin and resembled the overall fold of the entity1_term regulatory protein, entity2_term.
actin
profilin
1
The structure of entity1_term differed entirely from that of syntaxin and resembled the overall fold of the actin regulatory protein, entity2_term.
Ykt6pN
profilin
1
The structure of entity1_term differed entirely from that of entity2_term and resembled the overall fold of the actin regulatory protein, profilin.
Ykt6pN
syntaxin
1
The structure of Ykt6pN differed entirely from that of entity1_term and resembled the overall fold of the actin regulatory protein, entity2_term.
syntaxin
profilin
0
The structure of Ykt6pN differed entirely from that of entity1_term and resembled the overall fold of the entity2_term regulatory protein, profilin.
syntaxin
actin
0
The structure of entity1_term differed entirely from that of syntaxin and resembled the overall fold of the entity2_term regulatory protein, profilin.
Ykt6pN
actin
0
Native entity1_term, purified from extracts of lung epithelial cells by affinity binding to a poly-L-proline matrix, stimulated the entity2_term-saturated RSV transcription by 2.5- to 3-fold.
profilin
actin
1
It is estimated that at optimal levels of transcription, every molecule of viral genomic RNA associates with approximately the following number of protein molecules: 30 molecules of L, 120 molecules of entity1_term entity2_term, and 60 molecules each of actin and profilin.
phosphoprotein
P
1
It is estimated that at optimal levels of transcription, every molecule of viral genomic RNA associates with approximately the following number of protein molecules: 30 molecules of L, 120 molecules of phosphoprotein entity1_term, and 60 molecules each of actin and entity2_term.
P
profilin
0
It is estimated that at optimal levels of transcription, every molecule of viral genomic RNA associates with approximately the following number of protein molecules: 30 molecules of entity1_term, 120 molecules of phosphoprotein entity2_term, and 60 molecules each of actin and profilin.
L
P
0
It is estimated that at optimal levels of transcription, every molecule of viral genomic RNA associates with approximately the following number of protein molecules: 30 molecules of L, 120 molecules of phosphoprotein entity1_term, and 60 molecules each of entity2_term and profilin.
P
actin
0
It is estimated that at optimal levels of transcription, every molecule of viral genomic RNA associates with approximately the following number of protein molecules: 30 molecules of entity1_term, 120 molecules of phosphoprotein P, and 60 molecules each of actin and entity2_term.
L
profilin
0
It is estimated that at optimal levels of transcription, every molecule of viral genomic RNA associates with approximately the following number of protein molecules: 30 molecules of L, 120 molecules of entity1_term P, and 60 molecules each of actin and entity2_term.
phosphoprotein
profilin
0
It is estimated that at optimal levels of transcription, every molecule of viral genomic RNA associates with approximately the following number of protein molecules: 30 molecules of L, 120 molecules of phosphoprotein P, and 60 molecules each of entity1_term and entity2_term.
actin
profilin
0
It is estimated that at optimal levels of transcription, every molecule of viral genomic RNA associates with approximately the following number of protein molecules: 30 molecules of entity1_term, 120 molecules of entity2_term P, and 60 molecules each of actin and profilin.
L
phosphoprotein
0
It is estimated that at optimal levels of transcription, every molecule of viral genomic RNA associates with approximately the following number of protein molecules: 30 molecules of entity1_term, 120 molecules of phosphoprotein P, and 60 molecules each of entity2_term and profilin.
L
actin
0
It is estimated that at optimal levels of transcription, every molecule of viral genomic RNA associates with approximately the following number of protein molecules: 30 molecules of L, 120 molecules of entity1_term P, and 60 molecules each of entity2_term and profilin.
phosphoprotein
actin
0
Other entity1_term-associated proteins, including vinculin, talin, and entity2_term, are not present.
actin
ezrin
1
Other entity1_term-associated proteins, including vinculin, entity2_term, and ezrin, are not present.
actin
talin
1
Molecules known to link entity1_term filaments to membrane were also examined, including entity2_term, beta-catenin, plakoglobin, and zyxin, but none was identified at the host-parasite junction.
actin
alpha-catenin
1
Other entity1_term-associated proteins, including entity2_term, talin, and ezrin, are not present.
actin
vinculin
1
Molecules known to link entity1_term filaments to membrane were also examined, including alpha-catenin, beta-catenin, entity2_term, and zyxin, but none was identified at the host-parasite junction.
actin
plakoglobin
1
Molecules known to link entity1_term filaments to membrane were also examined, including alpha-catenin, beta-catenin, plakoglobin, and entity2_term, but none was identified at the host-parasite junction.
actin
zyxin
1
Molecules known to link entity1_term filaments to membrane were also examined, including alpha-catenin, entity2_term, plakoglobin, and zyxin, but none was identified at the host-parasite junction.
actin
beta-catenin
1
Other actin-associated proteins, including entity1_term, talin, and entity2_term, are not present.
vinculin
ezrin
0
Other actin-associated proteins, including entity1_term, entity2_term, and ezrin, are not present.
vinculin
talin
0
Molecules known to link actin filaments to membrane were also examined, including entity1_term, entity2_term, plakoglobin, and zyxin, but none was identified at the host-parasite junction.
alpha-catenin
beta-catenin
0
Molecules known to link actin filaments to membrane were also examined, including entity1_term, beta-catenin, plakoglobin, and entity2_term, but none was identified at the host-parasite junction.
alpha-catenin
zyxin
0
Molecules known to link actin filaments to membrane were also examined, including entity1_term, beta-catenin, entity2_term, and zyxin, but none was identified at the host-parasite junction.
alpha-catenin
plakoglobin
0
Other actin-associated proteins, including vinculin, entity1_term, and entity2_term, are not present.
talin
ezrin
0
Molecules known to link actin filaments to membrane were also examined, including alpha-catenin, entity1_term, plakoglobin, and entity2_term, but none was identified at the host-parasite junction.
beta-catenin
zyxin
0
Molecules known to link actin filaments to membrane were also examined, including alpha-catenin, entity1_term, entity2_term, and zyxin, but none was identified at the host-parasite junction.
beta-catenin
plakoglobin
0
Molecules known to link actin filaments to membrane were also examined, including alpha-catenin, beta-catenin, entity1_term, and entity2_term, but none was identified at the host-parasite junction.
plakoglobin
zyxin
0
Yeast entity1_term can sequester yeast actin monomers and thereby reduce the ability of yeast entity2_term to polymerize, whereas it has little effect on the degree of polymerization of rabbit skeletal muscle actin.
profilin
actin
1
Yeast entity1_term can sequester yeast actin monomers and thereby reduce the ability of yeast actin to polymerize, whereas it has little effect on the degree of polymerization of rabbit entity2_term.
profilin
skeletal muscle actin
1
We have characterized this actin with respect to its ability to interact with yeast profilin and entity1_term, the only yeast entity2_term so far purified and characterized.
tropomyosin
actin-binding proteins
1
Yeast entity1_term can sequester yeast entity2_term monomers and thereby reduce the ability of yeast actin to polymerize, whereas it has little effect on the degree of polymerization of rabbit skeletal muscle actin.
profilin
actin
1
We have characterized this entity1_term with respect to its ability to interact with yeast profilin and entity2_term, the only yeast actin-binding proteins so far purified and characterized.
actin
tropomyosin
1
We have characterized this actin with respect to its ability to interact with yeast entity1_term and tropomyosin, the only yeast entity2_term so far purified and characterized.
profilin
actin-binding proteins
1
We have characterized this entity1_term with respect to its ability to interact with yeast entity2_term and tropomyosin, the only yeast actin-binding proteins so far purified and characterized.
actin
profilin
1
Yeast profilin can sequester yeast entity1_term monomers and thereby reduce the ability of yeast entity2_term to polymerize, whereas it has little effect on the degree of polymerization of rabbit skeletal muscle actin.
actin
actin
0
Yeast profilin can sequester yeast entity1_term monomers and thereby reduce the ability of yeast actin to polymerize, whereas it has little effect on the degree of polymerization of rabbit entity2_term.
actin
skeletal muscle actin
0
Yeast profilin can sequester yeast actin monomers and thereby reduce the ability of yeast entity1_term to polymerize, whereas it has little effect on the degree of polymerization of rabbit entity2_term.
actin
skeletal muscle actin
0
We have characterized this actin with respect to its ability to interact with yeast entity1_term and entity2_term, the only yeast actin-binding proteins so far purified and characterized.
profilin
tropomyosin
0
We have characterized this entity1_term with respect to its ability to interact with yeast profilin and tropomyosin, the only yeast entity2_term so far purified and characterized.
actin
actin-binding proteins
0
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating entity1_term-8 and -10 in death signaling by the two death-inducing entity2_term 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
caspases
TRAIL receptors
1
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating entity1_term-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (entity2_term and TRAIL-R2) are controversial.
caspases
TRAIL-R1
1
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating entity1_term and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (entity2_term and TRAIL-R2) are controversial.
caspases-8
TRAIL-R1
1
The involvement of the death adaptor proteins FADD/entity1_term, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity2_term and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
MORT1
TRAIL receptors 1
1
The involvement of the death adaptor proteins FADD/entity1_term, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and entity2_term) are controversial.
MORT1
TRAIL-R2
1
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and entity1_term and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (entity2_term and TRAIL-R2) are controversial.
RIP
TRAIL-R1
1
The involvement of the death adaptor proteins FADD/entity1_term, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (entity2_term and TRAIL-R2) are controversial.
MORT1
TRAIL-R1
1
The involvement of the death adaptor proteins FADD/entity1_term, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity2_term 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
MORT1
TRAIL receptors
1
The involvement of the death adaptor proteins FADD/MORT1, entity1_term, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity2_term and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
TRADD
TRAIL receptors 1
1
The involvement of the death adaptor proteins FADD/MORT1, entity1_term, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and entity2_term) are controversial.
TRADD
TRAIL-R2
1
The involvement of the death adaptor proteins FADD/MORT1, entity1_term, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity2_term 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
TRADD
TRAIL receptors
1
The involvement of the death adaptor proteins entity1_term/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and entity2_term) are controversial.
FADD
TRAIL-R2
1
The involvement of the death adaptor proteins FADD/MORT1, entity1_term, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (entity2_term and TRAIL-R2) are controversial.
TRADD
TRAIL-R1
1
The involvement of the death adaptor proteins entity1_term/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity2_term 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
FADD
TRAIL receptors
1
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating entity1_term and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and entity2_term) are controversial.
caspases-8
TRAIL-R2
1
The involvement of the death adaptor proteins entity1_term/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity2_term and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
FADD
TRAIL receptors 1
1
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating entity1_term and -10 in death signaling by the two death-inducing entity2_term and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
caspases-8
TRAIL receptors 1
1
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and entity1_term and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and entity2_term) are controversial.
RIP
TRAIL-R2
1
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating entity1_term and -10 in death signaling by the two death-inducing entity2_term 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
caspases-8
TRAIL receptors
1
The involvement of the death adaptor proteins entity1_term/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (entity2_term and TRAIL-R2) are controversial.
FADD
TRAIL-R1
1
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating entity1_term-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and entity2_term) are controversial.
caspases
TRAIL-R2
1
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and entity1_term and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity2_term 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
RIP
TRAIL receptors
1
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating entity1_term-8 and -10 in death signaling by the two death-inducing entity2_term and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
caspases
TRAIL receptors 1
1
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and entity1_term and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity2_term and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
RIP
TRAIL receptors 1
1
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating entity1_termentity2_term and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
caspases
caspases-8
0
The involvement of the death adaptor proteins FADD/entity1_term, TRADD, and RIP and the apoptosis-initiating entity2_term-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
MORT1
caspases
0
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and entity1_term and the apoptosis-initiating entity2_term-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
RIP
caspases
0
The involvement of the death adaptor proteins FADD/MORT1, entity1_term, and RIP and the apoptosis-initiating entity2_term-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
TRADD
caspases
0
The involvement of the death adaptor proteins entity1_term/MORT1, TRADD, and RIP and the apoptosis-initiating entity2_term-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
FADD
caspases
0
The involvement of the death adaptor proteins FADD/entity1_term, TRADD, and RIP and the apoptosis-initiating entity2_term and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
MORT1
caspases-8
0
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and entity1_term and the apoptosis-initiating entity2_term and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
RIP
caspases-8
0
The involvement of the death adaptor proteins FADD/MORT1, entity1_term, and RIP and the apoptosis-initiating entity2_term and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
TRADD
caspases-8
0
The involvement of the death adaptor proteins entity1_term/MORT1, TRADD, and RIP and the apoptosis-initiating entity2_term and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
FADD
caspases-8
0
The involvement of the death adaptor proteins FADD/entity1_term, TRADD, and entity2_term and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
MORT1
RIP
0
The involvement of the death adaptor proteins FADD/entity1_term, entity2_term, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
MORT1
TRADD
0
The involvement of the death adaptor proteins entity1_term/entity2_term, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
FADD
MORT1
0
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (entity1_term and entity2_term) are controversial.
TRAIL-R1
TRAIL-R2
0
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity1_term 1 and 2 (TRAIL-R1 and entity2_term) are controversial.
TRAIL receptors
TRAIL-R2
0
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity1_term and 2 (TRAIL-R1 and entity2_term) are controversial.
TRAIL receptors 1
TRAIL-R2
0
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity1_term 1 and 2 (entity2_term and TRAIL-R2) are controversial.
TRAIL receptors
TRAIL-R1
0
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity1_term and 2 (entity2_term and TRAIL-R2) are controversial.
TRAIL receptors 1
TRAIL-R1
0
The involvement of the death adaptor proteins FADD/MORT1, TRADD, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing entity1_termentity2_term and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
TRAIL receptors
TRAIL receptors 1
0
The involvement of the death adaptor proteins FADD/MORT1, entity1_term, and entity2_term and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
TRADD
RIP
0
The involvement of the death adaptor proteins entity1_term/MORT1, TRADD, and entity2_term and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
FADD
RIP
0
The involvement of the death adaptor proteins entity1_term/MORT1, entity2_term, and RIP and the apoptosis-initiating caspases-8 and -10 in death signaling by the two death-inducing TRAIL receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are controversial.
FADD
TRADD
0
Evaluation of the binding of Acanthamoeba entity1_term to pyrene-labeled entity2_term by fluorescence enhancement.
profilin
actin
1
alpha-SNAP binds to predicted alpha-helical coiled-coil regions of entity1_term and entity2_term, shown previously to be engaged in their direct interaction.
syntaxin
SNAP-25
1
entity1_term binds to predicted alpha-helical coiled-coil regions of syntaxin and entity2_term, shown previously to be engaged in their direct interaction.
alpha-SNAP
SNAP-25
1
entity1_term binds to predicted alpha-helical coiled-coil regions of entity2_term and SNAP-25, shown previously to be engaged in their direct interaction.
alpha-SNAP
syntaxin
1
Hypertonicity provoked entity1_term-dependent tyrosine phosphorylation in beta-catenin, entity2_term, and p120(Cas) and caused the dissociation of beta-catenin from the contacts.
Fyn
alpha-catenin
1
Hypertonicity provoked entity1_term-dependent tyrosine phosphorylation in entity2_term, alpha-catenin, and p120(Cas) and caused the dissociation of beta-catenin from the contacts.
Fyn
beta-catenin
1
Hypertonicity provoked entity1_term-dependent tyrosine phosphorylation in beta-catenin, alpha-catenin, and entity2_term(Cas) and caused the dissociation of beta-catenin from the contacts.
Fyn
p120
1
Hypertonicity provoked entity1_term-dependent tyrosine phosphorylation in beta-catenin, alpha-catenin, and p120(entity2_term) and caused the dissociation of beta-catenin from the contacts.
Fyn
Cas
1
Hypertonicity provoked entity1_term-dependent tyrosine phosphorylation in beta-catenin, alpha-catenin, and p120(Cas) and caused the dissociation of entity2_term from the contacts.
Fyn
beta-catenin
0
Hypertonicity provoked Fyn-dependent tyrosine phosphorylation in beta-catenin, entity1_term, and p120(Cas) and caused the dissociation of entity2_term from the contacts.
alpha-catenin
beta-catenin
0
Hypertonicity provoked Fyn-dependent tyrosine phosphorylation in beta-catenin, alpha-catenin, and p120(entity1_term) and caused the dissociation of entity2_term from the contacts.
Cas
beta-catenin
0
Hypertonicity provoked Fyn-dependent tyrosine phosphorylation in beta-catenin, alpha-catenin, and entity1_term(Cas) and caused the dissociation of entity2_term from the contacts.
p120
beta-catenin
0
Hypertonicity provoked Fyn-dependent tyrosine phosphorylation in entity1_term, alpha-catenin, and p120(Cas) and caused the dissociation of entity2_term from the contacts.
beta-catenin
beta-catenin
0
Hypertonicity provoked Fyn-dependent tyrosine phosphorylation in beta-catenin, entity1_term, and p120(entity2_term) and caused the dissociation of beta-catenin from the contacts.
alpha-catenin
Cas
0
Hypertonicity provoked Fyn-dependent tyrosine phosphorylation in beta-catenin, entity1_term, and entity2_term(Cas) and caused the dissociation of beta-catenin from the contacts.
alpha-catenin
p120
0
Hypertonicity provoked Fyn-dependent tyrosine phosphorylation in entity1_term, entity2_term, and p120(Cas) and caused the dissociation of beta-catenin from the contacts.
beta-catenin
alpha-catenin
0
Hypertonicity provoked Fyn-dependent tyrosine phosphorylation in beta-catenin, alpha-catenin, and entity1_term(entity2_term) and caused the dissociation of beta-catenin from the contacts.
p120
Cas
0
Hypertonicity provoked Fyn-dependent tyrosine phosphorylation in entity1_term, alpha-catenin, and p120(entity2_term) and caused the dissociation of beta-catenin from the contacts.
beta-catenin
Cas
0
Hypertonicity provoked Fyn-dependent tyrosine phosphorylation in entity1_term, alpha-catenin, and entity2_term(Cas) and caused the dissociation of beta-catenin from the contacts.
beta-catenin
p120
0
RIPc, one of the cleavage products, enhanced interaction between entity1_term and FADD/entity2_term and increased cells' sensitivity to TNF.
TRADD
MORT1
1
entity1_term, one of the cleavage products, enhanced interaction between TRADD and FADD/entity2_term and increased cells' sensitivity to TNF.
RIPc
MORT1
1
entity1_term, one of the cleavage products, enhanced interaction between entity2_term and FADD/MORT1 and increased cells' sensitivity to TNF.
RIPc
TRADD
1
entity1_term, one of the cleavage products, enhanced interaction between TRADD and entity2_term/MORT1 and increased cells' sensitivity to TNF.
RIPc
FADD
1
RIPc, one of the cleavage products, enhanced interaction between entity1_term and entity2_term/MORT1 and increased cells' sensitivity to TNF.
TRADD
FADD
1
entity1_term, one of the cleavage products, enhanced interaction between TRADD and FADD/MORT1 and increased cells' sensitivity to entity2_term.
RIPc
TNF
1
RIPc, one of the cleavage products, enhanced interaction between TRADD and FADD/entity1_term and increased cells' sensitivity to entity2_term.
MORT1
TNF
0
RIPc, one of the cleavage products, enhanced interaction between TRADD and entity1_term/entity2_term and increased cells' sensitivity to TNF.
FADD
MORT1
0
RIPc, one of the cleavage products, enhanced interaction between entity1_term and FADD/MORT1 and increased cells' sensitivity to entity2_term.
TRADD
TNF
0
RIPc, one of the cleavage products, enhanced interaction between TRADD and entity1_term/MORT1 and increased cells' sensitivity to entity2_term.
FADD
TNF
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind entity1_term monomers, entity2_term (ADF), gelsolin, profilin, and thymosin beta4 (Tbeta4).
actin
actin depolymerizing factor
1
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind entity1_term monomers, actin depolymerizing factor (ADF), gelsolin, profilin, and thymosin beta4 (entity2_term).
actin
Tbeta4
1
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind entity1_term monomers, actin depolymerizing factor (ADF), gelsolin, entity2_term, and thymosin beta4 (Tbeta4).
actin
profilin
1
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind entity1_term monomers, actin depolymerizing factor (ADF), entity2_term, profilin, and thymosin beta4 (Tbeta4).
actin
gelsolin
1
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind entity1_term monomers, actin depolymerizing factor (entity2_term), gelsolin, profilin, and thymosin beta4 (Tbeta4).
actin
ADF
1
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind entity1_term monomers, actin depolymerizing factor (ADF), gelsolin, profilin, and entity2_term (Tbeta4).
actin
thymosin beta4
1
Chick embryo fibroblasts contain about 75-100 microM unpolymerized entity1_term and at least four proteins which can bind actin monomers, actin depolymerizing factor (ADF), gelsolin, entity2_term, and thymosin beta4 (Tbeta4).
actin
profilin
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized entity1_term and at least four proteins which can bind actin monomers, actin depolymerizing factor (entity2_term), gelsolin, profilin, and thymosin beta4 (Tbeta4).
actin
ADF
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized entity1_term and at least four proteins which can bind actin monomers, actin depolymerizing factor (ADF), gelsolin, profilin, and thymosin beta4 (entity2_term).
actin
Tbeta4
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized entity1_term and at least four proteins which can bind actin monomers, entity2_term (ADF), gelsolin, profilin, and thymosin beta4 (Tbeta4).
actin
actin depolymerizing factor
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized entity1_term and at least four proteins which can bind entity2_term monomers, actin depolymerizing factor (ADF), gelsolin, profilin, and thymosin beta4 (Tbeta4).
actin
actin
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized entity1_term and at least four proteins which can bind actin monomers, actin depolymerizing factor (ADF), entity2_term, profilin, and thymosin beta4 (Tbeta4).
actin
gelsolin
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized entity1_term and at least four proteins which can bind actin monomers, actin depolymerizing factor (ADF), gelsolin, profilin, and entity2_term (Tbeta4).
actin
thymosin beta4
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, actin depolymerizing factor (entity1_term), gelsolin, entity2_term, and thymosin beta4 (Tbeta4).
ADF
profilin
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, actin depolymerizing factor (ADF), gelsolin, entity1_term, and thymosin beta4 (entity2_term).
profilin
Tbeta4
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, entity1_term (ADF), gelsolin, entity2_term, and thymosin beta4 (Tbeta4).
actin depolymerizing factor
profilin
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, actin depolymerizing factor (ADF), entity1_term, entity2_term, and thymosin beta4 (Tbeta4).
gelsolin
profilin
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, actin depolymerizing factor (ADF), gelsolin, entity1_term, and entity2_term (Tbeta4).
profilin
thymosin beta4
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, actin depolymerizing factor (entity1_term), gelsolin, profilin, and thymosin beta4 (entity2_term).
ADF
Tbeta4
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, entity1_term (entity2_term), gelsolin, profilin, and thymosin beta4 (Tbeta4).
actin depolymerizing factor
ADF
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, actin depolymerizing factor (entity1_term), entity2_term, profilin, and thymosin beta4 (Tbeta4).
ADF
gelsolin
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, actin depolymerizing factor (entity1_term), gelsolin, profilin, and entity2_term (Tbeta4).
ADF
thymosin beta4
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, entity1_term (ADF), gelsolin, profilin, and thymosin beta4 (entity2_term).
actin depolymerizing factor
Tbeta4
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, actin depolymerizing factor (ADF), entity1_term, profilin, and thymosin beta4 (entity2_term).
gelsolin
Tbeta4
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, actin depolymerizing factor (ADF), gelsolin, profilin, and entity1_term (entity2_term).
thymosin beta4
Tbeta4
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, entity1_term (ADF), entity2_term, profilin, and thymosin beta4 (Tbeta4).
actin depolymerizing factor
gelsolin
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, entity1_term (ADF), gelsolin, profilin, and entity2_term (Tbeta4).
actin depolymerizing factor
thymosin beta4
0
Chick embryo fibroblasts contain about 75-100 microM unpolymerized actin and at least four proteins which can bind actin monomers, actin depolymerizing factor (ADF), entity1_term, profilin, and entity2_term (Tbeta4).
gelsolin
thymosin beta4
0
These results demonstrate that entity1_term plays a crucial role in vivo in rapid remodeling of the cortical entity2_term meshwork into bundles.
cofilin
actin
1
Live dynamics of Dictyostelium entity1_term suggests a role in remodeling entity2_term latticework into bundles.
cofilin
actin
1
These results show that cofilin/entity1_term is an important regulator of entity2_term-based cell motility during Drosophila development.
ADF
actin
1
These results show that entity1_term/ADF is an important regulator of entity2_term-based cell motility during Drosophila development.
cofilin
actin
1
These results show that entity1_term/entity2_term is an important regulator of actin-based cell motility during Drosophila development.
cofilin
ADF
0
A highly significant correlation was observed between the loss of expression of E-cadherin, alpha-catenin and entity1_term, but not entity2_term, with increased TNM stage (p <0.05).
gamma-catenin
beta-catenin
1
A highly significant correlation was observed between the loss of expression of entity1_term, alpha-catenin and gamma-catenin, but not entity2_term, with increased TNM stage (p <0.05).
E-cadherin
beta-catenin
1
A highly significant correlation was observed between the loss of expression of entity1_term, alpha-catenin and entity2_term, but not beta-catenin, with increased TNM stage (p <0.05).
E-cadherin
gamma-catenin
1
A highly significant correlation was observed between the loss of expression of E-cadherin, entity1_term and gamma-catenin, but not entity2_term, with increased TNM stage (p <0.05).
alpha-catenin
beta-catenin
1
A highly significant correlation was observed between the loss of expression of E-cadherin, entity1_term and entity2_term, but not beta-catenin, with increased TNM stage (p <0.05).
alpha-catenin
gamma-catenin
1
A highly significant correlation was observed between the loss of expression of entity1_term, entity2_term and gamma-catenin, but not beta-catenin, with increased TNM stage (p <0.05).
E-cadherin
alpha-catenin
1
Loss of normal surface entity1_term, alpha-catenin, beta-catenin and entity2_term expression was found in 52/68 (76.4%) tumors, 57/68 (83.8%) tumors, 54/68 (79.4%) tumors and 54/68 (79.4%) tumors (p <0.001).
E-cadherin
gamma-catenin
0
Loss of normal surface entity1_term, alpha-catenin, entity2_term and gamma-catenin expression was found in 52/68 (76.4%) tumors, 57/68 (83.8%) tumors, 54/68 (79.4%) tumors and 54/68 (79.4%) tumors (p <0.001).
E-cadherin
beta-catenin
0
Loss of normal surface entity1_term, entity2_term, beta-catenin and gamma-catenin expression was found in 52/68 (76.4%) tumors, 57/68 (83.8%) tumors, 54/68 (79.4%) tumors and 54/68 (79.4%) tumors (p <0.001).
E-cadherin
alpha-catenin
0
Loss of normal surface E-cadherin, alpha-catenin, entity1_term and entity2_term expression was found in 52/68 (76.4%) tumors, 57/68 (83.8%) tumors, 54/68 (79.4%) tumors and 54/68 (79.4%) tumors (p <0.001).
beta-catenin
gamma-catenin
0
Loss of normal surface E-cadherin, entity1_term, beta-catenin and entity2_term expression was found in 52/68 (76.4%) tumors, 57/68 (83.8%) tumors, 54/68 (79.4%) tumors and 54/68 (79.4%) tumors (p <0.001).
alpha-catenin
gamma-catenin
0
Loss of normal surface E-cadherin, entity1_term, entity2_term and gamma-catenin expression was found in 52/68 (76.4%) tumors, 57/68 (83.8%) tumors, 54/68 (79.4%) tumors and 54/68 (79.4%) tumors (p <0.001).
alpha-catenin
beta-catenin
0
MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of entity1_term, entity2_term, gamma-catenin and E-cadherin in 68 TCC and 14 normal bladder biopsies.
alpha-catenin
beta-catenin
0
MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, entity1_term, gamma-catenin and entity2_term in 68 TCC and 14 normal bladder biopsies.
beta-catenin
E-cadherin
0
MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, entity1_term, entity2_term and E-cadherin in 68 TCC and 14 normal bladder biopsies.
beta-catenin
gamma-catenin
0
MATERIALS AND METHODS: We used an entity1_term-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, entity2_term, gamma-catenin and E-cadherin in 68 TCC and 14 normal bladder biopsies.
avidin
beta-catenin
0
MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of entity1_term, beta-catenin, gamma-catenin and entity2_term in 68 TCC and 14 normal bladder biopsies.
alpha-catenin
E-cadherin
0
MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of entity1_term, beta-catenin, entity2_term and E-cadherin in 68 TCC and 14 normal bladder biopsies.
alpha-catenin
gamma-catenin
0
MATERIALS AND METHODS: We used an entity1_term-biotin immunoperoxidase technique to examine the cellular localization of entity2_term, beta-catenin, gamma-catenin and E-cadherin in 68 TCC and 14 normal bladder biopsies.
avidin
alpha-catenin
0
MATERIALS AND METHODS: We used an avidin-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, beta-catenin, entity1_term and entity2_term in 68 TCC and 14 normal bladder biopsies.
gamma-catenin
E-cadherin
0
MATERIALS AND METHODS: We used an entity1_term-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, beta-catenin, gamma-catenin and entity2_term in 68 TCC and 14 normal bladder biopsies.
avidin
E-cadherin
0
MATERIALS AND METHODS: We used an entity1_term-biotin immunoperoxidase technique to examine the cellular localization of alpha-catenin, beta-catenin, entity2_term and E-cadherin in 68 TCC and 14 normal bladder biopsies.
avidin
gamma-catenin
0
RESULTS: E-cadherin, entity1_term, beta-catenin and entity2_term were expressed in a normal membranous pattern in all normal bladder epithelium specimens.
alpha-catenin
gamma-catenin
0
RESULTS: entity1_term, entity2_term, beta-catenin and gamma-catenin were expressed in a normal membranous pattern in all normal bladder epithelium specimens.
E-cadherin
alpha-catenin
0
RESULTS: E-cadherin, entity1_term, entity2_term and gamma-catenin were expressed in a normal membranous pattern in all normal bladder epithelium specimens.
alpha-catenin
beta-catenin
0
RESULTS: entity1_term, alpha-catenin, beta-catenin and entity2_term were expressed in a normal membranous pattern in all normal bladder epithelium specimens.
E-cadherin
gamma-catenin
0
RESULTS: E-cadherin, alpha-catenin, entity1_term and entity2_term were expressed in a normal membranous pattern in all normal bladder epithelium specimens.
beta-catenin
gamma-catenin
0
RESULTS: entity1_term, alpha-catenin, entity2_term and gamma-catenin were expressed in a normal membranous pattern in all normal bladder epithelium specimens.
E-cadherin
beta-catenin
0
In the present work we have used entity1_term and entity2_term injections, as well as latrunculin B and cytochalasin D treatments, under quantitatively controlled conditions, to perturb actin microfilament structure and assembly in an attempt to answer this question.
profilin
DNAse I
0
In the present work we have used entity1_term and DNAse I injections, as well as latrunculin B and cytochalasin D treatments, under quantitatively controlled conditions, to perturb entity2_term microfilament structure and assembly in an attempt to answer this question.
profilin
actin
0
In the present work we have used profilin and entity1_term injections, as well as latrunculin B and cytochalasin D treatments, under quantitatively controlled conditions, to perturb entity2_term microfilament structure and assembly in an attempt to answer this question.
DNAse I
actin
0
The multifunctional protein entity1_term is one of the most abundant proteins in the cytoplasm and is thought to regulate entity2_term assembly and the phosphoinositide signaling pathway.
profilin
actin
1
Gel electrophoresis was used to measure changes in the relative amounts of entity1_term or myosin and of myosin heavy chain (entity2_term) isoforms.
actin
MHC
0
Gel electrophoresis was used to measure changes in the relative amounts of actin or entity1_term and of myosin heavy chain (entity2_term) isoforms.
myosin
MHC
0
Gel electrophoresis was used to measure changes in the relative amounts of actin or myosin and of entity1_term (entity2_term) isoforms.
myosin heavy chain
MHC
0
Gel electrophoresis was used to measure changes in the relative amounts of entity1_term or entity2_term and of myosin heavy chain (MHC) isoforms.
actin
myosin
0
Gel electrophoresis was used to measure changes in the relative amounts of entity1_term or myosin and of entity2_term (MHC) isoforms.
actin
myosin heavy chain
0
Gel electrophoresis was used to measure changes in the relative amounts of actin or entity1_term and of entity2_term (MHC) isoforms.
myosin
myosin heavy chain
0
These genes were designated UL5, UL8, UL9, entity1_term, and entity2_term and were predicted to encode proteins with molecular weights of, respectively, 99,000, 80,000, 94,000, 51,000, and 114,000.
UL42
UL52
0
These genes were designated entity1_term, UL8, UL9, UL42, and entity2_term and were predicted to encode proteins with molecular weights of, respectively, 99,000, 80,000, 94,000, 51,000, and 114,000.
UL5
UL52
0
These genes were designated UL5, entity1_term, UL9, UL42, and entity2_term and were predicted to encode proteins with molecular weights of, respectively, 99,000, 80,000, 94,000, 51,000, and 114,000.
UL8
UL52
0
These genes were designated UL5, UL8, entity1_term, UL42, and entity2_term and were predicted to encode proteins with molecular weights of, respectively, 99,000, 80,000, 94,000, 51,000, and 114,000.
UL9
UL52
0
These genes were designated entity1_term, UL8, UL9, entity2_term, and UL52 and were predicted to encode proteins with molecular weights of, respectively, 99,000, 80,000, 94,000, 51,000, and 114,000.
UL5
UL42
0
These genes were designated UL5, entity1_term, UL9, entity2_term, and UL52 and were predicted to encode proteins with molecular weights of, respectively, 99,000, 80,000, 94,000, 51,000, and 114,000.
UL8
UL42
0
These genes were designated UL5, UL8, entity1_term, entity2_term, and UL52 and were predicted to encode proteins with molecular weights of, respectively, 99,000, 80,000, 94,000, 51,000, and 114,000.
UL9
UL42
0
These genes were designated entity1_term, entity2_term, UL9, UL42, and UL52 and were predicted to encode proteins with molecular weights of, respectively, 99,000, 80,000, 94,000, 51,000, and 114,000.
UL5
UL8
0
These genes were designated entity1_term, UL8, entity2_term, UL42, and UL52 and were predicted to encode proteins with molecular weights of, respectively, 99,000, 80,000, 94,000, 51,000, and 114,000.
UL5
UL9
0
These genes were designated UL5, entity1_term, entity2_term, UL42, and UL52 and were predicted to encode proteins with molecular weights of, respectively, 99,000, 80,000, 94,000, 51,000, and 114,000.
UL8
UL9
0
Lack of detection in these preparations of a constituent that binds RBC entity1_term antibody plus the presence of significant quantities of actin, further suggests that the principal membrane skeletal element is actin with perhaps smaller quantities of a 240-kd component, identified by others as the protein entity2_term.
alpha-spectrin
talin
0
Lack of detection in these preparations of a constituent that binds RBC entity1_term antibody plus the presence of significant quantities of actin, further suggests that the principal membrane skeletal element is entity2_term with perhaps smaller quantities of a 240-kd component, identified by others as the protein talin.
alpha-spectrin
actin
0
Lack of detection in these preparations of a constituent that binds RBC entity1_term antibody plus the presence of significant quantities of entity2_term, further suggests that the principal membrane skeletal element is actin with perhaps smaller quantities of a 240-kd component, identified by others as the protein talin.
alpha-spectrin
actin
0
Lack of detection in these preparations of a constituent that binds RBC alpha-spectrin antibody plus the presence of significant quantities of actin, further suggests that the principal membrane skeletal element is entity1_term with perhaps smaller quantities of a 240-kd component, identified by others as the protein entity2_term.
actin
talin
0
Lack of detection in these preparations of a constituent that binds RBC alpha-spectrin antibody plus the presence of significant quantities of entity1_term, further suggests that the principal membrane skeletal element is actin with perhaps smaller quantities of a 240-kd component, identified by others as the protein entity2_term.
actin
talin
0
Lack of detection in these preparations of a constituent that binds RBC alpha-spectrin antibody plus the presence of significant quantities of entity1_term, further suggests that the principal membrane skeletal element is entity2_term with perhaps smaller quantities of a 240-kd component, identified by others as the protein talin.
actin
actin
0
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 nucleocapsid protein N, the phosphoprotein P, and the entity1_term entity2_term.
polymerase protein
L
1
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 nucleocapsid protein N, the entity1_term entity2_term, and the polymerase protein L.
phosphoprotein
P
1
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 entity1_term entity2_term, the phosphoprotein P, and the polymerase protein L.
nucleocapsid protein
N
1
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 nucleocapsid protein N, the phosphoprotein entity1_term, and the entity2_term L.
P
polymerase protein
0
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 nucleocapsid protein entity1_term, the phosphoprotein entity2_term, and the polymerase protein L.
N
P
0
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 entity1_term N, the phosphoprotein entity2_term, and the polymerase protein L.
nucleocapsid protein
P
0
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 nucleocapsid protein N, the phosphoprotein entity1_term, and the polymerase protein entity2_term.
P
L
0
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 nucleocapsid protein N, the entity1_term P, and the entity2_term L.
phosphoprotein
polymerase protein
0
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 nucleocapsid protein entity1_term, the phosphoprotein P, and the entity2_term L.
N
polymerase protein
0
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 entity1_term N, the phosphoprotein P, and the entity2_term L.
nucleocapsid protein
polymerase protein
0
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 nucleocapsid protein entity1_term, the entity2_term P, and the polymerase protein L.
N
phosphoprotein
0
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 entity1_term N, the entity2_term P, and the polymerase protein L.
nucleocapsid protein
phosphoprotein
0
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 nucleocapsid protein N, the entity1_term P, and the polymerase protein entity2_term.
phosphoprotein
L
0
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 nucleocapsid protein entity1_term, the phosphoprotein P, and the polymerase protein entity2_term.
N
L
0
These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 entity1_term N, the phosphoprotein P, and the polymerase protein entity2_term.
nucleocapsid protein
L
0
In this recombinant expression system, the entity1_term relatives, human dystrophin related protein (DRP or entity2_term) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.
dystrophin
utrophin
1
In this recombinant expression system, the entity1_term relatives, human dystrophin related protein (DRP or utrophin) and the entity2_term from Torpedo electric organ, also bind to translated beta 1-syntrophin.
dystrophin
87K postsynaptic protein
1
In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or entity1_term) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated entity2_term.
utrophin
beta 1-syntrophin
1
In this recombinant expression system, the entity1_term relatives, human entity2_term (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.
dystrophin
dystrophin related protein
1
In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or utrophin) and the entity1_term from Torpedo electric organ, also bind to translated entity2_term.
87K postsynaptic protein
beta 1-syntrophin
1
In this recombinant expression system, the entity1_term relatives, human dystrophin related protein (entity2_term or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.
dystrophin
DRP
1
In this recombinant expression system, the dystrophin relatives, human entity1_term (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated entity2_term.
dystrophin related protein
beta 1-syntrophin
1
In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (entity1_term or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated entity2_term.
DRP
beta 1-syntrophin
1
In this recombinant expression system, the entity1_term relatives, human dystrophin related protein (DRP or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated entity2_term.
dystrophin
beta 1-syntrophin
0
In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (entity1_term or entity2_term) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.
DRP
utrophin
0
In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (DRP or entity1_term) and the entity2_term from Torpedo electric organ, also bind to translated beta 1-syntrophin.
utrophin
87K postsynaptic protein
0
In this recombinant expression system, the dystrophin relatives, human entity1_term (DRP or entity2_term) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.
dystrophin related protein
utrophin
0
In this recombinant expression system, the dystrophin relatives, human dystrophin related protein (entity1_term or utrophin) and the entity2_term from Torpedo electric organ, also bind to translated beta 1-syntrophin.
DRP
87K postsynaptic protein
0
In this recombinant expression system, the dystrophin relatives, human entity1_term (entity2_term or utrophin) and the 87K postsynaptic protein from Torpedo electric organ, also bind to translated beta 1-syntrophin.
dystrophin related protein
DRP
0
In this recombinant expression system, the dystrophin relatives, human entity1_term (DRP or utrophin) and the entity2_term from Torpedo electric organ, also bind to translated beta 1-syntrophin.
dystrophin related protein
87K postsynaptic protein
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of E-cadherin (entity1_term), alpha-catenin (alpha-cat) and beta-catenin (entity2_term) in ACC, and compared it with that in the normal labial gland.
E-cad
beta-cat
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of E-cadherin (entity1_term), alpha-catenin (entity2_term) and beta-catenin (beta-cat) in ACC, and compared it with that in the normal labial gland.
E-cad
alpha-cat
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of entity1_term (entity2_term), alpha-catenin (alpha-cat) and beta-catenin (beta-cat) in ACC, and compared it with that in the normal labial gland.
E-cadherin
E-cad
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of E-cadherin (entity1_term), entity2_term (alpha-cat) and beta-catenin (beta-cat) in ACC, and compared it with that in the normal labial gland.
E-cad
alpha-catenin
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of E-cadherin (entity1_term), alpha-catenin (alpha-cat) and entity2_term (beta-cat) in ACC, and compared it with that in the normal labial gland.
E-cad
beta-catenin
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of E-cadherin (E-cad), alpha-catenin (entity1_term) and beta-catenin (entity2_term) in ACC, and compared it with that in the normal labial gland.
alpha-cat
beta-cat
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of entity1_term (E-cad), alpha-catenin (alpha-cat) and beta-catenin (entity2_term) in ACC, and compared it with that in the normal labial gland.
E-cadherin
beta-cat
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of E-cadherin (E-cad), entity1_term (alpha-cat) and beta-catenin (entity2_term) in ACC, and compared it with that in the normal labial gland.
alpha-catenin
beta-cat
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of E-cadherin (E-cad), alpha-catenin (alpha-cat) and entity1_term (entity2_term) in ACC, and compared it with that in the normal labial gland.
beta-catenin
beta-cat
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of entity1_term (E-cad), alpha-catenin (entity2_term) and beta-catenin (beta-cat) in ACC, and compared it with that in the normal labial gland.
E-cadherin
alpha-cat
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of E-cadherin (E-cad), entity1_term (entity2_term) and beta-catenin (beta-cat) in ACC, and compared it with that in the normal labial gland.
alpha-catenin
alpha-cat
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of E-cadherin (E-cad), alpha-catenin (entity1_term) and entity2_term (beta-cat) in ACC, and compared it with that in the normal labial gland.
alpha-cat
beta-catenin
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of entity1_term (E-cad), entity2_term (alpha-cat) and beta-catenin (beta-cat) in ACC, and compared it with that in the normal labial gland.
E-cadherin
alpha-catenin
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of entity1_term (E-cad), alpha-catenin (alpha-cat) and entity2_term (beta-cat) in ACC, and compared it with that in the normal labial gland.
E-cadherin
beta-catenin
0
AIMS: To investigate the disturbance of intercellular adhesion in adenoid cystic carcinoma (ACC), we examined the ultrastructural localization of E-cadherin (E-cad), entity1_term (alpha-cat) and entity2_term (beta-cat) in ACC, and compared it with that in the normal labial gland.
alpha-catenin
beta-catenin
0
The entity1_term-associated proteins, alpha-catenin and entity2_term, were present in both mesotheliomas and adenocarcinomas.
cadherin
beta-catenin
1
The entity1_term-associated proteins, entity2_term and beta-catenin, were present in both mesotheliomas and adenocarcinomas.
cadherin
alpha-catenin
1
The cadherin-associated proteins, entity1_term and entity2_term, were present in both mesotheliomas and adenocarcinomas.
alpha-catenin
beta-catenin
0
alpha-Sm actin inhibition also led to the formation of less prominent focal adhesions as revealed by immunofluorescence staining against entity1_term, entity2_term, and beta1-integrin.
vinculin
talin
0
alpha-Sm actin inhibition also led to the formation of less prominent focal adhesions as revealed by immunofluorescence staining against entity1_term, talin, and entity2_term.
vinculin
beta1-integrin
0
entity1_term inhibition also led to the formation of less prominent focal adhesions as revealed by immunofluorescence staining against entity2_term, talin, and beta1-integrin.
alpha-Sm actin
vinculin
0
alpha-Sm actin inhibition also led to the formation of less prominent focal adhesions as revealed by immunofluorescence staining against vinculin, entity1_term, and entity2_term.
talin
beta1-integrin
0
entity1_term inhibition also led to the formation of less prominent focal adhesions as revealed by immunofluorescence staining against vinculin, entity2_term, and beta1-integrin.
alpha-Sm actin
talin
0
entity1_term inhibition also led to the formation of less prominent focal adhesions as revealed by immunofluorescence staining against vinculin, talin, and entity2_term.
alpha-Sm actin
beta1-integrin
0
Moreover, addition of entity1_term to steady-state entity2_term filaments causes slow depolymerization.
profilin
actin
1
Characterization of the action of porcine entity1_term on entity2_term polymerization.
brain profilin
actin
1
Biochemical analyses revealed a strong induction of VEGF-receptor-2 (flk-1/entity1_term) tyrosine-autophosphorylation by entity2_term which was maximal after 5 minutes and was followed by receptor downregulation.
KDR
VEGF
1
Biochemical analyses revealed a strong induction of VEGF-receptor-2 (entity1_term/KDR) tyrosine-autophosphorylation by entity2_term which was maximal after 5 minutes and was followed by receptor downregulation.
flk-1
VEGF
1
Biochemical analyses revealed a strong induction of entity1_term (flk-1/KDR) tyrosine-autophosphorylation by entity2_term which was maximal after 5 minutes and was followed by receptor downregulation.
VEGF-receptor-2
VEGF
1
Biochemical analyses revealed a strong induction of entity1_term (entity2_term/KDR) tyrosine-autophosphorylation by VEGF which was maximal after 5 minutes and was followed by receptor downregulation.
VEGF-receptor-2
flk-1
0
Biochemical analyses revealed a strong induction of VEGF-receptor-2 (entity1_term/entity2_term) tyrosine-autophosphorylation by VEGF which was maximal after 5 minutes and was followed by receptor downregulation.
flk-1
KDR
0
Biochemical analyses revealed a strong induction of entity1_term (flk-1/entity2_term) tyrosine-autophosphorylation by VEGF which was maximal after 5 minutes and was followed by receptor downregulation.
VEGF-receptor-2
KDR
0
The viscoelasticity of entangled entity1_term networks: the influence of defects and modulation by talin and entity2_term.
actin
vinculin
1
A major point of interest was to clarify whether rheological, high precision measurements can yield quantitative information about the influence of entity1_term and vinculin on the structure, chain dynamics, elasticity and viscoelasticity of entity2_term filaments with time.
talin
actin
1
The viscoelasticity of entangled entity1_term networks: the influence of defects and modulation by entity2_term and vinculin.
actin
talin
1
A major point of interest was to clarify whether rheological, high precision measurements can yield quantitative information about the influence of talin and entity1_term on the structure, chain dynamics, elasticity and viscoelasticity of entity2_term filaments with time.
vinculin
actin
1
The viscoelasticity of entangled actin networks: the influence of defects and modulation by entity1_term and entity2_term.
talin
vinculin
0
A major point of interest was to clarify whether rheological, high precision measurements can yield quantitative information about the influence of entity1_term and entity2_term on the structure, chain dynamics, elasticity and viscoelasticity of actin filaments with time.
talin
vinculin
0
Even though rates of total protein and entity1_term synthesis resembled values measured in vivo, entity2_term fractional rate of synthesis was only 22% of in vivo levels.
actin
myosin heavy chain
0
The intracellular molecules entity1_term and profilin actively regulate entity2_term-based motility and participate in the signaling pathways used to steer growth cones.
calmodulin
actin
1
The intracellular molecules calmodulin and entity1_term actively regulate entity2_term-based motility and participate in the signaling pathways used to steer growth cones.
profilin
actin
1
The intracellular molecules entity1_term and entity2_term actively regulate actin-based motility and participate in the signaling pathways used to steer growth cones.
calmodulin
profilin
0
Here we show that the N-terminal domain of entity1_term binds one actin monomer, in a profilin-like fashion, and entity2_term2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
ActA
Arp
1
Here we show that the N-terminal domain of ActA binds one actin monomer, in a profilin-like fashion, and Arp2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by entity1_termentity2_term2/3 complex.
Arp2
Arp
1
Here we show that the N-terminal domain of entity1_term binds one entity2_term monomer, in a profilin-like fashion, and Arp2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
ActA
actin
1
Here we show that the N-terminal domain of ActA binds one actin monomer, in a profilin-like fashion, and entity1_termentity2_term2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
Arp2
Arp
1
Here we show that the N-terminal domain of entity1_term binds one actin monomer, in a profilin-like fashion, and entity2_term/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
ActA
Arp2
1
Here we show that the N-terminal domain of entity1_term binds one actin monomer, in a entity2_term-like fashion, and Arp2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
ActA
profilin
1
Here we show that the N-terminal domain of ActA binds one actin monomer, in a profilin-like fashion, and Arp2/3 complex and mimics the C-terminal domain of entity1_term family proteins in catalyzing filament barbed end branching by entity2_term2/3 complex.
WASp
Arp
0
Here we show that the N-terminal domain of ActA binds one entity1_term monomer, in a profilin-like fashion, and Arp2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by entity2_term2/3 complex.
actin
Arp
0
Here we show that the N-terminal domain of ActA binds one actin monomer, in a profilin-like fashion, and entity1_term2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by entity2_term2/3 complex.
Arp
Arp
0
Here we show that the N-terminal domain of entity1_term binds one actin monomer, in a profilin-like fashion, and Arp2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by entity2_term2/3 complex.
ActA
Arp
0
Here we show that the N-terminal domain of ActA binds one actin monomer, in a entity1_term-like fashion, and Arp2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by entity2_term2/3 complex.
profilin
Arp
0
Here we show that the N-terminal domain of ActA binds one actin monomer, in a profilin-like fashion, and entity1_term/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by entity2_term2/3 complex.
Arp2
Arp
0
Here we show that the N-terminal domain of ActA binds one entity1_term monomer, in a profilin-like fashion, and Arp2/3 complex and mimics the C-terminal domain of entity2_term family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
actin
WASp
0
Here we show that the N-terminal domain of ActA binds one actin monomer, in a profilin-like fashion, and entity1_term2/3 complex and mimics the C-terminal domain of entity2_term family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
Arp
WASp
0
Here we show that the N-terminal domain of entity1_term binds one actin monomer, in a profilin-like fashion, and Arp2/3 complex and mimics the C-terminal domain of entity2_term family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
ActA
WASp
0
Here we show that the N-terminal domain of ActA binds one actin monomer, in a entity1_term-like fashion, and Arp2/3 complex and mimics the C-terminal domain of entity2_term family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
profilin
WASp
0
Here we show that the N-terminal domain of ActA binds one actin monomer, in a profilin-like fashion, and Arp2/3 complex and mimics the C-terminal domain of entity1_term family proteins in catalyzing filament barbed end branching by entity2_term/3 complex.
WASp
Arp2
0
Here we show that the N-terminal domain of ActA binds one actin monomer, in a profilin-like fashion, and entity1_term/3 complex and mimics the C-terminal domain of entity2_term family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
Arp2
WASp
0
Here we show that the N-terminal domain of ActA binds one entity1_term monomer, in a profilin-like fashion, and entity2_term2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
actin
Arp
0
Here we show that the N-terminal domain of ActA binds one entity1_term monomer, in a entity2_term-like fashion, and Arp2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
actin
profilin
0
Here we show that the N-terminal domain of ActA binds one entity1_term monomer, in a profilin-like fashion, and Arp2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by entity2_term/3 complex.
actin
Arp2
0
Here we show that the N-terminal domain of ActA binds one entity1_term monomer, in a profilin-like fashion, and entity2_term/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
actin
Arp2
0
Here we show that the N-terminal domain of ActA binds one actin monomer, in a entity1_term-like fashion, and entity2_term2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
profilin
Arp
0
Here we show that the N-terminal domain of ActA binds one actin monomer, in a profilin-like fashion, and entity1_term2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by entity2_term/3 complex.
Arp
Arp2
0
Here we show that the N-terminal domain of entity1_term binds one actin monomer, in a profilin-like fashion, and Arp2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by entity2_term/3 complex.
ActA
Arp2
0
Here we show that the N-terminal domain of ActA binds one actin monomer, in a entity1_term-like fashion, and Arp2/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by entity2_term/3 complex.
profilin
Arp2
0
Here we show that the N-terminal domain of ActA binds one actin monomer, in a entity1_term-like fashion, and entity2_term/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by Arp2/3 complex.
profilin
Arp2
0
Here we show that the N-terminal domain of ActA binds one actin monomer, in a profilin-like fashion, and entity1_term/3 complex and mimics the C-terminal domain of WASp family proteins in catalyzing filament barbed end branching by entity2_term/3 complex.
Arp2
Arp2
0
Rod formation was prevented by coexpression of N-cadherin, APC, and entity1_term, which bind to the armadillo repeats of entity2_term, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
Tcf-4
beta-catenin
1
Rod formation was prevented by coexpression of entity1_term, APC, and Tcf-4, which bind to the armadillo repeats of entity2_term, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
N-cadherin
beta-catenin
1
Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although entity1_term expression did prevent accumulation of entity2_term in the nucleus.
alpha-catenin
beta-catenin
1
Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the entity1_term repeats of entity2_term, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
armadillo
beta-catenin
1
Rod formation was prevented by coexpression of N-cadherin, entity1_term, and Tcf-4, which bind to the armadillo repeats of entity2_term, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
APC
beta-catenin
1
Rod formation was prevented by coexpression of entity1_term, APC, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of entity2_term, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
N-cadherin
alpha-catenin
0
Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the entity1_term repeats of beta-catenin, but not by coexpression of entity2_term, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
armadillo
alpha-catenin
0
Rod formation was prevented by coexpression of N-cadherin, APC, and entity1_term, which bind to the armadillo repeats of beta-catenin, but not by coexpression of entity2_term, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
Tcf-4
alpha-catenin
0
Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the armadillo repeats of entity1_term, but not by coexpression of entity2_term, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
beta-catenin
alpha-catenin
0
Rod formation was prevented by coexpression of N-cadherin, entity1_term, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of entity2_term, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
APC
alpha-catenin
0
Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of entity1_term, although alpha-catenin expression did prevent accumulation of entity2_term in the nucleus.
alpha-catenin
beta-catenin
0
Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of entity1_term, although entity2_term expression did prevent accumulation of beta-catenin in the nucleus.
alpha-catenin
alpha-catenin
0
Rod formation was prevented by coexpression of entity1_term, APC, and Tcf-4, which bind to the entity2_term repeats of beta-catenin, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
N-cadherin
armadillo
0
Rod formation was prevented by coexpression of entity1_term, APC, and entity2_term, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
N-cadherin
Tcf-4
0
Rod formation was prevented by coexpression of entity1_term, entity2_term, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
N-cadherin
APC
0
Rod formation was prevented by coexpression of entity1_term, APC, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of entity2_term in the nucleus.
N-cadherin
beta-catenin
0
Rod formation was prevented by coexpression of entity1_term, APC, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although entity2_term expression did prevent accumulation of beta-catenin in the nucleus.
N-cadherin
alpha-catenin
0
Rod formation was prevented by coexpression of N-cadherin, APC, and entity1_term, which bind to the entity2_term repeats of beta-catenin, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
Tcf-4
armadillo
0
Rod formation was prevented by coexpression of N-cadherin, entity1_term, and Tcf-4, which bind to the entity2_term repeats of beta-catenin, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
APC
armadillo
0
Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the entity1_term repeats of beta-catenin, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of entity2_term in the nucleus.
armadillo
beta-catenin
0
Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the entity1_term repeats of beta-catenin, but not by coexpression of alpha-catenin, although entity2_term expression did prevent accumulation of beta-catenin in the nucleus.
armadillo
alpha-catenin
0
Rod formation was prevented by coexpression of N-cadherin, entity1_term, and entity2_term, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.
APC
Tcf-4
0
Rod formation was prevented by coexpression of N-cadherin, APC, and entity1_term, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of entity2_term in the nucleus.
Tcf-4
beta-catenin
0
Rod formation was prevented by coexpression of N-cadherin, APC, and entity1_term, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although entity2_term expression did prevent accumulation of beta-catenin in the nucleus.
Tcf-4
alpha-catenin
0
Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the armadillo repeats of entity1_term, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of entity2_term in the nucleus.
beta-catenin
beta-catenin
0
Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the armadillo repeats of entity1_term, but not by coexpression of alpha-catenin, although entity2_term expression did prevent accumulation of beta-catenin in the nucleus.
beta-catenin
alpha-catenin
0
Rod formation was prevented by coexpression of N-cadherin, entity1_term, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of entity2_term in the nucleus.
APC
beta-catenin
0
Rod formation was prevented by coexpression of N-cadherin, entity1_term, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although entity2_term expression did prevent accumulation of beta-catenin in the nucleus.
APC
alpha-catenin
0
Human platelets contain entity1_term, a potential regulator of entity2_term polymerisability.
profilin
actin
1
cDNA clones of the N, entity1_term, and entity2_term genes were constructed in pGEM-based expression plasmids and shown to direct expression of the appropriate polypeptides.
P
L
0
cDNA clones of the entity1_term, entity2_term, and L genes were constructed in pGEM-based expression plasmids and shown to direct expression of the appropriate polypeptides.
N
P
0
cDNA clones of the entity1_term, P, and entity2_term genes were constructed in pGEM-based expression plasmids and shown to direct expression of the appropriate polypeptides.
N
L
0
These were identified as myosin light chain 1, tropomyosin, entity1_term, heat shock protein (entity2_term)-60, an unidentified protein and myosin heavy chain, respectively.
actin
HSP
0
These were identified as myosin light chain 1, tropomyosin, actin, entity1_term (entity2_term)-60, an unidentified protein and myosin heavy chain, respectively.
heat shock protein
HSP
0
These were identified as myosin light chain 1, entity1_term, actin, heat shock protein (entity2_term)-60, an unidentified protein and myosin heavy chain, respectively.
tropomyosin
HSP
0
These were identified as entity1_term, tropomyosin, actin, heat shock protein (entity2_term)-60, an unidentified protein and myosin heavy chain, respectively.
myosin light chain 1
HSP
0
These were identified as myosin light chain 1, tropomyosin, actin, heat shock protein (entity1_term)-60, an unidentified protein and entity2_term, respectively.
HSP
myosin heavy chain
0
These were identified as myosin light chain 1, tropomyosin, entity1_term, entity2_term (HSP)-60, an unidentified protein and myosin heavy chain, respectively.
actin
heat shock protein
0
These were identified as myosin light chain 1, entity1_term, entity2_term, heat shock protein (HSP)-60, an unidentified protein and myosin heavy chain, respectively.
tropomyosin
actin
0
These were identified as entity1_term, tropomyosin, entity2_term, heat shock protein (HSP)-60, an unidentified protein and myosin heavy chain, respectively.
myosin light chain 1
actin
0
These were identified as myosin light chain 1, tropomyosin, entity1_term, heat shock protein (HSP)-60, an unidentified protein and entity2_term, respectively.
actin
myosin heavy chain
0
These were identified as myosin light chain 1, entity1_term, actin, entity2_term (HSP)-60, an unidentified protein and myosin heavy chain, respectively.
tropomyosin
heat shock protein
0
These were identified as entity1_term, tropomyosin, actin, entity2_term (HSP)-60, an unidentified protein and myosin heavy chain, respectively.
myosin light chain 1
heat shock protein
0
These were identified as myosin light chain 1, tropomyosin, actin, entity1_term (HSP)-60, an unidentified protein and entity2_term, respectively.
heat shock protein
myosin heavy chain
0
These were identified as entity1_term, entity2_term, actin, heat shock protein (HSP)-60, an unidentified protein and myosin heavy chain, respectively.
myosin light chain 1
tropomyosin
0
These were identified as myosin light chain 1, entity1_term, actin, heat shock protein (HSP)-60, an unidentified protein and entity2_term, respectively.
tropomyosin
myosin heavy chain
0
These were identified as entity1_term, tropomyosin, actin, heat shock protein (HSP)-60, an unidentified protein and entity2_term, respectively.
myosin light chain 1
myosin heavy chain
0
In this study, the expressions of smooth muscle-specific proteins (desmin, alpha-smooth muscle actin, basic calponin and the entity1_term isoforms of entity2_term and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
smooth muscle myosin heavy-chain
SM1
1
In this study, the expressions of smooth muscle-specific proteins (desmin, alpha-smooth muscle actin, basic calponin and the entity1_term isoforms of SM1 and entity2_term) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
smooth muscle myosin heavy-chain
SM2
1
In this study, the expressions of smooth muscle-specific proteins (desmin, entity1_term, basic calponin and the smooth muscle myosin heavy-chain isoforms of entity2_term and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
alpha-smooth muscle actin
SM1
0
In this study, the expressions of smooth muscle-specific proteins (desmin, entity1_term, basic calponin and the smooth muscle myosin heavy-chain isoforms of SM1 and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-entity2_term chain reaction (RT-PCR).
alpha-smooth muscle actin
polymerase
0
In this study, the expressions of smooth muscle-specific proteins (desmin, entity1_term, basic calponin and the entity2_term isoforms of SM1 and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
alpha-smooth muscle actin
smooth muscle myosin heavy-chain
0
In this study, the expressions of smooth muscle-specific proteins (desmin, entity1_term, entity2_term and the smooth muscle myosin heavy-chain isoforms of SM1 and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
alpha-smooth muscle actin
basic calponin
0
In this study, the expressions of smooth muscle-specific proteins (entity1_term, entity2_term, basic calponin and the smooth muscle myosin heavy-chain isoforms of SM1 and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
desmin
alpha-smooth muscle actin
0
In this study, the expressions of smooth muscle-specific proteins (desmin, entity1_term, basic calponin and the smooth muscle myosin heavy-chain isoforms of SM1 and entity2_term) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
alpha-smooth muscle actin
SM2
0
In this study, the expressions of smooth muscle-specific proteins (desmin, alpha-smooth muscle actin, basic calponin and the smooth muscle myosin heavy-chain isoforms of entity1_term and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-entity2_term chain reaction (RT-PCR).
SM1
polymerase
0
In this study, the expressions of smooth muscle-specific proteins (desmin, alpha-smooth muscle actin, entity1_term and the smooth muscle myosin heavy-chain isoforms of entity2_term and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
basic calponin
SM1
0
In this study, the expressions of smooth muscle-specific proteins (entity1_term, alpha-smooth muscle actin, basic calponin and the smooth muscle myosin heavy-chain isoforms of entity2_term and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
desmin
SM1
0
In this study, the expressions of smooth muscle-specific proteins (desmin, alpha-smooth muscle actin, basic calponin and the smooth muscle myosin heavy-chain isoforms of entity1_term and entity2_term) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
SM1
SM2
0
In this study, the expressions of smooth muscle-specific proteins (desmin, alpha-smooth muscle actin, basic calponin and the entity1_term isoforms of SM1 and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-entity2_term chain reaction (RT-PCR).
smooth muscle myosin heavy-chain
polymerase
0
In this study, the expressions of smooth muscle-specific proteins (desmin, alpha-smooth muscle actin, entity1_term and the smooth muscle myosin heavy-chain isoforms of SM1 and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-entity2_term chain reaction (RT-PCR).
basic calponin
polymerase
0
In this study, the expressions of smooth muscle-specific proteins (entity1_term, alpha-smooth muscle actin, basic calponin and the smooth muscle myosin heavy-chain isoforms of SM1 and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-entity2_term chain reaction (RT-PCR).
desmin
polymerase
0
In this study, the expressions of smooth muscle-specific proteins (desmin, alpha-smooth muscle actin, basic calponin and the smooth muscle myosin heavy-chain isoforms of SM1 and entity1_term) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-entity2_term chain reaction (RT-PCR).
SM2
polymerase
0
In this study, the expressions of smooth muscle-specific proteins (desmin, alpha-smooth muscle actin, entity1_term and the entity2_term isoforms of SM1 and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
basic calponin
smooth muscle myosin heavy-chain
0
In this study, the expressions of smooth muscle-specific proteins (entity1_term, alpha-smooth muscle actin, basic calponin and the entity2_term isoforms of SM1 and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
desmin
smooth muscle myosin heavy-chain
0
In this study, the expressions of smooth muscle-specific proteins (entity1_term, alpha-smooth muscle actin, entity2_term and the smooth muscle myosin heavy-chain isoforms of SM1 and SM2) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
desmin
basic calponin
0
In this study, the expressions of smooth muscle-specific proteins (desmin, alpha-smooth muscle actin, entity1_term and the smooth muscle myosin heavy-chain isoforms of SM1 and entity2_term) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
basic calponin
SM2
0
In this study, the expressions of smooth muscle-specific proteins (entity1_term, alpha-smooth muscle actin, basic calponin and the smooth muscle myosin heavy-chain isoforms of SM1 and entity2_term) in three parent and four cloned neuroblastoma cell lines, composed of S-type cells, were examined by indirect immunofluorescence, Western blot and/or by reverse transcription-polymerase chain reaction (RT-PCR).
desmin
SM2
0
The majority of the aromatic residues in entity1_term are exposed to solvent and lie in either of two hydrophobic patches, neither of which takes part in an interface with entity2_term.
profilin
actin
1
Frozen tissue sections, isolated cardiomyocytes, cultured neonatal cardiomyocytes and fibroblasts were hybridized with DNA probes for type-specific entity1_term, entity2_term, and myosin heavy chain.
collagens
actin
0
Frozen tissue sections, isolated cardiomyocytes, cultured neonatal cardiomyocytes and fibroblasts were hybridized with DNA probes for type-specific entity1_term, actin, and entity2_term.
collagens
myosin heavy chain
0
Frozen tissue sections, isolated cardiomyocytes, cultured neonatal cardiomyocytes and fibroblasts were hybridized with DNA probes for type-specific collagens, entity1_term, and entity2_term.
actin
myosin heavy chain
0
The entity1_term-like central (vc) region of entity2_term induces Arp2/3 complex-dependent actin nucleation.
verprolin
Wiskott-Aldrich syndrome protein
1
The verprolin-like central (vc) region of Wiskott-Aldrich syndrome protein induces entity1_termentity2_term/3 complex-dependent actin nucleation.
Arp
Arp2
1
The verprolin-like central (vc) region of Wiskott-Aldrich syndrome protein induces entity1_term/3 complex-dependent entity2_term nucleation.
Arp2
actin
1
The verprolin-like central (vc) region of entity1_term induces Arp2/3 complex-dependent entity2_term nucleation.
Wiskott-Aldrich syndrome protein
actin
1
The verprolin-like central (vc) region of Wiskott-Aldrich syndrome protein induces entity1_term2/3 complex-dependent entity2_term nucleation.
Arp
actin
1
The verprolin-like central (vc) region of entity1_term induces entity2_term/3 complex-dependent actin nucleation.
Wiskott-Aldrich syndrome protein
Arp2
0
The entity1_term-like central (vc) region of Wiskott-Aldrich syndrome protein induces entity2_term/3 complex-dependent actin nucleation.
verprolin
Arp2
0
The verprolin-like central (vc) region of entity1_term induces entity2_term2/3 complex-dependent actin nucleation.
Wiskott-Aldrich syndrome protein
Arp
0
The entity1_term-like central (vc) region of Wiskott-Aldrich syndrome protein induces Arp2/3 complex-dependent entity2_term nucleation.
verprolin
actin
0
The entity1_term-like central (vc) region of Wiskott-Aldrich syndrome protein induces entity2_term2/3 complex-dependent actin nucleation.
verprolin
Arp
0
Suppression of cell transformation by the entity1_term entity2_term requires binding to proliferating cell nuclear antigen.
cyclin-dependent kinase inhibitor
p57KIP2
1
Suppression of cell transformation by the cyclin-dependent kinase inhibitor entity1_term requires binding to entity2_term.
p57KIP2
proliferating cell nuclear antigen
1
Suppression of cell transformation by the entity1_term p57KIP2 requires binding to entity2_term.
cyclin-dependent kinase inhibitor
proliferating cell nuclear antigen
0
The Saccharomyces cerevisiae entity1_term gene belongs to the entity2_term, MEC3 and RAD24 epistasis group which, together with RAD9, is proposed to act at the beginning of the DNA damage checkpoint pathway.
DDC1
RAD17
1
The Saccharomyces cerevisiae entity1_term gene belongs to the RAD17, MEC3 and entity2_term epistasis group which, together with RAD9, is proposed to act at the beginning of the DNA damage checkpoint pathway.
DDC1
RAD24
1
The Saccharomyces cerevisiae DDC1 gene belongs to the entity1_term, MEC3 and entity2_term epistasis group which, together with RAD9, is proposed to act at the beginning of the DNA damage checkpoint pathway.
RAD17
RAD24
1
The Saccharomyces cerevisiae entity1_term gene belongs to the RAD17, entity2_term and RAD24 epistasis group which, together with RAD9, is proposed to act at the beginning of the DNA damage checkpoint pathway.
DDC1
MEC3
1
The Saccharomyces cerevisiae DDC1 gene belongs to the entity1_term, entity2_term and RAD24 epistasis group which, together with RAD9, is proposed to act at the beginning of the DNA damage checkpoint pathway.
RAD17
MEC3
1
The Saccharomyces cerevisiae DDC1 gene belongs to the RAD17, entity1_term and entity2_term epistasis group which, together with RAD9, is proposed to act at the beginning of the DNA damage checkpoint pathway.
MEC3
RAD24
1
The Saccharomyces cerevisiae DDC1 gene belongs to the entity1_term, MEC3 and RAD24 epistasis group which, together with entity2_term, is proposed to act at the beginning of the DNA damage checkpoint pathway.
RAD17
RAD9
0
The Saccharomyces cerevisiae DDC1 gene belongs to the RAD17, entity1_term and RAD24 epistasis group which, together with entity2_term, is proposed to act at the beginning of the DNA damage checkpoint pathway.
MEC3
RAD9
0
The Saccharomyces cerevisiae entity1_term gene belongs to the RAD17, MEC3 and RAD24 epistasis group which, together with entity2_term, is proposed to act at the beginning of the DNA damage checkpoint pathway.
DDC1
RAD9
0
The Saccharomyces cerevisiae DDC1 gene belongs to the RAD17, MEC3 and entity1_term epistasis group which, together with entity2_term, is proposed to act at the beginning of the DNA damage checkpoint pathway.
RAD24
RAD9
0
Characterization of entity1_term truncates that inhibit entity2_term depolymerization by severing activity of gelsolin and cofilin.
gelsolin
actin
1
Characterization of entity1_term truncates that inhibit actin depolymerization by severing activity of entity2_term and cofilin.
gelsolin
gelsolin
1
Characterization of entity1_term truncates that inhibit actin depolymerization by severing activity of gelsolin and entity2_term.
gelsolin
cofilin
1
Characterization of gelsolin truncates that inhibit entity1_term depolymerization by severing activity of entity2_term and cofilin.
actin
gelsolin
1
Characterization of gelsolin truncates that inhibit entity1_term depolymerization by severing activity of gelsolin and entity2_term.
actin
cofilin
1
Characterization of gelsolin truncates that inhibit actin depolymerization by severing activity of entity1_term and entity2_term.
gelsolin
cofilin
0
Our data indicate that even profilins of highly distant evolutionary origin can functionally substitute for each other and support the hypothesis that in animal cells, entity1_term are engaged in regulating either the stability or the kinetic properties of entity2_term filaments.
profilins
actin
1
Our data indicate that even entity1_term of highly distant evolutionary origin can functionally substitute for each other and support the hypothesis that in animal cells, entity2_term are engaged in regulating either the stability or the kinetic properties of actin filaments.
profilins
profilins
0
Our data indicate that even entity1_term of highly distant evolutionary origin can functionally substitute for each other and support the hypothesis that in animal cells, profilins are engaged in regulating either the stability or the kinetic properties of entity2_term filaments.
profilins
actin
0
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "entity1_term" with alpha-catenin, entity2_term, p120, and vinculin, and the association of these complexes with the actin microfilaments.
pancadherin
beta-catenin
1
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "entity1_term" with entity2_term, beta-catenin, p120, and vinculin, and the association of these complexes with the actin microfilaments.
pancadherin
alpha-catenin
1
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "entity1_term" with alpha-catenin, beta-catenin, p120, and entity2_term, and the association of these complexes with the actin microfilaments.
pancadherin
vinculin
1
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "entity1_term" with alpha-catenin, beta-catenin, entity2_term, and vinculin, and the association of these complexes with the actin microfilaments.
pancadherin
p120
1
We describe the localization of cadherin-11 and entity1_term along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, entity2_term, p120, and vinculin, and the association of these complexes with the actin microfilaments.
N-cadherin
beta-catenin
0
We describe the localization of cadherin-11 and entity1_term along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with entity2_term, beta-catenin, p120, and vinculin, and the association of these complexes with the actin microfilaments.
N-cadherin
alpha-catenin
0
We describe the localization of cadherin-11 and entity1_term along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, beta-catenin, p120, and entity2_term, and the association of these complexes with the actin microfilaments.
N-cadherin
vinculin
0
We describe the localization of entity1_term and entity2_term along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, beta-catenin, p120, and vinculin, and the association of these complexes with the actin microfilaments.
cadherin-11
N-cadherin
0
We describe the localization of cadherin-11 and entity1_term along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, beta-catenin, p120, and vinculin, and the association of these complexes with the entity2_term microfilaments.
N-cadherin
actin
0
We describe the localization of cadherin-11 and entity1_term along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, beta-catenin, entity2_term, and vinculin, and the association of these complexes with the actin microfilaments.
N-cadherin
p120
0
We describe the localization of cadherin-11 and entity1_term along the cell margins of mouse osteoblast-like cells, the colocalization of "entity2_term" with alpha-catenin, beta-catenin, p120, and vinculin, and the association of these complexes with the actin microfilaments.
N-cadherin
pancadherin
0
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with entity1_term, entity2_term, p120, and vinculin, and the association of these complexes with the actin microfilaments.
alpha-catenin
beta-catenin
0
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, entity1_term, p120, and entity2_term, and the association of these complexes with the actin microfilaments.
beta-catenin
vinculin
0
We describe the localization of entity1_term and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, entity2_term, p120, and vinculin, and the association of these complexes with the actin microfilaments.
cadherin-11
beta-catenin
0
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, entity1_term, p120, and vinculin, and the association of these complexes with the entity2_term microfilaments.
beta-catenin
actin
0
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, entity1_term, entity2_term, and vinculin, and the association of these complexes with the actin microfilaments.
beta-catenin
p120
0
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with entity1_term, beta-catenin, p120, and entity2_term, and the association of these complexes with the actin microfilaments.
alpha-catenin
vinculin
0
We describe the localization of entity1_term and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with entity2_term, beta-catenin, p120, and vinculin, and the association of these complexes with the actin microfilaments.
cadherin-11
alpha-catenin
0
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with entity1_term, beta-catenin, p120, and vinculin, and the association of these complexes with the entity2_term microfilaments.
alpha-catenin
actin
0
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with entity1_term, beta-catenin, entity2_term, and vinculin, and the association of these complexes with the actin microfilaments.
alpha-catenin
p120
0
We describe the localization of entity1_term and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, beta-catenin, p120, and entity2_term, and the association of these complexes with the actin microfilaments.
cadherin-11
vinculin
0
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, beta-catenin, p120, and entity1_term, and the association of these complexes with the entity2_term microfilaments.
vinculin
actin
0
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, beta-catenin, entity1_term, and entity2_term, and the association of these complexes with the actin microfilaments.
p120
vinculin
0
We describe the localization of entity1_term and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, beta-catenin, p120, and vinculin, and the association of these complexes with the entity2_term microfilaments.
cadherin-11
actin
0
We describe the localization of entity1_term and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, beta-catenin, entity2_term, and vinculin, and the association of these complexes with the actin microfilaments.
cadherin-11
p120
0
We describe the localization of entity1_term and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "entity2_term" with alpha-catenin, beta-catenin, p120, and vinculin, and the association of these complexes with the actin microfilaments.
cadherin-11
pancadherin
0
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "pancadherin" with alpha-catenin, beta-catenin, entity1_term, and vinculin, and the association of these complexes with the entity2_term microfilaments.
p120
actin
0
We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of "entity1_term" with alpha-catenin, beta-catenin, p120, and vinculin, and the association of these complexes with the entity2_term microfilaments.
pancadherin
actin
0
entity1_term binds to entity2_term in vitro and hence is an actin binding protein.
Platelet talin
actin
1
entity1_term binds to actin in vitro and hence is an entity2_term.
Platelet talin
actin binding protein
1
Binding of entity1_term to entity2_term occurs at a maximal molar ratio of 1:3 as determined by fluorescencetitration under G-buffer conditions.
talin
actin
1
Platelet talin binds to entity1_term in vitro and hence is an entity2_term.
actin
actin binding protein
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the entity1_term (CKIs) p27 and entity2_term, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin-dependent kinase inhibitors
p57
1
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the entity1_term (CKIs) entity2_term and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin-dependent kinase inhibitors
p27
1
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors (entity1_term) p27 and entity2_term, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
CKIs
p57
1
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors (entity1_term) entity2_term and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
CKIs
p27
1
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, entity1_term, cyclin D1, the cyclin-dependent kinase inhibitors (CKIs) p27 and entity2_term, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin B1
p57
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, entity1_term, entity2_term, the cyclin-dependent kinase inhibitors (CKIs) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin B1
cyclin D1
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of entity1_term, entity2_term, cyclin D1, the cyclin-dependent kinase inhibitors (CKIs) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin A
cyclin B1
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, entity1_term, cyclin D1, the cyclin-dependent kinase inhibitors (CKIs) entity2_term and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin B1
p27
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, entity1_term, cyclin D1, the entity2_term (CKIs) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin B1
cyclin-dependent kinase inhibitors
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, entity1_term, cyclin D1, the cyclin-dependent kinase inhibitors (entity2_term) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin B1
CKIs
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, entity1_term, the cyclin-dependent kinase inhibitors (CKIs) p27 and entity2_term, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin D1
p57
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of entity1_term, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors (CKIs) p27 and entity2_term, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin A
p57
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors (CKIs) entity1_term and entity2_term, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
p27
p57
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of entity1_term, cyclin B1, entity2_term, the cyclin-dependent kinase inhibitors (CKIs) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin A
cyclin D1
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, entity1_term, the cyclin-dependent kinase inhibitors (CKIs) entity2_term and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin D1
p27
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, entity1_term, the entity2_term (CKIs) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin D1
cyclin-dependent kinase inhibitors
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, entity1_term, the cyclin-dependent kinase inhibitors (entity2_term) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin D1
CKIs
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of entity1_term, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors (CKIs) entity2_term and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin A
p27
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of entity1_term, cyclin B1, cyclin D1, the entity2_term (CKIs) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin A
cyclin-dependent kinase inhibitors
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of entity1_term, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors (entity2_term) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin A
CKIs
0
To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the entity1_term (entity2_term) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.
cyclin-dependent kinase inhibitors
CKIs
0
Impact of entity1_term on actin-bound nucleotide exchange and entity2_term polymerization dynamics.
profilin
actin
1
Impact of entity1_term on entity2_term-bound nucleotide exchange and actin polymerization dynamics.
profilin
actin
0
Impact of profilin on entity1_term-bound nucleotide exchange and entity2_term polymerization dynamics.
actin
actin
0
In this study, we evaluated the prognostic significance of entity1_term, entity2_term, and beta-catenin expressions in the metastatic foci of patients with colorectal carcinoma.
E-cadherin
alpha-catenin
0
In this study, we evaluated the prognostic significance of E-cadherin, entity1_term, and entity2_term expressions in the metastatic foci of patients with colorectal carcinoma.
alpha-catenin
beta-catenin
0
RESULTS: Reduced normal expression of entity1_term, alpha-catenin, and entity2_term in comparison with normal epithelium was detected in 78 primary tumors, respectively.
E-cadherin
beta-catenin
0
RESULTS: Reduced normal expression of entity1_term, entity2_term, and beta-catenin in comparison with normal epithelium was detected in 78 primary tumors, respectively.
E-cadherin
alpha-catenin
0
In this study, we evaluated the prognostic significance of entity1_term, alpha-catenin, and entity2_term expressions in the metastatic foci of patients with colorectal carcinoma.
E-cadherin
beta-catenin
0
RESULTS: Reduced normal expression of E-cadherin, entity1_term, and entity2_term in comparison with normal epithelium was detected in 78 primary tumors, respectively.
alpha-catenin
beta-catenin
0
BACKGROUND AND OBJECTIVES: Reduced expressions of cell adhesion molecules (entity1_term, entity2_term, and beta-catenin) has been reported to be associated with tumor metastasis.
E-cadherin
alpha-catenin
0
BACKGROUND AND OBJECTIVES: Reduced expressions of cell adhesion molecules (entity1_term, alpha-catenin, and entity2_term) has been reported to be associated with tumor metastasis.
E-cadherin
beta-catenin
0
BACKGROUND AND OBJECTIVES: Reduced expressions of cell adhesion molecules (E-cadherin, entity1_term, and entity2_term) has been reported to be associated with tumor metastasis.
alpha-catenin
beta-catenin
0
We have analyzed the expression levels of the genes encoding entity1_term, beta-catenin and plakoglobin in correlation to the entity2_term expression levels in cell lines derived from human cervical carcinomas.
alpha-catenin
E-cadherin
0
We have analyzed the expression levels of the genes encoding alpha-catenin, entity1_term and plakoglobin in correlation to the entity2_term expression levels in cell lines derived from human cervical carcinomas.
beta-catenin
E-cadherin
0
We have analyzed the expression levels of the genes encoding alpha-catenin, beta-catenin and entity1_term in correlation to the entity2_term expression levels in cell lines derived from human cervical carcinomas.
plakoglobin
E-cadherin
0
We have analyzed the expression levels of the genes encoding entity1_term, entity2_term and plakoglobin in correlation to the E-cadherin expression levels in cell lines derived from human cervical carcinomas.
alpha-catenin
beta-catenin
0
We have analyzed the expression levels of the genes encoding entity1_term, beta-catenin and entity2_term in correlation to the E-cadherin expression levels in cell lines derived from human cervical carcinomas.
alpha-catenin
plakoglobin
0
We have analyzed the expression levels of the genes encoding alpha-catenin, entity1_term and entity2_term in correlation to the E-cadherin expression levels in cell lines derived from human cervical carcinomas.
beta-catenin
plakoglobin
0
Our results showed that cell morphology, cell adhesion pattern, entity1_term organization, and distribution of integrin subunits, talin, vinculin, and phosphotyrosine-containing proteins are dependent on the supramolecular organization of the entity2_term.
actin
collagens
1
Our results showed that cell morphology, cell adhesion pattern, actin organization, and distribution of integrin subunits, talin, entity1_term, and phosphotyrosine-containing proteins are dependent on the supramolecular organization of the entity2_term.
vinculin
collagens
1
Our results showed that cell morphology, cell adhesion pattern, actin organization, and distribution of integrin subunits, entity1_term, vinculin, and phosphotyrosine-containing proteins are dependent on the supramolecular organization of the entity2_term.
talin
collagens
1
Our results showed that cell morphology, cell adhesion pattern, actin organization, and distribution of entity1_term subunits, talin, vinculin, and phosphotyrosine-containing proteins are dependent on the supramolecular organization of the entity2_term.
integrin
collagens
1
Our results showed that cell morphology, cell adhesion pattern, entity1_term organization, and distribution of entity2_term subunits, talin, vinculin, and phosphotyrosine-containing proteins are dependent on the supramolecular organization of the collagens.
actin
integrin
0
Our results showed that cell morphology, cell adhesion pattern, entity1_term organization, and distribution of integrin subunits, entity2_term, vinculin, and phosphotyrosine-containing proteins are dependent on the supramolecular organization of the collagens.
actin
talin
0
Our results showed that cell morphology, cell adhesion pattern, entity1_term organization, and distribution of integrin subunits, talin, entity2_term, and phosphotyrosine-containing proteins are dependent on the supramolecular organization of the collagens.
actin
vinculin
0
Our results showed that cell morphology, cell adhesion pattern, actin organization, and distribution of entity1_term subunits, entity2_term, vinculin, and phosphotyrosine-containing proteins are dependent on the supramolecular organization of the collagens.
integrin
talin
0
Our results showed that cell morphology, cell adhesion pattern, actin organization, and distribution of entity1_term subunits, talin, entity2_term, and phosphotyrosine-containing proteins are dependent on the supramolecular organization of the collagens.
integrin
vinculin
0
Our results showed that cell morphology, cell adhesion pattern, actin organization, and distribution of integrin subunits, entity1_term, entity2_term, and phosphotyrosine-containing proteins are dependent on the supramolecular organization of the collagens.
talin
vinculin
0
To check its applicability, well characterized, commercially available antibodies (against entity1_term, entity2_term, and beta-catenin) were used on sections of human small intestine.
E-cadherin
alpha-catenin
0
To check its applicability, well characterized, commercially available antibodies (against E-cadherin, entity1_term, and entity2_term) were used on sections of human small intestine.
alpha-catenin
beta-catenin
0
To check its applicability, well characterized, commercially available antibodies (against entity1_term, alpha-catenin, and entity2_term) were used on sections of human small intestine.
E-cadherin
beta-catenin
0
Immunostaining showed that APBs also contain entity1_term, entity2_term, and RAD52, proteins involved in DNA synthesis and recombination.
replication factor A
RAD51
1
Immunostaining showed that APBs also contain entity1_term, RAD51, and entity2_term, proteins involved in DNA synthesis and recombination.
replication factor A
RAD52
1
Immunostaining showed that APBs also contain replication factor A, entity1_term, and entity2_term, proteins involved in DNA synthesis and recombination.
RAD51
RAD52
1
We examined the role of the actin monomer sequestering protein, entity1_term, in the regulation of entity2_term filament assembly during chemoattractant stimulation using a Triton extraction method.
profilin
PMN actin
1
Although profilin released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of entity1_term in PMN was insufficient to explain the high unpolymerized entity2_term content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
profilin
actin
1
We examined the role of the entity1_term monomer sequestering protein, entity2_term, in the regulation of PMN actin filament assembly during chemoattractant stimulation using a Triton extraction method.
actin
profilin
1
Although profilin released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of entity1_term released from entity2_term too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
actin
profilin
1
Although profilin released entity1_term at the appropriate time to stimulate entity2_term assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
actin
actin
1
Although entity1_term released entity2_term at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
profilin
actin
1
Although profilin released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of entity1_term released from profilin too small to account for the large shifts from unpolymerized to polymerized entity2_term associated with maximal chemoattractant stimulation.
actin
actin
1
Although entity1_term released actin at the appropriate time to stimulate entity2_term assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
profilin
actin
1
Although entity1_term released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of entity2_term released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
profilin
actin
0
Although entity1_term released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of entity2_term in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
profilin
profilin
0
Although entity1_term released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized entity2_term associated with maximal chemoattractant stimulation.
profilin
actin
0
Although entity1_term released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized entity2_term content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
profilin
actin
0
Although entity1_term released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from entity2_term too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
profilin
profilin
0
Although profilin released actin at the appropriate time to stimulate entity1_term assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of entity2_term released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
actin
actin
0
Although profilin released actin at the appropriate time to stimulate entity1_term assembly during exposure to chemoattractants, the concentration of entity2_term in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
actin
profilin
0
Although profilin released actin at the appropriate time to stimulate entity1_term assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized entity2_term associated with maximal chemoattractant stimulation.
actin
actin
0
Although profilin released actin at the appropriate time to stimulate entity1_term assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized entity2_term content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
actin
actin
0
Although profilin released actin at the appropriate time to stimulate entity1_term assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from entity2_term too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
actin
profilin
0
Although profilin released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of entity1_term in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of entity2_term released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
profilin
actin
0
Although profilin released entity1_term at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of entity2_term released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
actin
actin
0
Although profilin released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized entity1_term content in unstimulated PMN and the quantity of entity2_term released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
actin
actin
0
Although profilin released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of entity1_term in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized entity2_term associated with maximal chemoattractant stimulation.
profilin
actin
0
Although profilin released entity1_term at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of entity2_term in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
actin
profilin
0
Although profilin released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of entity1_term in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from entity2_term too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
profilin
profilin
0
Although profilin released entity1_term at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized entity2_term associated with maximal chemoattractant stimulation.
actin
actin
0
Although profilin released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized entity1_term content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized entity2_term associated with maximal chemoattractant stimulation.
actin
actin
0
Although profilin released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from entity1_term too small to account for the large shifts from unpolymerized to polymerized entity2_term associated with maximal chemoattractant stimulation.
profilin
actin
0
Although profilin released entity1_term at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized entity2_term content in unstimulated PMN and the quantity of actin released from profilin too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
actin
actin
0
Although profilin released entity1_term at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized actin content in unstimulated PMN and the quantity of actin released from entity2_term too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
actin
profilin
0
Although profilin released actin at the appropriate time to stimulate actin assembly during exposure to chemoattractants, the concentration of profilin in PMN was insufficient to explain the high unpolymerized entity1_term content in unstimulated PMN and the quantity of actin released from entity2_term too small to account for the large shifts from unpolymerized to polymerized actin associated with maximal chemoattractant stimulation.
actin
profilin
0
Determination of the total entity1_term and actin concentrations in PMN revealed that the molar ratio of profilin to entity2_term was 1 to 5.2.
profilin
actin
0
Determination of the total profilin and actin concentrations in PMN revealed that the molar ratio of entity1_term to entity2_term was 1 to 5.2.
profilin
actin
0
Determination of the total profilin and entity1_term concentrations in PMN revealed that the molar ratio of profilin to entity2_term was 1 to 5.2.
actin
actin
0
Determination of the total entity1_term and actin concentrations in PMN revealed that the molar ratio of entity2_term to actin was 1 to 5.2.
profilin
profilin
0
Determination of the total entity1_term and entity2_term concentrations in PMN revealed that the molar ratio of profilin to actin was 1 to 5.2.
profilin
actin
0
Determination of the total profilin and entity1_term concentrations in PMN revealed that the molar ratio of entity2_term to actin was 1 to 5.2.
actin
profilin
0
We examined the role of the entity1_term monomer sequestering protein, profilin, in the regulation of entity2_term filament assembly during chemoattractant stimulation using a Triton extraction method.
actin
PMN actin
0
Location of entity1_term at presynaptic sites in the cerebellar cortex; implication for the regulation of the entity2_term-polymerization state during axonal elongation and synaptogenesis.
profilin
actin
0
The most significant finding was the re-expression of entity1_term, alpha-catenin, and beta-catenin, and increased down-regulation of entity2_term, in metastatic lesions.
E-cadherin
gamma-catenin
0
The most significant finding was the re-expression of entity1_term, alpha-catenin, and entity2_term, and increased down-regulation of gamma-catenin, in metastatic lesions.
E-cadherin
beta-catenin
0
The most significant finding was the re-expression of entity1_term, entity2_term, and beta-catenin, and increased down-regulation of gamma-catenin, in metastatic lesions.
E-cadherin
alpha-catenin
0
The most significant finding was the re-expression of E-cadherin, alpha-catenin, and entity1_term, and increased down-regulation of entity2_term, in metastatic lesions.
beta-catenin
gamma-catenin
0
The most significant finding was the re-expression of E-cadherin, entity1_term, and beta-catenin, and increased down-regulation of entity2_term, in metastatic lesions.
alpha-catenin
gamma-catenin
0
The most significant finding was the re-expression of E-cadherin, entity1_term, and entity2_term, and increased down-regulation of gamma-catenin, in metastatic lesions.
alpha-catenin
beta-catenin
0
The herpes simplex virus type 1 (HSV) entity1_term, UL8, and entity2_term proteins form a helicase-primase complex in infected cells.
UL5
UL52
1
The herpes simplex virus type 1 (HSV) entity1_term, entity2_term, and UL52 proteins form a helicase-primase complex in infected cells.
UL5
UL8
1
The entity1_term component of the herpes simplex virus helicase-primase complex stimulates primer synthesis by a subassembly of the entity2_term and UL52 components.
UL8
UL5
1
The herpes simplex virus type 1 (HSV) UL5, entity1_term, and entity2_term proteins form a helicase-primase complex in infected cells.
UL8
UL52
1
The UL8 component of the herpes simplex virus helicase-primase complex stimulates primer synthesis by a subassembly of the entity1_term and entity2_term components.
UL5
UL52
1
The entity1_term component of the herpes simplex virus entity2_term complex stimulates primer synthesis by a subassembly of the UL5 and UL52 components.
UL8
helicase-primase
1
The entity1_term component of the herpes simplex virus helicase-primase complex stimulates primer synthesis by a subassembly of the UL5 and entity2_term components.
UL8
UL52
1
The UL8 component of the herpes simplex virus entity1_term complex stimulates primer synthesis by a subassembly of the entity2_term and UL52 components.
helicase-primase
UL5
0
The UL8 component of the herpes simplex virus entity1_term complex stimulates primer synthesis by a subassembly of the UL5 and entity2_term components.
helicase-primase
UL52
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of entity1_term, alpha-catenin, entity2_term, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.
N-cadherin
beta-catenin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, entity1_term, plakoglobin, entity2_term, alpha-actinin and vinculin that were equivalent to epithelioid cells.
beta-catenin
p120
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, entity1_term, entity2_term, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.
alpha-catenin
beta-catenin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, entity1_term, plakoglobin, p120, entity2_term and vinculin that were equivalent to epithelioid cells.
beta-catenin
alpha-actinin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, entity1_term, entity2_term, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.
beta-catenin
plakoglobin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, entity1_term, plakoglobin, p120, alpha-actinin and entity2_term that were equivalent to epithelioid cells.
beta-catenin
vinculin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of entity1_term, alpha-catenin, beta-catenin, plakoglobin, entity2_term, alpha-actinin and vinculin that were equivalent to epithelioid cells.
N-cadherin
p120
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of entity1_term, entity2_term, beta-catenin, plakoglobin, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.
N-cadherin
alpha-catenin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of entity1_term, alpha-catenin, beta-catenin, plakoglobin, p120, entity2_term and vinculin that were equivalent to epithelioid cells.
N-cadherin
alpha-actinin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of entity1_term, alpha-catenin, beta-catenin, entity2_term, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.
N-cadherin
plakoglobin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of entity1_term, alpha-catenin, beta-catenin, plakoglobin, p120, alpha-actinin and entity2_term that were equivalent to epithelioid cells.
N-cadherin
vinculin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, entity1_term, beta-catenin, plakoglobin, entity2_term, alpha-actinin and vinculin that were equivalent to epithelioid cells.
alpha-catenin
p120
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, entity1_term, entity2_term and vinculin that were equivalent to epithelioid cells.
p120
alpha-actinin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, entity1_term, entity2_term, alpha-actinin and vinculin that were equivalent to epithelioid cells.
plakoglobin
p120
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, entity1_term, alpha-actinin and entity2_term that were equivalent to epithelioid cells.
p120
vinculin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, entity1_term, beta-catenin, plakoglobin, p120, entity2_term and vinculin that were equivalent to epithelioid cells.
alpha-catenin
alpha-actinin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, entity1_term, beta-catenin, entity2_term, p120, alpha-actinin and vinculin that were equivalent to epithelioid cells.
alpha-catenin
plakoglobin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, entity1_term, beta-catenin, plakoglobin, p120, alpha-actinin and entity2_term that were equivalent to epithelioid cells.
alpha-catenin
vinculin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, entity1_term, p120, entity2_term and vinculin that were equivalent to epithelioid cells.
plakoglobin
alpha-actinin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, plakoglobin, p120, entity1_term and entity2_term that were equivalent to epithelioid cells.
alpha-actinin
vinculin
0
Fusiform RPE, however, were not deficient in these proteins, expressing amounts of N-cadherin, alpha-catenin, beta-catenin, entity1_term, p120, alpha-actinin and entity2_term that were equivalent to epithelioid cells.
plakoglobin
vinculin
0
Structural studies on the ribbon-to-helix transition in entity1_term: entity2_term crystals.
profilin
actin
0
entity1_term is a T cell activation antigen known to bind adenosine deaminase and have entity2_term activity.
CD26
dipeptidyl peptidase IV
1
entity1_term is a T cell activation antigen known to bind entity2_term and have dipeptidyl peptidase IV activity.
CD26
adenosine deaminase
1
CD26 is a T cell activation antigen known to bind entity1_term and have entity2_term activity.
adenosine deaminase
dipeptidyl peptidase IV
0
These findings reveal striking differences between S. cerevisiae and vertebrates in the functions of entity1_term and entity2_term.
RAD51
RAD52
0
Transcriptional regulation in the galactose regulon of yeast is determined by an interplay between a positive regulatory protein, entity1_term, and a negative regulatory protein, entity2_term.
GAL4
GAL80
1
In addition to the TNF-alpha-induced increase in the general protein synthesis, stimulation with entity1_term led to a 2.4-fold increase in net entity2_term protein synthesis and a 3.3-fold increase in net myosin heavy chain synthesis.
TNF-alpha
actin
1
In addition to the TNF-alpha-induced increase in the general protein synthesis, stimulation with entity1_term led to a 2.4-fold increase in net actin protein synthesis and a 3.3-fold increase in net entity2_term synthesis.
TNF-alpha
myosin heavy chain
1
In addition to the entity1_term-induced increase in the general protein synthesis, stimulation with entity2_term led to a 2.4-fold increase in net actin protein synthesis and a 3.3-fold increase in net myosin heavy chain synthesis.
TNF-alpha
TNF-alpha
0
In addition to the entity1_term-induced increase in the general protein synthesis, stimulation with TNF-alpha led to a 2.4-fold increase in net actin protein synthesis and a 3.3-fold increase in net entity2_term synthesis.
TNF-alpha
myosin heavy chain
0
In addition to the TNF-alpha-induced increase in the general protein synthesis, stimulation with TNF-alpha led to a 2.4-fold increase in net entity1_term protein synthesis and a 3.3-fold increase in net entity2_term synthesis.
actin
myosin heavy chain
0
In addition to the entity1_term-induced increase in the general protein synthesis, stimulation with TNF-alpha led to a 2.4-fold increase in net entity2_term protein synthesis and a 3.3-fold increase in net myosin heavy chain synthesis.
TNF-alpha
actin
0
entity1_term binds profilin likely to promote entity2_term polymerization.
mDia
actin
1
mDia binds entity1_term likely to promote entity2_term polymerization.
profilin
actin
1
entity1_term binds entity2_term likely to promote actin polymerization.
mDia
profilin
1
Immuno-EM double-labeling experiments were conducted with antibodies to actin together with antibodies to the entity1_term Abp1p and entity2_term.
actin binding proteins
cofilin
1
Immuno-EM double-labeling experiments were conducted with antibodies to actin together with antibodies to the entity1_term entity2_term and cofilin.
actin binding proteins
Abp1p
1
As expected from immunofluorescence experiments, entity1_term, entity2_term, and actin colocalized in immuno-EM to the dense patchlike structures but not to the cables.
Abp1p
cofilin
1
As expected from immunofluorescence experiments, entity1_term, cofilin, and entity2_term colocalized in immuno-EM to the dense patchlike structures but not to the cables.
Abp1p
actin
1
As expected from immunofluorescence experiments, Abp1p, entity1_term, and entity2_term colocalized in immuno-EM to the dense patchlike structures but not to the cables.
cofilin
actin
1
Immuno-EM double-labeling experiments were conducted with antibodies to entity1_term together with antibodies to the actin binding proteins entity2_term and cofilin.
actin
Abp1p
0
Immuno-EM double-labeling experiments were conducted with antibodies to actin together with antibodies to the actin binding proteins entity1_term and entity2_term.
Abp1p
cofilin
0
Immuno-EM double-labeling experiments were conducted with antibodies to entity1_term together with antibodies to the actin binding proteins Abp1p and entity2_term.
actin
cofilin
0
Immuno-EM double-labeling experiments were conducted with antibodies to entity1_term together with antibodies to the entity2_term Abp1p and cofilin.
actin
actin binding proteins
0
Only the unphosphorylated form of entity1_term is an active form that binds entity2_term, whereas the regulatory mechanisms of cofilin have not been elucidated.
cofilin
actin
1
Only the unphosphorylated form of entity1_term is an active form that binds actin, whereas the regulatory mechanisms of entity2_term have not been elucidated.
cofilin
cofilin
0
Only the unphosphorylated form of cofilin is an active form that binds entity1_term, whereas the regulatory mechanisms of entity2_term have not been elucidated.
actin
cofilin
0
We investigated entity1_term filament turnover rates, length, number, barbed end exposure, and binding of entity2_term in bovine arterial endothelial cells moving at different speeds depending on their position in a confluent monolayer.
actin
cofilin
1
Since entity1_term is required for cadherin-mediated adhesion, the entity2_term repeat region alone probably cannot promote cell adhesion, making it unlikely that beta-catenin induces axis duplication by increasing cell adhesion.
alpha-catenin
armadillo
0
Since entity1_term is required for cadherin-mediated adhesion, the armadillo repeat region alone probably cannot promote cell adhesion, making it unlikely that entity2_term induces axis duplication by increasing cell adhesion.
alpha-catenin
beta-catenin
0
Since entity1_term is required for entity2_term-mediated adhesion, the armadillo repeat region alone probably cannot promote cell adhesion, making it unlikely that beta-catenin induces axis duplication by increasing cell adhesion.
alpha-catenin
cadherin
0
Since alpha-catenin is required for cadherin-mediated adhesion, the entity1_term repeat region alone probably cannot promote cell adhesion, making it unlikely that entity2_term induces axis duplication by increasing cell adhesion.
armadillo
beta-catenin
0
Since alpha-catenin is required for entity1_term-mediated adhesion, the entity2_term repeat region alone probably cannot promote cell adhesion, making it unlikely that beta-catenin induces axis duplication by increasing cell adhesion.
cadherin
armadillo
0
Since alpha-catenin is required for entity1_term-mediated adhesion, the armadillo repeat region alone probably cannot promote cell adhesion, making it unlikely that entity2_term induces axis duplication by increasing cell adhesion.
cadherin
beta-catenin
0
The results clearly showed that the mutated cofilin possessing KTLKK instead of KKRKK did not translocate into the nuclei in response to heat shock whereas a recombinant entity1_term with the unaltered sequence of KKRKK responded to heat shock and formed intranuclear rods together with entity2_term.
cofilin
actin
1
The results clearly showed that the mutated entity1_term possessing KTLKK instead of KKRKK did not translocate into the nuclei in response to heat shock whereas a recombinant entity2_term with the unaltered sequence of KKRKK responded to heat shock and formed intranuclear rods together with actin.
cofilin
cofilin
0
The results clearly showed that the mutated entity1_term possessing KTLKK instead of KKRKK did not translocate into the nuclei in response to heat shock whereas a recombinant cofilin with the unaltered sequence of KKRKK responded to heat shock and formed intranuclear rods together with entity2_term.
cofilin
actin
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, entity1_term and membrane protein (M) gene sequences; another, entity2_term and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains entity1_term (NP) and phosphoprotein (P) gene sequences; another, entity2_term and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
nucleocapsid protein
P
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, entity1_term and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, entity2_term and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, entity1_term and membrane protein (entity2_term) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and entity1_term (P) gene sequences; another, entity2_term and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
phosphoprotein
P
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (entity1_term) and phosphoprotein (P) gene sequences; another, entity2_term and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
NP
P
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, entity1_term and membrane protein (M) gene sequences; another, M and fusion protein (entity2_term) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, entity1_term and membrane protein (M) gene sequences; another, M and entity2_term (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
fusion protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, entity1_term and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (entity2_term) gene sequences.
P
HN
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (entity1_term) gene sequences; another, entity2_term and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
P
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, entity1_term and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and entity2_term (HN) gene sequences.
P
hemagglutinin-neuraminidase protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, entity1_term and entity2_term (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
membrane protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains entity1_term (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, entity2_term and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
nucleocapsid protein
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, entity1_term and fusion protein (F0) gene sequences; and another, entity2_term and hemagglutinin-neuraminidase protein (HN) gene sequences.
M
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (entity1_term) gene sequences; another, entity2_term and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
M
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and entity1_term (P) gene sequences; another, P and membrane protein (M) gene sequences; another, entity2_term and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
phosphoprotein
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (entity1_term) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, entity2_term and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
NP
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, entity1_term and fusion protein (entity2_term) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
M
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, entity1_term and entity2_term (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
M
fusion protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, entity1_term and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (entity2_term) gene sequences.
M
HN
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (entity1_term) gene sequences; another, P and membrane protein (M) gene sequences; another, entity2_term and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, entity1_term and fusion protein (F0) gene sequences; and another, F0 and entity2_term (HN) gene sequences.
M
hemagglutinin-neuraminidase protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and entity1_term (M) gene sequences; another, entity2_term and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
membrane protein
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains entity1_term (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, entity2_term and hemagglutinin-neuraminidase protein (HN) gene sequences.
nucleocapsid protein
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains entity1_term (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (entity2_term) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
nucleocapsid protein
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains entity1_term (NP) and entity2_term (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
nucleocapsid protein
phosphoprotein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains entity1_term (entity2_term) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
nucleocapsid protein
NP
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains entity1_term (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (entity2_term) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
nucleocapsid protein
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains entity1_term (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and entity2_term (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
nucleocapsid protein
fusion protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains entity1_term (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (entity2_term) gene sequences.
nucleocapsid protein
HN
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains entity1_term (NP) and phosphoprotein (entity2_term) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
nucleocapsid protein
P
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains entity1_term (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and entity2_term (HN) gene sequences.
nucleocapsid protein
hemagglutinin-neuraminidase protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains entity1_term (NP) and phosphoprotein (P) gene sequences; another, P and entity2_term (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
nucleocapsid protein
membrane protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (entity1_term) gene sequences; another, M and fusion protein (F0) gene sequences; and another, entity2_term and hemagglutinin-neuraminidase protein (HN) gene sequences.
M
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and entity1_term (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, entity2_term and hemagglutinin-neuraminidase protein (HN) gene sequences.
phosphoprotein
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (entity1_term) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, entity2_term and hemagglutinin-neuraminidase protein (HN) gene sequences.
NP
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (entity1_term) gene sequences; and another, entity2_term and hemagglutinin-neuraminidase protein (HN) gene sequences.
F0
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and entity1_term (F0) gene sequences; and another, entity2_term and hemagglutinin-neuraminidase protein (HN) gene sequences.
fusion protein
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, entity1_term and hemagglutinin-neuraminidase protein (entity2_term) gene sequences.
F0
HN
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (entity1_term) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, entity2_term and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, entity1_term and entity2_term (HN) gene sequences.
F0
hemagglutinin-neuraminidase protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and entity1_term (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, entity2_term and hemagglutinin-neuraminidase protein (HN) gene sequences.
membrane protein
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and entity1_term (P) gene sequences; another, P and membrane protein (entity2_term) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
phosphoprotein
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (entity1_term) and phosphoprotein (P) gene sequences; another, P and membrane protein (entity2_term) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
NP
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (entity1_term) gene sequences; another, M and fusion protein (entity2_term) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
M
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (entity1_term) gene sequences; another, M and entity2_term (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
M
fusion protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (entity1_term) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (entity2_term) gene sequences.
M
HN
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (entity1_term) gene sequences; another, P and membrane protein (entity2_term) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (entity1_term) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and entity2_term (HN) gene sequences.
M
hemagglutinin-neuraminidase protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and entity1_term (entity2_term) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
membrane protein
M
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (entity1_term) and entity2_term (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
NP
phosphoprotein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and entity1_term (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (entity2_term) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
phosphoprotein
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and entity1_term (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and entity2_term (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
phosphoprotein
fusion protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and entity1_term (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (entity2_term) gene sequences.
phosphoprotein
HN
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and entity1_term (entity2_term) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
phosphoprotein
P
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and entity1_term (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and entity2_term (HN) gene sequences.
phosphoprotein
hemagglutinin-neuraminidase protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and entity1_term (P) gene sequences; another, P and entity2_term (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
phosphoprotein
membrane protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (entity1_term) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (entity2_term) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
NP
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (entity1_term) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and entity2_term (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
NP
fusion protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (entity1_term) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (entity2_term) gene sequences.
NP
HN
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (entity1_term) and phosphoprotein (entity2_term) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
NP
P
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (entity1_term) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and entity2_term (HN) gene sequences.
NP
hemagglutinin-neuraminidase protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (entity1_term) and phosphoprotein (P) gene sequences; another, P and entity2_term (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
NP
membrane protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and entity1_term (entity2_term) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
fusion protein
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (entity1_term) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (entity2_term) gene sequences.
F0
HN
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (entity1_term) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (entity2_term) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (entity1_term) gene sequences; and another, F0 and entity2_term (HN) gene sequences.
F0
hemagglutinin-neuraminidase protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and entity1_term (M) gene sequences; another, M and fusion protein (entity2_term) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
membrane protein
F0
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and entity1_term (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (entity2_term) gene sequences.
fusion protein
HN
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (entity1_term) gene sequences; another, P and membrane protein (M) gene sequences; another, M and entity2_term (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
fusion protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and entity1_term (F0) gene sequences; and another, F0 and entity2_term (HN) gene sequences.
fusion protein
hemagglutinin-neuraminidase protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and entity1_term (M) gene sequences; another, M and entity2_term (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
membrane protein
fusion protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (entity1_term) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (entity2_term) gene sequences.
P
HN
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and entity1_term (entity2_term) gene sequences.
hemagglutinin-neuraminidase protein
HN
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and entity1_term (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (entity2_term) gene sequences.
membrane protein
HN
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (entity1_term) gene sequences; another, P and membrane protein (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and entity2_term (HN) gene sequences.
P
hemagglutinin-neuraminidase protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (entity1_term) gene sequences; another, P and entity2_term (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and hemagglutinin-neuraminidase protein (HN) gene sequences.
P
membrane protein
0
By this method, it was shown that four of these large RNA species are polycistronic transcripts containing sequences from two genes: one species contains nucleocapsid protein (NP) and phosphoprotein (P) gene sequences; another, P and entity1_term (M) gene sequences; another, M and fusion protein (F0) gene sequences; and another, F0 and entity2_term (HN) gene sequences.
membrane protein
hemagglutinin-neuraminidase protein
0
entity1_term binds to and inhibits complexes formed by cyclin E-cdk2, cyclin A-cdk2, and cyclin D-entity2_term.
p27
cdk4
1
entity1_term binds to and inhibits complexes formed by cyclin E-entity2_term, cyclin A-cdk2, and cyclin D-cdk4.
p27
cdk2
1
entity1_term binds to and inhibits complexes formed by cyclin E-cdk2, cyclin A-cdk2, and entity2_term-cdk4.
p27
cyclin D
1
entity1_term binds to and inhibits complexes formed by cyclin E-cdk2, cyclin A-entity2_term, and cyclin D-cdk4.
p27
cdk2
1
entity1_term binds to and inhibits complexes formed by cyclin E-cdk2, entity2_term-cdk2, and cyclin D-cdk4.
p27
cyclin A
1
p27 binds to and inhibits complexes formed by cyclin E-cdk2, cyclin A-cdk2, and entity1_term-entity2_term.
cyclin D
cdk4
1
entity1_term binds to and inhibits complexes formed by entity2_term-cdk2, cyclin A-cdk2, and cyclin D-cdk4.
p27
cyclin E
1
p27 binds to and inhibits complexes formed by cyclin E-cdk2, entity1_term-entity2_term, and cyclin D-cdk4.
cyclin A
cdk2
1
p27 binds to and inhibits complexes formed by entity1_term-entity2_term, cyclin A-cdk2, and cyclin D-cdk4.
cyclin E
cdk2
1
p27 binds to and inhibits complexes formed by cyclin E-entity1_term, cyclin A-entity2_term, and cyclin D-cdk4.
cdk2
cdk2
0
p27 binds to and inhibits complexes formed by cyclin E-entity1_term, cyclin A-cdk2, and cyclin D-entity2_term.
cdk2
cdk4
0
p27 binds to and inhibits complexes formed by cyclin E-entity1_term, cyclin A-cdk2, and entity2_term-cdk4.
cdk2
cyclin D
0
p27 binds to and inhibits complexes formed by cyclin E-entity1_term, entity2_term-cdk2, and cyclin D-cdk4.
cdk2
cyclin A
0
p27 binds to and inhibits complexes formed by cyclin E-cdk2, cyclin A-entity1_term, and cyclin D-entity2_term.
cdk2
cdk4
0
p27 binds to and inhibits complexes formed by entity1_term-cdk2, cyclin A-entity2_term, and cyclin D-cdk4.
cyclin E
cdk2
0
p27 binds to and inhibits complexes formed by cyclin E-cdk2, cyclin A-entity1_term, and entity2_term-cdk4.
cdk2
cyclin D
0
p27 binds to and inhibits complexes formed by entity1_term-cdk2, cyclin A-cdk2, and cyclin D-entity2_term.
cyclin E
cdk4
0
p27 binds to and inhibits complexes formed by cyclin E-cdk2, entity1_term-cdk2, and cyclin D-entity2_term.
cyclin A
cdk4
0
p27 binds to and inhibits complexes formed by entity1_term-cdk2, cyclin A-cdk2, and entity2_term-cdk4.
cyclin E
cyclin D
0
p27 binds to and inhibits complexes formed by entity1_term-cdk2, entity2_term-cdk2, and cyclin D-cdk4.
cyclin E
cyclin A
0
p27 binds to and inhibits complexes formed by cyclin E-cdk2, entity1_term-cdk2, and entity2_term-cdk4.
cyclin A
cyclin D
0
The entity1_term dimer, which is crucial for entity2_term and lipid binding, is built of a backbone containing the 200 kDa rod portions, at both ends of which a 47 kDa globular domain is attached.
talin
actin
1
Hence, we conclude that in its dimeric form, which is used in entity1_term and lipid binding, entity2_term is a dumbbell-shaped molecule built of two antiparallel subunits.
actin
talin
1
The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the fibronectin receptor, entity1_term, entity2_term and actin.
talin
vinculin
0
The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the fibronectin receptor, entity1_term, vinculin and entity2_term.
talin
actin
0
The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the entity1_term, entity2_term, vinculin and actin.
fibronectin receptor
talin
0
The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the fibronectin receptor, talin, entity1_term and entity2_term.
vinculin
actin
0
The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the entity1_term, talin, entity2_term and actin.
fibronectin receptor
vinculin
0
The cellular morphological changes were analyzed and correlated with the distribution of cell-substratum contacts viewed by confocal images obtained after immunostaining with antibodies raised against the entity1_term, talin, vinculin and entity2_term.
fibronectin receptor
actin
0
Membranous staining and concomitant cytoplasmic localization of entity1_term, alpha-catenin and entity2_term were seen in one case with abnormal beta-catenin immunoreactivity.
E-cadherin
gamma-catenin
1
Membranous staining and concomitant cytoplasmic localization of entity1_term, entity2_term and gamma-catenin were seen in one case with abnormal beta-catenin immunoreactivity.
E-cadherin
alpha-catenin
1
Membranous staining and concomitant cytoplasmic localization of E-cadherin, entity1_term and entity2_term were seen in one case with abnormal beta-catenin immunoreactivity.
alpha-catenin
gamma-catenin
1
Membranous staining and concomitant cytoplasmic localization of E-cadherin, alpha-catenin and entity1_term were seen in one case with abnormal entity2_term immunoreactivity.
gamma-catenin
beta-catenin
0
Membranous staining and concomitant cytoplasmic localization of entity1_term, alpha-catenin and gamma-catenin were seen in one case with abnormal entity2_term immunoreactivity.
E-cadherin
beta-catenin
0
Membranous staining and concomitant cytoplasmic localization of E-cadherin, entity1_term and gamma-catenin were seen in one case with abnormal entity2_term immunoreactivity.
alpha-catenin
beta-catenin
0
Specific interaction between the nucleocapsid protein (entity1_term) and the entity2_term (P) of vesicular stomatitis virus (VSV), an important step in the life-cycle of the virus, was studied by using a two-hybrid system.
N
phosphoprotein
1
Specific interaction between the nucleocapsid protein (entity1_term) and the phosphoprotein (entity2_term) of vesicular stomatitis virus (VSV), an important step in the life-cycle of the virus, was studied by using a two-hybrid system.
N
P
1
Specific interaction between the entity1_term (N) and the entity2_term (P) of vesicular stomatitis virus (VSV), an important step in the life-cycle of the virus, was studied by using a two-hybrid system.
nucleocapsid protein
phosphoprotein
1
Specific interaction between the entity1_term (N) and the phosphoprotein (entity2_term) of vesicular stomatitis virus (VSV), an important step in the life-cycle of the virus, was studied by using a two-hybrid system.
nucleocapsid protein
P
1
Specific interaction between the entity1_term (entity2_term) and the phosphoprotein (P) of vesicular stomatitis virus (VSV), an important step in the life-cycle of the virus, was studied by using a two-hybrid system.
nucleocapsid protein
N
0
Specific interaction between the nucleocapsid protein (N) and the entity1_term (entity2_term) of vesicular stomatitis virus (VSV), an important step in the life-cycle of the virus, was studied by using a two-hybrid system.
phosphoprotein
P
0
Calorimetric data show ternary complex formation between entity1_term, vinculin, and entity2_term.
talin
actin
1
Calorimetric data show ternary complex formation between entity1_term, entity2_term, and actin.
talin
vinculin
1
Calorimetric data show ternary complex formation between talin, entity1_term, and entity2_term.
vinculin
actin
1
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the entity1_term entity2_term and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
histone
H4
1
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone entity1_term and histone H2b genes encode < 10% of the total entity2_term and H2b mRNA.
H4
H4
1
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone entity1_term genes encode < 10% of the total H4 and entity2_term mRNA.
H2b
H2b
1
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and entity1_term entity2_term genes encode < 10% of the total H4 and H2b mRNA.
histone
H2b
1
There are three histone H3 genes, two of which are identical; four histone H2a genes, two of which are identical, one histone H4 gene; and two entity1_term entity2_term genes.
histone
H2b
1
These histone H3 and entity1_term genes encode approximately 40% of the total H3 and entity2_term mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H2a
H2a
1
There are three histone H3 genes, two of which are identical; four histone H2a genes, two of which are identical, one entity1_term entity2_term gene; and two histone H2b genes.
histone
H4
1
There are three histone H3 genes, two of which are identical; four entity1_term entity2_term genes, two of which are identical, one histone H4 gene; and two histone H2b genes.
histone
H2a
1
There are three entity1_term entity2_term genes, two of which are identical; four histone H2a genes, two of which are identical, one histone H4 gene; and two histone H2b genes.
histone
H3
1
These histone entity1_term and H2a genes encode approximately 40% of the total entity2_term and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H3
H3
1
These entity1_term H3 and entity2_term genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
histone
H2a
1
These entity1_term entity2_term and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
histone
H3
1
There are three histone entity1_term genes, two of which are identical; four histone H2a genes, two of which are identical, one entity2_term H4 gene; and two histone H2b genes.
H3
histone
0
There are three histone entity1_term genes, two of which are identical; four histone H2a genes, two of which are identical, one histone entity2_term gene; and two histone H2b genes.
H3
H4
0
There are three histone entity1_term genes, two of which are identical; four histone entity2_term genes, two of which are identical, one histone H4 gene; and two histone H2b genes.
H3
H2a
0
There are three histone entity1_term genes, two of which are identical; four entity2_term H2a genes, two of which are identical, one histone H4 gene; and two histone H2b genes.
H3
histone
0
There are three histone entity1_term genes, two of which are identical; four histone H2a genes, two of which are identical, one histone H4 gene; and two entity2_term H2b genes.
H3
histone
0
There are three histone entity1_term genes, two of which are identical; four histone H2a genes, two of which are identical, one histone H4 gene; and two histone entity2_term genes.
H3
H2b
0
There are three entity1_term H3 genes, two of which are identical; four histone H2a genes, two of which are identical, one entity2_term H4 gene; and two histone H2b genes.
histone
histone
0
There are three histone H3 genes, two of which are identical; four histone entity1_term genes, two of which are identical, one entity2_term H4 gene; and two histone H2b genes.
H2a
histone
0
There are three histone H3 genes, two of which are identical; four entity1_term H2a genes, two of which are identical, one entity2_term H4 gene; and two histone H2b genes.
histone
histone
0
There are three histone H3 genes, two of which are identical; four histone H2a genes, two of which are identical, one entity1_term H4 gene; and two entity2_term H2b genes.
histone
histone
0
There are three histone H3 genes, two of which are identical; four histone H2a genes, two of which are identical, one entity1_term H4 gene; and two histone entity2_term genes.
histone
H2b
0
There are three entity1_term H3 genes, two of which are identical; four histone H2a genes, two of which are identical, one histone entity2_term gene; and two histone H2b genes.
histone
H4
0
There are three entity1_term H3 genes, two of which are identical; four histone entity2_term genes, two of which are identical, one histone H4 gene; and two histone H2b genes.
histone
H2a
0
There are three entity1_term H3 genes, two of which are identical; four entity2_term H2a genes, two of which are identical, one histone H4 gene; and two histone H2b genes.
histone
histone
0
There are three entity1_term H3 genes, two of which are identical; four histone H2a genes, two of which are identical, one histone H4 gene; and two entity2_term H2b genes.
histone
histone
0
There are three entity1_term H3 genes, two of which are identical; four histone H2a genes, two of which are identical, one histone H4 gene; and two histone entity2_term genes.
histone
H2b
0
There are three histone H3 genes, two of which are identical; four histone entity1_term genes, two of which are identical, one histone entity2_term gene; and two histone H2b genes.
H2a
H4
0
There are three histone H3 genes, two of which are identical; four entity1_term H2a genes, two of which are identical, one histone entity2_term gene; and two histone H2b genes.
histone
H4
0
There are three histone H3 genes, two of which are identical; four histone H2a genes, two of which are identical, one histone entity1_term gene; and two entity2_term H2b genes.
H4
histone
0
There are three histone H3 genes, two of which are identical; four histone H2a genes, two of which are identical, one histone entity1_term gene; and two histone entity2_term genes.
H4
H2b
0
There are three histone H3 genes, two of which are identical; four histone entity1_term genes, two of which are identical, one histone H4 gene; and two entity2_term H2b genes.
H2a
histone
0
There are three histone H3 genes, two of which are identical; four histone entity1_term genes, two of which are identical, one histone H4 gene; and two histone entity2_term genes.
H2a
H2b
0
There are three histone H3 genes, two of which are identical; four entity1_term H2a genes, two of which are identical, one histone H4 gene; and two entity2_term H2b genes.
histone
histone
0
There are three histone H3 genes, two of which are identical; four entity1_term H2a genes, two of which are identical, one histone H4 gene; and two histone entity2_term genes.
histone
H2b
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the entity1_term H4 and histone H2b genes encode < 10% of the total H4 and entity2_term mRNA.
histone
H2b
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone entity1_term and histone H2b genes encode < 10% of the total H4 and entity2_term mRNA.
H4
H2b
0
These histone entity1_term and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and entity2_term mRNA.
H3
H2b
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and entity1_term mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and entity2_term mRNA.
H2a
H2b
0
These histone H3 and entity1_term genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and entity2_term mRNA.
H2a
H2b
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total entity1_term and entity2_term mRNA.
H4
H2b
0
These entity1_term H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and entity2_term mRNA.
histone
H2b
0
These histone H3 and H2a genes encode approximately 40% of the total entity1_term and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and entity2_term mRNA.
H3
H2b
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and entity1_term H2b genes encode < 10% of the total H4 and entity2_term mRNA.
histone
H2b
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the entity1_term H4 and histone entity2_term genes encode < 10% of the total H4 and H2b mRNA.
histone
H2b
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone entity1_term and histone entity2_term genes encode < 10% of the total H4 and H2b mRNA.
H4
H2b
0
These histone entity1_term and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone entity2_term genes encode < 10% of the total H4 and H2b mRNA.
H3
H2b
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and entity1_term mRNA, whereas the histone H4 and histone entity2_term genes encode < 10% of the total H4 and H2b mRNA.
H2a
H2b
0
These histone H3 and entity1_term genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone entity2_term genes encode < 10% of the total H4 and H2b mRNA.
H2a
H2b
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone entity1_term genes encode < 10% of the total entity2_term and H2b mRNA.
H2b
H4
0
These entity1_term H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone entity2_term genes encode < 10% of the total H4 and H2b mRNA.
histone
H2b
0
These histone H3 and H2a genes encode approximately 40% of the total entity1_term and H2a mRNA, whereas the histone H4 and histone entity2_term genes encode < 10% of the total H4 and H2b mRNA.
H3
H2b
0
These histone entity1_term and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the entity2_term H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H3
histone
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and entity1_term mRNA, whereas the entity2_term H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H2a
histone
0
These histone H3 and entity1_term genes encode approximately 40% of the total H3 and H2a mRNA, whereas the entity2_term H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H2a
histone
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the entity1_term H4 and histone H2b genes encode < 10% of the total entity2_term and H2b mRNA.
histone
H4
0
These entity1_term H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the entity2_term H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
histone
histone
0
These histone H3 and H2a genes encode approximately 40% of the total entity1_term and H2a mRNA, whereas the entity2_term H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H3
histone
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the entity1_term H4 and entity2_term H2b genes encode < 10% of the total H4 and H2b mRNA.
histone
histone
0
These histone entity1_term and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone entity2_term and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H3
H4
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and entity1_term mRNA, whereas the histone entity2_term and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H2a
H4
0
These histone H3 and entity1_term genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone entity2_term and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H2a
H4
0
These entity1_term H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone entity2_term and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
histone
H4
0
These histone H3 and H2a genes encode approximately 40% of the total entity1_term and H2a mRNA, whereas the histone entity2_term and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H3
H4
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone entity1_term and entity2_term H2b genes encode < 10% of the total H4 and H2b mRNA.
H4
histone
0
These histone entity1_term and H2a genes encode approximately 40% of the total H3 and entity2_term mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H3
H2a
0
These histone entity1_term and entity2_term genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H3
H2a
0
These histone entity1_term and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total entity2_term and H2b mRNA.
H3
H4
0
These histone entity1_term and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and entity2_term H2b genes encode < 10% of the total H4 and H2b mRNA.
H3
histone
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and entity1_term mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total entity2_term and H2b mRNA.
H2a
H4
0
These entity1_term H3 and H2a genes encode approximately 40% of the total H3 and entity2_term mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
histone
H2a
0
These histone H3 and H2a genes encode approximately 40% of the total entity1_term and entity2_term mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H3
H2a
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and entity1_term mRNA, whereas the histone H4 and entity2_term H2b genes encode < 10% of the total H4 and H2b mRNA.
H2a
histone
0
These histone H3 and entity1_term genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total entity2_term and H2b mRNA.
H2a
H4
0
These histone H3 and entity1_term genes encode approximately 40% of the total entity2_term and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
H2a
H3
0
These histone H3 and entity1_term genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and entity2_term H2b genes encode < 10% of the total H4 and H2b mRNA.
H2a
histone
0
These entity1_term H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total entity2_term and H2b mRNA.
histone
H4
0
These histone H3 and H2a genes encode approximately 40% of the total entity1_term and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total entity2_term and H2b mRNA.
H3
H4
0
These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and entity1_term H2b genes encode < 10% of the total entity2_term and H2b mRNA.
histone
H4
0
These entity1_term H3 and H2a genes encode approximately 40% of the total entity2_term and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.
histone
H3
0
These entity1_term H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and entity2_term H2b genes encode < 10% of the total H4 and H2b mRNA.
histone
histone
0
These histone H3 and H2a genes encode approximately 40% of the total entity1_term and H2a mRNA, whereas the histone H4 and entity2_term H2b genes encode < 10% of the total H4 and H2b mRNA.
H3
histone
0
The role of entity1_term in entity2_term polymerization and nucleotide exchange.
profilin
actin
1
The mutants ranged in affinity, from those that only weakly affected polymerization of actin to one that bound entity1_term more strongly than wild-type entity2_term.
actin
profilin
1
With entity1_term, whose sequestering activity was low, the concentration of free actin monomers observed at steady-state of polymerization [Afree], was close to that seen with entity2_term alone ([Acc], critical concentration of polymerization).
profilins
actin
0
With entity1_term, whose sequestering activity was low, the concentration of free entity2_term monomers observed at steady-state of polymerization [Afree], was close to that seen with actin alone ([Acc], critical concentration of polymerization).
profilins
actin
0
With profilins, whose sequestering activity was low, the concentration of free entity1_term monomers observed at steady-state of polymerization [Afree], was close to that seen with entity2_term alone ([Acc], critical concentration of polymerization).
actin
actin
0
The mutants ranged in affinity, from those that only weakly affected polymerization of entity1_term to one that bound actin more strongly than wild-type entity2_term.
actin
profilin
0
The mutants ranged in affinity, from those that only weakly affected polymerization of entity1_term to one that bound entity2_term more strongly than wild-type profilin.
actin
actin
0
The comparison of entity1_term proteins synthesized by E62 and E24 cell lines revealed no structural or functional differences because both localized at cell-cell contacts and associated with alpha-catenin, entity2_term, and plakoglobin.
E-CD
beta-catenin
1
The comparison of entity1_term proteins synthesized by E62 and E24 cell lines revealed no structural or functional differences because both localized at cell-cell contacts and associated with entity2_term, beta-catenin, and plakoglobin.
E-CD
alpha-catenin
1
The comparison of entity1_term proteins synthesized by E62 and E24 cell lines revealed no structural or functional differences because both localized at cell-cell contacts and associated with alpha-catenin, beta-catenin, and entity2_term.
E-CD
plakoglobin
1
The comparison of E-CD proteins synthesized by E62 and E24 cell lines revealed no structural or functional differences because both localized at cell-cell contacts and associated with entity1_term, entity2_term, and plakoglobin.
alpha-catenin
beta-catenin
0
The comparison of E-CD proteins synthesized by E62 and E24 cell lines revealed no structural or functional differences because both localized at cell-cell contacts and associated with entity1_term, beta-catenin, and entity2_term.
alpha-catenin
plakoglobin
0
The comparison of E-CD proteins synthesized by E62 and E24 cell lines revealed no structural or functional differences because both localized at cell-cell contacts and associated with alpha-catenin, entity1_term, and entity2_term.
beta-catenin
plakoglobin
0
Genetic analysis suggested that this phenotype was due to msh6-F337A sequestering entity1_term and preventing it from interacting with MSH3 and entity2_term.
MSH2
MSH6
1
Genetic analysis suggested that this phenotype was due to msh6-F337A sequestering entity1_term and preventing it from interacting with entity2_term and MSH6.
MSH2
MSH3
1
Genetic analysis suggested that this phenotype was due to entity1_term sequestering MSH2 and preventing it from interacting with entity2_term and MSH6.
msh6-F337A
MSH3
1
Genetic analysis suggested that this phenotype was due to entity1_term sequestering entity2_term and preventing it from interacting with MSH3 and MSH6.
msh6-F337A
MSH2
1
Genetic analysis suggested that this phenotype was due to entity1_term sequestering MSH2 and preventing it from interacting with MSH3 and entity2_term.
msh6-F337A
MSH6
1
Genetic analysis suggested that this phenotype was due to msh6-F337A sequestering MSH2 and preventing it from interacting with entity1_term and entity2_term.
MSH3
MSH6
0
These results indicate that (i) cotranslational assembly of entity1_term is developmentally regulated, (ii) structures containing entity2_term and not microtubules may mediate initial association of the heavy chains with the cytoskeleton, and (iii) the site of translation dictates where a significant fraction of the heavy chains will be inserted into the cytoskeleton.
myosin heavy chains
actin
1
In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the entity1_term-associated protein entity2_term/MORT1 or the TNF receptor-associated protein TRADD [2-4].
Fas
FADD
1
In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the Fas-associated protein FADD/MORT1 or the entity1_term-associated protein entity2_term [2-4].
TNF receptor
TRADD
1
In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the entity1_term-associated protein FADD/entity2_term or the TNF receptor-associated protein TRADD [2-4].
Fas
MORT1
1
In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the Fas-associated protein entity1_term/entity2_term or the TNF receptor-associated protein TRADD [2-4].
FADD
MORT1
0
In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the Fas-associated protein FADD/entity1_term or the entity2_term-associated protein TRADD [2-4].
MORT1
TNF receptor
0
In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the Fas-associated protein FADD/entity1_term or the TNF receptor-associated protein entity2_term [2-4].
MORT1
TRADD
0
In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the Fas-associated protein entity1_term/MORT1 or the entity2_term-associated protein TRADD [2-4].
FADD
TNF receptor
0
In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the Fas-associated protein entity1_term/MORT1 or the TNF receptor-associated protein entity2_term [2-4].
FADD
TRADD
0
In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the entity1_term-associated protein FADD/MORT1 or the entity2_term-associated protein TRADD [2-4].
Fas
TNF receptor
0
In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the entity1_term-associated protein FADD/MORT1 or the TNF receptor-associated protein entity2_term [2-4].
Fas
TRADD
0
Transfection of alpha-catenin-deficient colon carcinoma cells recruited entity1_term and entity2_term to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way.
E-cadherin
beta-catenin
0
Transfection of alpha-catenin-deficient colon carcinoma cells recruited entity1_term and beta-catenin to cell-cell contacts and functional entity2_term-mediated cell-cell adhesion was restored in this way.
E-cadherin
cadherin
0
Transfection of entity1_term-deficient colon carcinoma cells recruited entity2_term and beta-catenin to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way.
alpha-catenin
E-cadherin
0
Transfection of alpha-catenin-deficient colon carcinoma cells recruited E-cadherin and entity1_term to cell-cell contacts and functional entity2_term-mediated cell-cell adhesion was restored in this way.
beta-catenin
cadherin
0
Transfection of entity1_term-deficient colon carcinoma cells recruited E-cadherin and entity2_term to cell-cell contacts and functional cadherin-mediated cell-cell adhesion was restored in this way.
alpha-catenin
beta-catenin
0
Transfection of entity1_term-deficient colon carcinoma cells recruited E-cadherin and beta-catenin to cell-cell contacts and functional entity2_term-mediated cell-cell adhesion was restored in this way.
alpha-catenin
cadherin
0
The interaction between calf entity1_term and actin depends critically on the status of the C-terminus of the entity2_term, and in the case of profilin, the C-terminus is of great importance for the physiochemical behaviour of the protein.
spleen profilin
actin
1
The interaction between calf entity1_termentity2_term and actin depends critically on the status of the C-terminus of the actin, and in the case of profilin, the C-terminus is of great importance for the physiochemical behaviour of the protein.
spleen
spleen profilin
1
Analysis of the formation of the calf spleen complex in the presence of varying concentrations of divalent cations gave evidence for the presence of a high-affinity divalent-cation-binding site on the entity1_term (beta, gamma) which appears to regulate the interaction with entity2_term.
spleen actin
profilin
1
The interaction between calf entity1_term profilin and actin depends critically on the status of the C-terminus of the entity2_term, and in the case of profilin, the C-terminus is of great importance for the physiochemical behaviour of the protein.
spleen
actin
1
Analysis of the formation of the calf spleen complex in the presence of varying concentrations of divalent cations gave evidence for the presence of a high-affinity divalent-cation-binding site on the entity1_term (beta, gamma) which appears to regulate the interaction with entity2_term.
spleen actin
profilin
1
The interaction between calf entity1_term profilin and actin depends critically on the status of the C-terminus of the actin, and in the case of entity2_term, the C-terminus is of great importance for the physiochemical behaviour of the protein.
spleen
profilin
0
The interaction between calf entity1_term and actin depends critically on the status of the C-terminus of the actin, and in the case of entity2_term, the C-terminus is of great importance for the physiochemical behaviour of the protein.
spleen profilin
profilin
0
The interaction between calf spleen profilin and actin depends critically on the status of the C-terminus of the entity1_term, and in the case of entity2_term, the C-terminus is of great importance for the physiochemical behaviour of the protein.
actin
profilin
0
Analysis of the formation of the calf spleen complex in the presence of varying concentrations of divalent cations gave evidence for the presence of a high-affinity divalent-cation-binding site on the entity1_termentity2_term (beta, gamma) which appears to regulate the interaction with profilin.
spleen actin
spleen actin
0
In addition, we have demonstrated that increased gene dosage of either entity1_term or SIR4, two other factors required for silencing, suppresses the silencing defect of the entity2_term mutants.
SIR1
rap1
1
In addition, we have demonstrated that increased gene dosage of either SIR1 or entity1_term, two other factors required for silencing, suppresses the silencing defect of the entity2_term mutants.
SIR4
rap1
1
In addition, we have demonstrated that increased gene dosage of either entity1_term or entity2_term, two other factors required for silencing, suppresses the silencing defect of the rap1 mutants.
SIR1
SIR4
0
We have established an MSH3-deficient HHUA/chr.2 cell line by introducing human chromosome 2, which carries wild-type entity1_term and entity2_term genes, to HHUA cells.
MSH6
MSH2
0
We have established an entity1_term-deficient HHUA/chr.2 cell line by introducing human chromosome 2, which carries wild-type MSH6 and entity2_term genes, to HHUA cells.
MSH3
MSH2
0
We have established an entity1_term-deficient HHUA/chr.2 cell line by introducing human chromosome 2, which carries wild-type entity2_term and MSH2 genes, to HHUA cells.
MSH3
MSH6
0
One such protein is the yeast actin-binding protein entity1_term, which is homologous to vertebrate entity2_term (Adams, A. E. M., D. Botstein, and D. G. Drubin.
Sac6p
fimbrin
1
One such protein is the yeast entity1_term entity2_term, which is homologous to vertebrate fimbrin (Adams, A. E. M., D. Botstein, and D. G. Drubin.
actin-binding protein
Sac6p
1
One such protein is the yeast entity1_term Sac6p, which is homologous to vertebrate entity2_term (Adams, A. E. M., D. Botstein, and D. G. Drubin.
actin-binding protein
fimbrin
0
At least one element of the entity1_term-binding region of human entity2_term is an alpha-helix.
actin
profilin
1
Spontaneous and mitomycin C-induced SCE levels were significantly reduced for chicken DT40 B cells lacking the key HR genes entity1_term and entity2_term but not for nonhomologous DNA end-joining (NHEJ)-defective KU70(-/-) cells.
RAD51
RAD54
0
Cardiac hypertrophy and the steady state level of the "fetal" genes, entity1_term, alpha-skeletal actin (entity2_term), and beta myosin heavy chain (beta-MHC) mRNAs were assessed.
ANP
alpha-skA
0
Cardiac hypertrophy and the steady state level of the "fetal" genes, entity1_term, alpha-skeletal actin (alpha-skA), and beta myosin heavy chain (entity2_term) mRNAs were assessed.
ANP
beta-MHC
0
Cardiac hypertrophy and the steady state level of the "fetal" genes, entity1_term, alpha-skeletal actin (alpha-skA), and entity2_term (beta-MHC) mRNAs were assessed.
ANP
beta myosin heavy chain
0
Cardiac hypertrophy and the steady state level of the "fetal" genes, entity1_term, entity2_term (alpha-skA), and beta myosin heavy chain (beta-MHC) mRNAs were assessed.
ANP
alpha-skeletal actin
0
Cardiac hypertrophy and the steady state level of the "fetal" genes, ANP, alpha-skeletal actin (entity1_term), and beta myosin heavy chain (entity2_term) mRNAs were assessed.
alpha-skA
beta-MHC
0
Cardiac hypertrophy and the steady state level of the "fetal" genes, ANP, alpha-skeletal actin (entity1_term), and entity2_term (beta-MHC) mRNAs were assessed.
alpha-skA
beta myosin heavy chain
0
Cardiac hypertrophy and the steady state level of the "fetal" genes, ANP, entity1_term (entity2_term), and beta myosin heavy chain (beta-MHC) mRNAs were assessed.
alpha-skeletal actin
alpha-skA
0
Cardiac hypertrophy and the steady state level of the "fetal" genes, ANP, alpha-skeletal actin (alpha-skA), and entity1_term (entity2_term) mRNAs were assessed.
beta myosin heavy chain
beta-MHC
0
Cardiac hypertrophy and the steady state level of the "fetal" genes, ANP, entity1_term (alpha-skA), and beta myosin heavy chain (entity2_term) mRNAs were assessed.
alpha-skeletal actin
beta-MHC
0
Cardiac hypertrophy and the steady state level of the "fetal" genes, ANP, entity1_term (alpha-skA), and entity2_term (beta-MHC) mRNAs were assessed.
alpha-skeletal actin
beta myosin heavy chain
0
The contents of entity1_term, myosin light chain 2, actin, entity2_term in 125-week-old rats decreased compared with those of 12-week-old rats.
myosin heavy chain
troponin-I
0
The contents of entity1_term, myosin light chain 2, entity2_term, troponin-I in 125-week-old rats decreased compared with those of 12-week-old rats.
myosin heavy chain
actin
0
The contents of entity1_term, entity2_term, actin, troponin-I in 125-week-old rats decreased compared with those of 12-week-old rats.
myosin heavy chain
myosin light chain 2
0
The contents of myosin heavy chain, myosin light chain 2, entity1_term, entity2_term in 125-week-old rats decreased compared with those of 12-week-old rats.
actin
troponin-I
0
The contents of myosin heavy chain, entity1_term, actin, entity2_term in 125-week-old rats decreased compared with those of 12-week-old rats.
myosin light chain 2
troponin-I
0
The contents of myosin heavy chain, entity1_term, entity2_term, troponin-I in 125-week-old rats decreased compared with those of 12-week-old rats.
myosin light chain 2
actin
0
The sequences of the predicted HMP-1, entity1_term, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/entity2_term, and classical cadherin, respectively.
HMP-2
Armadillo
1
The sequences of the predicted entity1_term, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins entity2_term, beta-catenin/Armadillo, and classical cadherin, respectively.
HMP-1
alpha-catenin
1
The sequences of the predicted HMP-1, HMP-2, and entity1_term proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/Armadillo, and entity2_term, respectively.
HMR-1
classical cadherin
1
The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the entity1_term alpha-catenin, beta-catenin/Armadillo, and entity2_term, respectively.
cell adhesion proteins
classical cadherin
1
The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the entity1_term alpha-catenin, beta-catenin/entity2_term, and classical cadherin, respectively.
cell adhesion proteins
Armadillo
1
The sequences of the predicted HMP-1, entity1_term, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, entity2_term/Armadillo, and classical cadherin, respectively.
HMP-2
beta-catenin
1
The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the entity1_term entity2_term, beta-catenin/Armadillo, and classical cadherin, respectively.
cell adhesion proteins
alpha-catenin
1
The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the entity1_term alpha-catenin, entity2_term/Armadillo, and classical cadherin, respectively.
cell adhesion proteins
beta-catenin
1
The sequences of the predicted HMP-1, HMP-2, and entity1_term proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/entity2_term, and classical cadherin, respectively.
HMR-1
Armadillo
0
The sequences of the predicted HMP-1, entity1_term, and entity2_term proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/Armadillo, and classical cadherin, respectively.
HMP-2
HMR-1
0
The sequences of the predicted entity1_term, HMP-2, and entity2_term proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/Armadillo, and classical cadherin, respectively.
HMP-1
HMR-1
0
The sequences of the predicted HMP-1, HMP-2, and entity1_term proteins are related to the cell adhesion proteins alpha-catenin, entity2_term/Armadillo, and classical cadherin, respectively.
HMR-1
beta-catenin
0
The sequences of the predicted HMP-1, HMP-2, and entity1_term proteins are related to the cell adhesion proteins entity2_term, beta-catenin/Armadillo, and classical cadherin, respectively.
HMR-1
alpha-catenin
0
The sequences of the predicted HMP-1, HMP-2, and entity1_term proteins are related to the entity2_term alpha-catenin, beta-catenin/Armadillo, and classical cadherin, respectively.
HMR-1
cell adhesion proteins
0
The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/entity1_term, and entity2_term, respectively.
Armadillo
classical cadherin
0
The sequences of the predicted entity1_term, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/entity2_term, and classical cadherin, respectively.
HMP-1
Armadillo
0
The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, entity1_term/entity2_term, and classical cadherin, respectively.
beta-catenin
Armadillo
0
The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins entity1_term, beta-catenin/entity2_term, and classical cadherin, respectively.
alpha-catenin
Armadillo
0
The sequences of the predicted HMP-1, entity1_term, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/Armadillo, and entity2_term, respectively.
HMP-2
classical cadherin
0
The sequences of the predicted entity1_term, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/Armadillo, and entity2_term, respectively.
HMP-1
classical cadherin
0
The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, entity1_term/Armadillo, and entity2_term, respectively.
beta-catenin
classical cadherin
0
The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins entity1_term, beta-catenin/Armadillo, and entity2_term, respectively.
alpha-catenin
classical cadherin
0
The sequences of the predicted entity1_term, entity2_term, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, beta-catenin/Armadillo, and classical cadherin, respectively.
HMP-1
HMP-2
0
The sequences of the predicted HMP-1, entity1_term, and HMR-1 proteins are related to the cell adhesion proteins entity2_term, beta-catenin/Armadillo, and classical cadherin, respectively.
HMP-2
alpha-catenin
0
The sequences of the predicted HMP-1, entity1_term, and HMR-1 proteins are related to the entity2_term alpha-catenin, beta-catenin/Armadillo, and classical cadherin, respectively.
HMP-2
cell adhesion proteins
0
The sequences of the predicted entity1_term, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins alpha-catenin, entity2_term/Armadillo, and classical cadherin, respectively.
HMP-1
beta-catenin
0
The sequences of the predicted entity1_term, HMP-2, and HMR-1 proteins are related to the entity2_term alpha-catenin, beta-catenin/Armadillo, and classical cadherin, respectively.
HMP-1
cell adhesion proteins
0
The sequences of the predicted HMP-1, HMP-2, and HMR-1 proteins are related to the cell adhesion proteins entity1_term, entity2_term/Armadillo, and classical cadherin, respectively.
alpha-catenin
beta-catenin
0
In the cytoplasm, HBx was shown to stimulate the Ras-Raf-entity1_term (MAP kinase) cascade, which is essential for activation of transcription factor entity2_term.
mitogen-activated protein kinase
AP-1
1
In the cytoplasm, HBx was shown to stimulate the Ras-entity1_term-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor entity2_term.
Raf
AP-1
1
In the cytoplasm, HBx was shown to stimulate the Ras-Raf-entity1_term (entity2_term) cascade, which is essential for activation of transcription factor AP-1.
mitogen-activated protein kinase
MAP kinase
1
In the cytoplasm, HBx was shown to stimulate the Ras-entity1_term-mitogen-activated protein kinase (entity2_term) cascade, which is essential for activation of transcription factor AP-1.
Raf
MAP kinase
1
In the cytoplasm, HBx was shown to stimulate the entity1_term-entity2_term-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.
Ras
Raf
1
In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (entity1_term) cascade, which is essential for activation of transcription factor entity2_term.
MAP kinase
AP-1
1
In the cytoplasm, HBx was shown to stimulate the entity1_term-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor entity2_term.
Ras
AP-1
1
In the cytoplasm, HBx was shown to stimulate the entity1_term-Raf-entity2_term (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.
Ras
mitogen-activated protein kinase
1
In the cytoplasm, HBx was shown to stimulate the entity1_term-Raf-mitogen-activated protein kinase (entity2_term) cascade, which is essential for activation of transcription factor AP-1.
Ras
MAP kinase
1
In the cytoplasm, HBx was shown to stimulate the Ras-entity1_term-entity2_term (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.
Raf
mitogen-activated protein kinase
1
In the cytoplasm, entity1_term was shown to stimulate the Ras-entity2_term-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.
HBx
Raf
0
In the cytoplasm, entity1_term was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor entity2_term.
HBx
AP-1
0
In the cytoplasm, entity1_term was shown to stimulate the Ras-Raf-entity2_term (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.
HBx
mitogen-activated protein kinase
0
In the cytoplasm, entity1_term was shown to stimulate the entity2_term-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.
HBx
Ras
0
In the cytoplasm, entity1_term was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (entity2_term) cascade, which is essential for activation of transcription factor AP-1.
HBx
MAP kinase
0
Adherens junction proteins (N-cadherin, E-cadherin, alpha-catenin, entity1_term, plakoglobin, and entity2_term) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
beta-catenin
actin
0
Adherens junction proteins (entity1_term, E-cadherin, alpha-catenin, beta-catenin, plakoglobin, and entity2_term) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
N-cadherin
actin
0
Adherens junction proteins (N-cadherin, E-cadherin, alpha-catenin, beta-catenin, plakoglobin, and entity1_term) and the proliferation marker entity2_term were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
actin
Ki-67
0
Adherens junction proteins (N-cadherin, E-cadherin, alpha-catenin, beta-catenin, entity1_term, and entity2_term) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
plakoglobin
actin
0
Adherens junction proteins (N-cadherin, E-cadherin, entity1_term, beta-catenin, plakoglobin, and entity2_term) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
alpha-catenin
actin
0
Adherens junction proteins (N-cadherin, entity1_term, alpha-catenin, beta-catenin, plakoglobin, and entity2_term) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
E-cadherin
actin
0
Adherens junction proteins (entity1_term, E-cadherin, alpha-catenin, entity2_term, plakoglobin, and actin) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
N-cadherin
beta-catenin
0
Adherens junction proteins (N-cadherin, E-cadherin, alpha-catenin, entity1_term, plakoglobin, and actin) and the proliferation marker entity2_term were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
beta-catenin
Ki-67
0
Adherens junction proteins (N-cadherin, E-cadherin, alpha-catenin, entity1_term, entity2_term, and actin) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
beta-catenin
plakoglobin
0
Adherens junction proteins (N-cadherin, E-cadherin, entity1_term, entity2_term, plakoglobin, and actin) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
alpha-catenin
beta-catenin
0
Adherens junction proteins (N-cadherin, entity1_term, alpha-catenin, entity2_term, plakoglobin, and actin) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
E-cadherin
beta-catenin
0
Adherens junction proteins (entity1_term, E-cadherin, alpha-catenin, beta-catenin, plakoglobin, and actin) and the proliferation marker entity2_term were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
N-cadherin
Ki-67
0
Adherens junction proteins (entity1_term, E-cadherin, alpha-catenin, beta-catenin, entity2_term, and actin) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
N-cadherin
plakoglobin
0
Adherens junction proteins (entity1_term, E-cadherin, entity2_term, beta-catenin, plakoglobin, and actin) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
N-cadherin
alpha-catenin
0
Adherens junction proteins (entity1_term, entity2_term, alpha-catenin, beta-catenin, plakoglobin, and actin) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
N-cadherin
E-cadherin
0
Adherens junction proteins (N-cadherin, E-cadherin, alpha-catenin, beta-catenin, entity1_term, and actin) and the proliferation marker entity2_term were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
plakoglobin
Ki-67
0
Adherens junction proteins (N-cadherin, E-cadherin, entity1_term, beta-catenin, plakoglobin, and actin) and the proliferation marker entity2_term were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
alpha-catenin
Ki-67
0
Adherens junction proteins (N-cadherin, entity1_term, alpha-catenin, beta-catenin, plakoglobin, and actin) and the proliferation marker entity2_term were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
E-cadherin
Ki-67
0
Adherens junction proteins (N-cadherin, E-cadherin, entity1_term, beta-catenin, entity2_term, and actin) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
alpha-catenin
plakoglobin
0
Adherens junction proteins (N-cadherin, entity1_term, alpha-catenin, beta-catenin, entity2_term, and actin) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
E-cadherin
plakoglobin
0
Adherens junction proteins (N-cadherin, entity1_term, entity2_term, beta-catenin, plakoglobin, and actin) and the proliferation marker Ki-67 were localized in the cultures by fluorescence microscopy, and in vitro wound healing was compared.
E-cadherin
alpha-catenin
0
Mammalian homologues of two important yeast genes involved in DNA double-strand break repair and recombination, entity1_term and entity2_term, have been isolated.
RAD51
RAD54
0
Immunohistochemical investigation of entity1_term-anchoring proteins vinculin, entity2_term and paxillin in rat brain following lesion: a moderate reaction, confined to the astroglia of brain tracts.
actin
talin
1
Immunohistochemical investigation of entity1_term-anchoring proteins entity2_term, talin and paxillin in rat brain following lesion: a moderate reaction, confined to the astroglia of brain tracts.
actin
vinculin
1
Immunohistochemical investigation of entity1_term-anchoring proteins vinculin, talin and entity2_term in rat brain following lesion: a moderate reaction, confined to the astroglia of brain tracts.
actin
paxillin
1
Immunohistochemical investigation of actin-anchoring proteins entity1_term, entity2_term and paxillin in rat brain following lesion: a moderate reaction, confined to the astroglia of brain tracts.
vinculin
talin
0
Immunohistochemical investigation of actin-anchoring proteins entity1_term, talin and entity2_term in rat brain following lesion: a moderate reaction, confined to the astroglia of brain tracts.
vinculin
paxillin
0
Immunohistochemical investigation of actin-anchoring proteins vinculin, entity1_term and entity2_term in rat brain following lesion: a moderate reaction, confined to the astroglia of brain tracts.
talin
paxillin
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba entity1_term has an NMR spectrum identical with that of native entity2_term; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilin-I
profilin-I
1
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba entity1_term inhibit entity2_term polymerization.
profilins
actin
1
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to entity1_term in the same way as native, conventionally purified entity2_term without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
actin
profilin
1
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human entity1_term rebind quantitatively to poly-L-proline and bind to entity2_term in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
actin
1
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed entity1_term form 3-D crystals under the same conditions as native entity2_term; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilins
1
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native entity1_term; and 4) dialyzed human and Acanthamoeba entity2_term inhibit actin polymerization.
profilin-I
profilins
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to entity1_term in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native entity2_term; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
actin
profilin-I
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native entity1_term; and 4) dialyzed human and Acanthamoeba profilins inhibit entity2_term polymerization.
profilin-I
actin
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed entity1_term form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native entity2_term; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilin-I
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human entity1_term rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native entity2_term; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilin-I
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native entity1_term; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native entity2_term; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilin-I
0
Several lines of evidence show that the entity1_term fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native entity2_term; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilin-I
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified entity1_term without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native entity2_term; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilin
profilin-I
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to entity1_term in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba entity2_term inhibit actin polymerization.
actin
profilins
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed entity1_term form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba entity2_term inhibit actin polymerization.
profilins
profilins
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba entity1_term has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba entity2_term inhibit actin polymerization.
profilin-I
profilins
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human entity1_term rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba entity2_term inhibit actin polymerization.
profilins
profilins
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native entity1_term; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba entity2_term inhibit actin polymerization.
profilins
profilins
0
Several lines of evidence show that the entity1_term fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba entity2_term inhibit actin polymerization.
profilins
profilins
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified entity1_term without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba entity2_term inhibit actin polymerization.
profilin
profilins
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to entity1_term in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit entity2_term polymerization.
actin
actin
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to entity1_term in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed entity2_term form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
actin
profilins
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to entity1_term in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba entity2_term has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
actin
profilin-I
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to entity1_term in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native entity2_term; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
actin
profilins
0
Several lines of evidence show that the entity1_term fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to entity2_term in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
actin
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed entity1_term form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit entity2_term polymerization.
profilins
actin
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba entity1_term has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit entity2_term polymerization.
profilin-I
actin
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human entity1_term rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit entity2_term polymerization.
profilins
actin
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native entity1_term; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit entity2_term polymerization.
profilins
actin
0
Several lines of evidence show that the entity1_term fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit entity2_term polymerization.
profilins
actin
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified entity1_term without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit entity2_term polymerization.
profilin
actin
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed entity1_term form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba entity2_term has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilin-I
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human entity1_term rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed entity2_term form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilins
0
Several lines of evidence show that the entity1_term fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed entity2_term form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilins
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified entity1_term without urea treatment; 2) dialyzed entity2_term form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilin
profilins
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human entity1_term rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba entity2_term has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilin-I
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native entity1_term; 3) dialyzed Acanthamoeba entity2_term has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilin-I
0
Several lines of evidence show that the entity1_term fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba entity2_term has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilin-I
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified entity1_term without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba entity2_term has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilin
profilin-I
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human entity1_term rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native entity2_term; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilins
0
Several lines of evidence show that the entity1_term fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human entity2_term rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilins
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human entity1_term rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified entity2_term without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilin
0
Several lines of evidence show that the entity1_term fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified profilin without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native entity2_term; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilins
0
Several lines of evidence show that the profilins fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified entity1_term without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native entity2_term; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilin
profilins
0
Several lines of evidence show that the entity1_term fully renature after removal of the urea by dialysis: 1) dialyzed Acanthamoeba and human profilins rebind quantitatively to poly-L-proline and bind to actin in the same way as native, conventionally purified entity2_term without urea treatment; 2) dialyzed profilins form 3-D crystals under the same conditions as native profilins; 3) dialyzed Acanthamoeba profilin-I has an NMR spectrum identical with that of native profilin-I; and 4) dialyzed human and Acanthamoeba profilins inhibit actin polymerization.
profilins
profilin
0
Conversely, inhibition of entity1_term's activity by expressing a dominant negative construct, entity2_term, or expression of the constitutively active S3A cofilin mutant induces loss of actin filaments at the phagocytic cup and also inhibits phagocytosis.
LIMK
LIMK1-
1
Conversely, inhibition of LIMK's activity by expressing a dominant negative construct, LIMK1-, or expression of the constitutively active S3A entity1_term mutant induces loss of entity2_term filaments at the phagocytic cup and also inhibits phagocytosis.
cofilin
actin
1
Conversely, inhibition of LIMK's activity by expressing a dominant negative construct, entity1_term, or expression of the constitutively active S3A cofilin mutant induces loss of entity2_term filaments at the phagocytic cup and also inhibits phagocytosis.
LIMK1-
actin
1
Conversely, inhibition of entity1_term's activity by expressing a dominant negative construct, LIMK1-, or expression of the constitutively active S3A cofilin mutant induces loss of entity2_term filaments at the phagocytic cup and also inhibits phagocytosis.
LIMK
actin
1
Conversely, inhibition of LIMK's activity by expressing a dominant negative construct, entity1_term, or expression of the constitutively active S3A entity2_term mutant induces loss of actin filaments at the phagocytic cup and also inhibits phagocytosis.
LIMK1-
cofilin
0
Conversely, inhibition of entity1_term's activity by expressing a dominant negative construct, LIMK1-, or expression of the constitutively active S3A entity2_term mutant induces loss of actin filaments at the phagocytic cup and also inhibits phagocytosis.
LIMK
cofilin
0
The herpes simplex virus type-1 entity1_term, UL8, and UL52 genes encode an essential heterotrimeric entity2_term that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork.
UL5
DNA helicase-primase
1
The herpes simplex virus type-1 UL5, UL8, and entity1_term genes encode an essential heterotrimeric entity2_term that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork.
UL52
DNA helicase-primase
1
The herpes simplex virus type-1 UL5, entity1_term, and UL52 genes encode an essential heterotrimeric entity2_term that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork.
UL8
DNA helicase-primase
1
The herpes simplex virus type-1 UL5, entity1_term, and entity2_term genes encode an essential heterotrimeric DNA helicase-primase that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork.
UL8
UL52
0
The herpes simplex virus type-1 entity1_term, entity2_term, and UL52 genes encode an essential heterotrimeric DNA helicase-primase that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork.
UL5
UL8
0
The herpes simplex virus type-1 entity1_term, UL8, and entity2_term genes encode an essential heterotrimeric DNA helicase-primase that is responsible for concomitant DNA unwinding and primer synthesis at the viral DNA replication fork.
UL5
UL52
0
Effects of entity1_term on entity2_term in the presence and absence of acumentin and gelsolin.
macrophage profilin
actin
1
Effects of entity1_term on actin in the presence and absence of acumentin and entity2_term.
macrophage profilin
gelsolin
0
Effects of entity1_term on actin in the presence and absence of entity2_term and gelsolin.
macrophage profilin
acumentin
0
Effects of macrophage profilin on entity1_term in the presence and absence of acumentin and entity2_term.
actin
gelsolin
0
Effects of macrophage profilin on entity1_term in the presence and absence of entity2_term and gelsolin.
actin
acumentin
0
Effects of macrophage profilin on actin in the presence and absence of entity1_term and entity2_term.
acumentin
gelsolin
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
CDC39
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
TEC1
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, entity1_term, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
CDC55
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, entity1_term, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
WHI3
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, entity1_term, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
NAB1
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
STE12
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, entity1_term, DFG5, DFG9, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
BNI1
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, entity1_term, entity2_term and DFG16, mutations that block filamentous growth.
DFG10
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, entity1_term and entity2_term, mutations that block filamentous growth.
BUD8
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, entity1_term, SPA2, BNI1, DFG5, DFG9, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
TPM1
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, entity1_term, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
DFG9
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, entity1_term, BNI1, DFG5, DFG9, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
SPA2
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, entity1_term, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
DBR1
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, entity1_term, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
SRV2
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, entity1_term, DFG9, DFG10, entity2_term and DFG16, mutations that block filamentous growth.
DFG5
BUD8
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, entity2_term, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
TEC1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, WHI3, NAB1, DBR1, entity2_term, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
CDC55
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, entity2_term, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
WHI3
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, WHI3, entity2_term, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
NAB1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, entity2_term, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
STE12
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, entity2_term, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
BNI1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
CDC39
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, entity2_term, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
TPM1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, entity2_term, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
DFG9
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, entity2_term, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
SPA2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, WHI3, NAB1, entity2_term, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
DBR1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, entity2_term, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
SRV2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, entity1_term, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, entity2_term, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC39
DFG5
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, WHI3, NAB1, DBR1, entity2_term, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TEC1
CDC55
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, entity2_term, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TEC1
WHI3
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, WHI3, entity2_term, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TEC1
NAB1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, entity2_term, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
STE12
TEC1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, entity2_term, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TEC1
BNI1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
TEC1
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
TEC1
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, WHI3, NAB1, DBR1, CDC55, SRV2, entity2_term, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TEC1
TPM1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, entity2_term, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TEC1
DFG9
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, entity2_term, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TEC1
SPA2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, WHI3, NAB1, entity2_term, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TEC1
DBR1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, WHI3, NAB1, DBR1, CDC55, entity2_term, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TEC1
SRV2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, entity1_term, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, entity2_term, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TEC1
DFG5
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, entity1_term, NAB1, DBR1, entity2_term, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
WHI3
CDC55
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, entity1_term, DBR1, entity2_term, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
NAB1
CDC55
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, WHI3, NAB1, DBR1, entity2_term, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
STE12
CDC55
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, entity1_term, SRV2, TPM1, SPA2, entity2_term, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC55
BNI1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, entity1_term, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
CDC55
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, entity1_term, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
CDC55
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, entity1_term, SRV2, entity2_term, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC55
TPM1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, entity1_term, SRV2, TPM1, SPA2, BNI1, DFG5, entity2_term, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC55
DFG9
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, entity1_term, SRV2, TPM1, entity2_term, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC55
SPA2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, entity1_term, entity2_term, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
DBR1
CDC55
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, entity1_term, entity2_term, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC55
SRV2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, entity1_term, SRV2, TPM1, SPA2, BNI1, entity2_term, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
CDC55
DFG5
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, entity1_term, entity2_term, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
WHI3
NAB1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, entity2_term, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
STE12
WHI3
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, entity1_term, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, entity2_term, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
WHI3
BNI1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, entity1_term, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
WHI3
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, entity1_term, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
WHI3
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, entity1_term, NAB1, DBR1, CDC55, SRV2, entity2_term, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
WHI3
TPM1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, entity1_term, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, entity2_term, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
WHI3
DFG9
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, entity1_term, NAB1, DBR1, CDC55, SRV2, TPM1, entity2_term, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
WHI3
SPA2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, entity1_term, NAB1, entity2_term, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
WHI3
DBR1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, entity1_term, NAB1, DBR1, CDC55, entity2_term, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
WHI3
SRV2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, entity1_term, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, entity2_term, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
WHI3
DFG5
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, WHI3, entity2_term, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
STE12
NAB1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, entity1_term, DBR1, CDC55, SRV2, TPM1, SPA2, entity2_term, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
NAB1
BNI1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, entity1_term, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
NAB1
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, entity1_term, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
NAB1
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, entity1_term, DBR1, CDC55, SRV2, entity2_term, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
NAB1
TPM1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, entity1_term, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, entity2_term, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
NAB1
DFG9
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, entity1_term, DBR1, CDC55, SRV2, TPM1, entity2_term, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
NAB1
SPA2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, entity1_term, entity2_term, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
NAB1
DBR1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, entity1_term, DBR1, CDC55, entity2_term, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
NAB1
SRV2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, entity1_term, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, entity2_term, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
NAB1
DFG5
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, entity2_term, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
STE12
BNI1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
STE12
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
STE12
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, entity2_term, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
STE12
TPM1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, entity2_term, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
STE12
DFG9
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, entity2_term, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
STE12
SPA2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, WHI3, NAB1, entity2_term, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
STE12
DBR1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, WHI3, NAB1, DBR1, CDC55, entity2_term, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
STE12
SRV2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, entity1_term, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, entity2_term, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
STE12
DFG5
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, entity1_term, DFG5, DFG9, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
BNI1
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, entity1_term, DFG5, DFG9, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
BNI1
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, entity1_term, SPA2, entity2_term, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TPM1
BNI1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, entity1_term, DFG5, entity2_term, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
BNI1
DFG9
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, entity1_term, entity2_term, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
SPA2
BNI1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, entity1_term, CDC55, SRV2, TPM1, SPA2, entity2_term, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
DBR1
BNI1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, entity1_term, TPM1, SPA2, entity2_term, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
SRV2
BNI1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, entity1_term, entity2_term, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
BNI1
DFG5
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, entity1_term, BUD8 and entity2_term, mutations that block filamentous growth.
DFG10
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, entity1_term, SPA2, BNI1, DFG5, DFG9, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
TPM1
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, entity1_term, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
DFG9
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, entity1_term, BNI1, DFG5, DFG9, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
SPA2
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, entity1_term, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
DBR1
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, entity1_term, TPM1, SPA2, BNI1, DFG5, DFG9, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
SRV2
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, entity1_term, DFG9, entity2_term, BUD8 and DFG16, mutations that block filamentous growth.
DFG5
DFG10
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, entity1_term, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
TPM1
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, entity1_term, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
DFG9
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, entity1_term, BNI1, DFG5, DFG9, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
SPA2
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, entity1_term, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
DBR1
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, entity1_term, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
SRV2
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, entity1_term, DFG9, DFG10, BUD8 and entity2_term, mutations that block filamentous growth.
DFG5
DFG16
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, entity1_term, SPA2, BNI1, DFG5, entity2_term, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TPM1
DFG9
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, entity1_term, entity2_term, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TPM1
SPA2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, entity1_term, CDC55, SRV2, entity2_term, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
DBR1
TPM1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, entity1_term, entity2_term, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
SRV2
TPM1
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, entity1_term, SPA2, BNI1, entity2_term, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
TPM1
DFG5
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, entity1_term, BNI1, DFG5, entity2_term, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
SPA2
DFG9
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, entity1_term, CDC55, SRV2, TPM1, SPA2, BNI1, DFG5, entity2_term, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
DBR1
DFG9
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, entity1_term, TPM1, SPA2, BNI1, DFG5, entity2_term, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
SRV2
DFG9
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, SPA2, BNI1, entity1_term, entity2_term, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
DFG5
DFG9
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, entity1_term, CDC55, SRV2, TPM1, entity2_term, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
DBR1
SPA2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, entity1_term, TPM1, entity2_term, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
SRV2
SPA2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, SRV2, TPM1, entity1_term, BNI1, entity2_term, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
SPA2
DFG5
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, entity1_term, CDC55, entity2_term, TPM1, SPA2, BNI1, DFG5, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
DBR1
SRV2
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, entity1_term, CDC55, SRV2, TPM1, SPA2, BNI1, entity2_term, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
DBR1
DFG5
0
Here, we designed a genetic screen for mutant strains defective for filamentous growth (dfg) to identify novel targets of the filamentation signaling pathway, and we thereby identified 16 different genes, CDC39, STE12, TEC1, WHI3, NAB1, DBR1, CDC55, entity1_term, TPM1, SPA2, BNI1, entity2_term, DFG9, DFG10, BUD8 and DFG16, mutations that block filamentous growth.
SRV2
DFG5
0
Purification of cofilin, a 21,000 molecular weight actin-binding protein, from porcine kidney and identification of the entity1_term-binding site in the entity2_term sequence.
cofilin
actin
1
Purification of entity1_term, a 21,000 molecular weight entity2_term, from porcine kidney and identification of the cofilin-binding site in the actin sequence.
cofilin
actin-binding protein
1
Analysis of this product by peptide mapping (Sutoh (1982) Biochemistry 21, 3654-3661) showed that entity1_term was cross-linked with the N-terminal segment of entity2_term containing residues 1-12.
cofilin
actin
1
Purification of entity1_term, a 21,000 molecular weight actin-binding protein, from porcine kidney and identification of the entity2_term-binding site in the actin sequence.
cofilin
cofilin
0
Purification of entity1_term, a 21,000 molecular weight actin-binding protein, from porcine kidney and identification of the cofilin-binding site in the entity2_term sequence.
cofilin
actin
0
Purification of cofilin, a 21,000 molecular weight entity1_term, from porcine kidney and identification of the entity2_term-binding site in the actin sequence.
actin-binding protein
cofilin
0
Purification of cofilin, a 21,000 molecular weight entity1_term, from porcine kidney and identification of the cofilin-binding site in the entity2_term sequence.
actin-binding protein
actin
0
At the light microscope level, brush cells can be identified by antibodies against the entity1_term filament crosslinking proteins villin and entity2_term that not only stain the apical tuft of microvilli and their rootlets, but also label projections emanating from the basolateral surface of these cells.
actin
fimbrin
1
At the light microscope level, brush cells can be identified by antibodies against the entity1_term filament crosslinking proteins entity2_term and fimbrin that not only stain the apical tuft of microvilli and their rootlets, but also label projections emanating from the basolateral surface of these cells.
actin
villin
1
At the light microscope level, brush cells can be identified by antibodies against the actin filament crosslinking proteins entity1_term and entity2_term that not only stain the apical tuft of microvilli and their rootlets, but also label projections emanating from the basolateral surface of these cells.
villin
fimbrin
0
Ser-133 phosphorylation enhances entity1_term activity by promoting interaction with a 265-kDa entity2_term referred to as CBP (Arias, J., Alberts, A., Brindle, P., Claret, F., Smeal, T., Karin, M., Feramisco, J., and Montminy, M. (1994) Nature 370, 226-228; Chrivia, J. C., Kwok, R. P., Lamb, N., Hagiwara, M., Montminy, M. R., and Goodman, R. H. (1993) Nature 365, 855-859).
CREB
CREB binding protein
1
Ser-133 phosphorylation enhances entity1_term activity by promoting interaction with a 265-kDa CREB binding protein referred to as entity2_term (Arias, J., Alberts, A., Brindle, P., Claret, F., Smeal, T., Karin, M., Feramisco, J., and Montminy, M. (1994) Nature 370, 226-228; Chrivia, J. C., Kwok, R. P., Lamb, N., Hagiwara, M., Montminy, M. R., and Goodman, R. H. (1993) Nature 365, 855-859).
CREB
CBP
1
Ser-133 phosphorylation enhances CREB activity by promoting interaction with a 265-kDa entity1_term referred to as entity2_term (Arias, J., Alberts, A., Brindle, P., Claret, F., Smeal, T., Karin, M., Feramisco, J., and Montminy, M. (1994) Nature 370, 226-228; Chrivia, J. C., Kwok, R. P., Lamb, N., Hagiwara, M., Montminy, M. R., and Goodman, R. H. (1993) Nature 365, 855-859).
CREB binding protein
CBP
0
Immunohistochemistry revealed that arteries had three distinct populations of cells in respect to entity1_term, smooth muscle myosin heavy chain and vimentin (staining intensities '-', '+' or '++' for each protein), but only two populations in respect to entity2_term ('-' and '+').
alpha-smooth muscle actin
desmin
0
Immunohistochemistry revealed that arteries had three distinct populations of cells in respect to alpha-smooth muscle actin, entity1_term and vimentin (staining intensities '-', '+' or '++' for each protein), but only two populations in respect to entity2_term ('-' and '+').
smooth muscle myosin heavy chain
desmin
0
Immunohistochemistry revealed that arteries had three distinct populations of cells in respect to alpha-smooth muscle actin, smooth muscle myosin heavy chain and entity1_term (staining intensities '-', '+' or '++' for each protein), but only two populations in respect to entity2_term ('-' and '+').
vimentin
desmin
0
Immunohistochemistry revealed that arteries had three distinct populations of cells in respect to entity1_term, entity2_term and vimentin (staining intensities '-', '+' or '++' for each protein), but only two populations in respect to desmin ('-' and '+').
alpha-smooth muscle actin
smooth muscle myosin heavy chain
0
Immunohistochemistry revealed that arteries had three distinct populations of cells in respect to entity1_term, smooth muscle myosin heavy chain and entity2_term (staining intensities '-', '+' or '++' for each protein), but only two populations in respect to desmin ('-' and '+').
alpha-smooth muscle actin
vimentin
0
Immunohistochemistry revealed that arteries had three distinct populations of cells in respect to alpha-smooth muscle actin, entity1_term and entity2_term (staining intensities '-', '+' or '++' for each protein), but only two populations in respect to desmin ('-' and '+').
smooth muscle myosin heavy chain
vimentin
0
Confluent calf pulmonary artery endothelial monolayers exposed to 95% oxygen for 1, 2, or 3 days exhibit a time-dependent increase in adherence to substratum, which closely parallels changes in entity1_term cytoarchitecture and the distribution of focal contact proteins entity2_term and talin.
actin
vinculin
0
Confluent calf pulmonary artery endothelial monolayers exposed to 95% oxygen for 1, 2, or 3 days exhibit a time-dependent increase in adherence to substratum, which closely parallels changes in entity1_term cytoarchitecture and the distribution of focal contact proteins vinculin and entity2_term.
actin
talin
0
Confluent calf pulmonary artery endothelial monolayers exposed to 95% oxygen for 1, 2, or 3 days exhibit a time-dependent increase in adherence to substratum, which closely parallels changes in actin cytoarchitecture and the distribution of focal contact proteins entity1_term and entity2_term.
vinculin
talin
0
During incubation of whole myofibrils at 37 degrees C, entity1_term, alpha actinin, actin and entity2_term suffered degradation.
myosin heavy chain
troponin T
0
During incubation of whole myofibrils at 37 degrees C, myosin heavy chain, entity1_term, actin and entity2_term suffered degradation.
alpha actinin
troponin T
0
During incubation of whole myofibrils at 37 degrees C, myosin heavy chain, alpha actinin, entity1_term and entity2_term suffered degradation.
actin
troponin T
0
During incubation of whole myofibrils at 37 degrees C, entity1_term, entity2_term, actin and troponin T suffered degradation.
myosin heavy chain
alpha actinin
0
During incubation of whole myofibrils at 37 degrees C, entity1_term, alpha actinin, entity2_term and troponin T suffered degradation.
myosin heavy chain
actin
0
During incubation of whole myofibrils at 37 degrees C, myosin heavy chain, entity1_term, entity2_term and troponin T suffered degradation.
alpha actinin
actin
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of cyclin D1, the entity1_term entity2_term and of p53 and decreased expression of the cyclin dependent kinase inhibitor p27kip1.
cyclin dependent kinase inhibitor
p16ink4a
1
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of cyclin D1, the cyclin dependent kinase inhibitor p16ink4a and of p53 and decreased expression of the entity1_term entity2_term.
cyclin dependent kinase inhibitor
p27kip1
1
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of entity1_term, the cyclin dependent kinase inhibitor entity2_term and of p53 and decreased expression of the cyclin dependent kinase inhibitor p27kip1.
cyclin D1
p16ink4a
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of entity1_term, the entity2_term p16ink4a and of p53 and decreased expression of the cyclin dependent kinase inhibitor p27kip1.
cyclin D1
cyclin dependent kinase inhibitor
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of entity1_term, the cyclin dependent kinase inhibitor p16ink4a and of p53 and decreased expression of the entity2_term p27kip1.
cyclin D1
cyclin dependent kinase inhibitor
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of entity1_term, the cyclin dependent kinase inhibitor p16ink4a and of entity2_term and decreased expression of the cyclin dependent kinase inhibitor p27kip1.
cyclin D1
p53
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of entity1_term, the cyclin dependent kinase inhibitor p16ink4a and of p53 and decreased expression of the cyclin dependent kinase inhibitor entity2_term.
cyclin D1
p27kip1
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of cyclin D1, the cyclin dependent kinase inhibitor entity1_term and of p53 and decreased expression of the entity2_term p27kip1.
p16ink4a
cyclin dependent kinase inhibitor
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of cyclin D1, the cyclin dependent kinase inhibitor entity1_term and of entity2_term and decreased expression of the cyclin dependent kinase inhibitor p27kip1.
p16ink4a
p53
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of cyclin D1, the cyclin dependent kinase inhibitor entity1_term and of p53 and decreased expression of the cyclin dependent kinase inhibitor entity2_term.
p16ink4a
p27kip1
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of cyclin D1, the entity1_term p16ink4a and of p53 and decreased expression of the entity2_term p27kip1.
cyclin dependent kinase inhibitor
cyclin dependent kinase inhibitor
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of cyclin D1, the entity1_term p16ink4a and of entity2_term and decreased expression of the cyclin dependent kinase inhibitor p27kip1.
cyclin dependent kinase inhibitor
p53
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of cyclin D1, the entity1_term p16ink4a and of p53 and decreased expression of the cyclin dependent kinase inhibitor entity2_term.
cyclin dependent kinase inhibitor
p27kip1
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of cyclin D1, the cyclin dependent kinase inhibitor p16ink4a and of entity1_term and decreased expression of the entity2_term p27kip1.
p53
cyclin dependent kinase inhibitor
0
The hyperproliferative response observed in the gastric mucosa is secondary to this initial insult and is associated with increased expression of cyclin D1, the cyclin dependent kinase inhibitor p16ink4a and of entity1_term and decreased expression of the cyclin dependent kinase inhibitor entity2_term.
p53
p27kip1
0
Here, we have detected a polypeptide in rat rod outer segments that is recognized by myosin heavy chain antibodies and was found to possess other characteristics of conventional entity1_term: it comigrates in SDS-PAGE with non-muscle myosin heavy chain; it associates with the cytoskeleton of rod outer segments in an ATP-sensitive manner; and it binds to purified entity2_term filaments in the absence of ATP.
non-muscle myosin heavy chain
actin
1
Here, we have detected a polypeptide in rat rod outer segments that is recognized by myosin heavy chain antibodies and was found to possess other characteristics of conventional non-muscle myosin heavy chain: it comigrates in SDS-PAGE with entity1_term; it associates with the cytoskeleton of rod outer segments in an ATP-sensitive manner; and it binds to purified entity2_term filaments in the absence of ATP.
non-muscle myosin heavy chain
actin
0
Here, we have detected a polypeptide in rat rod outer segments that is recognized by entity1_term antibodies and was found to possess other characteristics of conventional non-muscle myosin heavy chain: it comigrates in SDS-PAGE with non-muscle myosin heavy chain; it associates with the cytoskeleton of rod outer segments in an ATP-sensitive manner; and it binds to purified entity2_term filaments in the absence of ATP.
myosin heavy chain
actin
0
Here, we have detected a polypeptide in rat rod outer segments that is recognized by myosin heavy chain antibodies and was found to possess other characteristics of conventional entity1_term: it comigrates in SDS-PAGE with entity2_term; it associates with the cytoskeleton of rod outer segments in an ATP-sensitive manner; and it binds to purified actin filaments in the absence of ATP.
non-muscle myosin heavy chain
non-muscle myosin heavy chain
0
Here, we have detected a polypeptide in rat rod outer segments that is recognized by entity1_term antibodies and was found to possess other characteristics of conventional non-muscle myosin heavy chain: it comigrates in SDS-PAGE with entity2_term; it associates with the cytoskeleton of rod outer segments in an ATP-sensitive manner; and it binds to purified actin filaments in the absence of ATP.
myosin heavy chain
non-muscle myosin heavy chain
0
Here, we have detected a polypeptide in rat rod outer segments that is recognized by entity1_term antibodies and was found to possess other characteristics of conventional entity2_term: it comigrates in SDS-PAGE with non-muscle myosin heavy chain; it associates with the cytoskeleton of rod outer segments in an ATP-sensitive manner; and it binds to purified actin filaments in the absence of ATP.
myosin heavy chain
non-muscle myosin heavy chain
0
We propose that entity1_term may act by forming, during the critical period of cerebellar development, a reserve pool of monomeric entity2_term that can easily be mobilized in cell regions such as growth cones or synaptic junctions where filamentous actin is highly concentrated.
profilin
actin
1
We propose that entity1_term may act by forming, during the critical period of cerebellar development, a reserve pool of monomeric actin that can easily be mobilized in cell regions such as growth cones or synaptic junctions where filamentous entity2_term is highly concentrated.
profilin
actin
0
We propose that profilin may act by forming, during the critical period of cerebellar development, a reserve pool of monomeric entity1_term that can easily be mobilized in cell regions such as growth cones or synaptic junctions where filamentous entity2_term is highly concentrated.
actin
actin
0
The results indicate that (a) plakoglobin and entity1_term differ in their nuclear translocation and complexing with LEF-1 and entity2_term; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
beta-catenin
vinculin
1
The results indicate that (a) entity1_term and entity2_term differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
plakoglobin
beta-catenin
1
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of entity1_term, entity2_term and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
beta-catenin
cadherin
1
The results indicate that (a) entity1_term and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and entity2_term; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
plakoglobin
vinculin
1
The results indicate that (a) plakoglobin and entity1_term differ in their nuclear translocation and complexing with entity2_term and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
beta-catenin
LEF-1
1
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of entity1_term, cadherin and entity2_term, can sequester it to the cytoplasm and inhibit its transcriptional activity.
beta-catenin
alpha-catenin
1
The results indicate that (a) entity1_term and beta-catenin differ in their nuclear translocation and complexing with entity2_term and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
plakoglobin
LEF-1
1
The results indicate that (a) entity1_term and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, entity2_term and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
plakoglobin
cadherin
0
The results indicate that (a) entity1_term and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of entity2_term, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
plakoglobin
beta-catenin
0
The results indicate that (a) entity1_term and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by entity2_term; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
plakoglobin
beta-catenin
0
The results indicate that (a) entity1_term and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) entity2_term-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
plakoglobin
LEF-1
0
The results indicate that (a) entity1_term and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and entity2_term, can sequester it to the cytoplasm and inhibit its transcriptional activity.
plakoglobin
alpha-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and entity1_term; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, entity2_term and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
vinculin
cadherin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by entity1_term; and (c) the cytoplasmic partners of beta-catenin, entity2_term and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
beta-catenin
cadherin
0
The results indicate that (a) plakoglobin and entity1_term differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, entity2_term and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
beta-catenin
cadherin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) entity1_term-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, entity2_term and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
LEF-1
cadherin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, entity1_term and entity2_term, can sequester it to the cytoplasm and inhibit its transcriptional activity.
cadherin
alpha-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with entity1_term and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, entity2_term and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
LEF-1
cadherin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and entity1_term; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of entity2_term, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
vinculin
beta-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by entity1_term; and (c) the cytoplasmic partners of entity2_term, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
beta-catenin
beta-catenin
0
The results indicate that (a) plakoglobin and entity1_term differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of entity2_term, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
beta-catenin
beta-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) entity1_term-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of entity2_term, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
LEF-1
beta-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with entity1_term and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of entity2_term, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
LEF-1
beta-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and entity1_term; (b) LEF-1-dependent transactivation is preferentially driven by entity2_term; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
vinculin
beta-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and entity1_term; (b) entity2_term-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
vinculin
LEF-1
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and entity1_term; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and entity2_term, can sequester it to the cytoplasm and inhibit its transcriptional activity.
vinculin
alpha-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with entity1_term and entity2_term; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
LEF-1
vinculin
0
The results indicate that (a) plakoglobin and entity1_term differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by entity2_term; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
beta-catenin
beta-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) entity1_term-dependent transactivation is preferentially driven by entity2_term; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
LEF-1
beta-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by entity1_term; and (c) the cytoplasmic partners of beta-catenin, cadherin and entity2_term, can sequester it to the cytoplasm and inhibit its transcriptional activity.
beta-catenin
alpha-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with entity1_term and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by entity2_term; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
LEF-1
beta-catenin
0
The results indicate that (a) plakoglobin and entity1_term differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) entity2_term-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
beta-catenin
LEF-1
0
The results indicate that (a) plakoglobin and entity1_term differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and entity2_term, can sequester it to the cytoplasm and inhibit its transcriptional activity.
beta-catenin
alpha-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with LEF-1 and vinculin; (b) entity1_term-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and entity2_term, can sequester it to the cytoplasm and inhibit its transcriptional activity.
LEF-1
alpha-catenin
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with entity1_term and vinculin; (b) entity2_term-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and alpha-catenin, can sequester it to the cytoplasm and inhibit its transcriptional activity.
LEF-1
LEF-1
0
The results indicate that (a) plakoglobin and beta-catenin differ in their nuclear translocation and complexing with entity1_term and vinculin; (b) LEF-1-dependent transactivation is preferentially driven by beta-catenin; and (c) the cytoplasmic partners of beta-catenin, cadherin and entity2_term, can sequester it to the cytoplasm and inhibit its transcriptional activity.
LEF-1
alpha-catenin
0
The polycystic kidney disease 1 gene product mediates protein kinase C alpha-dependent and entity1_term-dependent activation of the transcription factor entity2_term.
c-Jun N-terminal kinase
AP-1
1
The entity1_term gene product mediates protein kinase C alpha-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor entity2_term.
polycystic kidney disease 1
AP-1
1
The polycystic kidney disease 1 gene product mediates entity1_term-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor entity2_term.
protein kinase C alpha
AP-1
1
The entity1_term gene product mediates entity2_term-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor AP-1.
polycystic kidney disease 1
protein kinase C alpha
0
The polycystic kidney disease 1 gene product mediates entity1_term-dependent and entity2_term-dependent activation of the transcription factor AP-1.
protein kinase C alpha
c-Jun N-terminal kinase
0
The entity1_term gene product mediates protein kinase C alpha-dependent and entity2_term-dependent activation of the transcription factor AP-1.
polycystic kidney disease 1
c-Jun N-terminal kinase
0
Recently, we have shown that the small entity1_term-depolymerizing protein entity2_term represents a component of a co-stimulatory signaling pathway in human T cells.
actin
cofilin
1
These results suggest that entity1_term provides an as yet missing link between functionally crucial T cell surface receptors and rearrangements of the entity2_term cytoskeleton.
cofilin
actin
1
Here we demonstrate that accessory receptor triggering induces the transient association of entity1_term with the entity2_term cytoskeleton.
cofilin
actin
1
These observations demonstrate that cardiac development in man, in contrast to rodent heart, is characterized by an up-regulation of the skeletal actin gene, the expression of which does not change in hypertrophied and failing hearts, and suggest that the entity1_term and entity2_term families are independently regulated in human heart.
actin
myosin heavy chain
1
These observations demonstrate that cardiac development in man, in contrast to rodent heart, is characterized by an up-regulation of the entity1_term gene, the expression of which does not change in hypertrophied and failing hearts, and suggest that the actin and entity2_term families are independently regulated in human heart.
skeletal actin
myosin heavy chain
0
These observations demonstrate that cardiac development in man, in contrast to rodent heart, is characterized by an up-regulation of the entity1_term gene, the expression of which does not change in hypertrophied and failing hearts, and suggest that the entity2_term and myosin heavy chain families are independently regulated in human heart.
skeletal actin
actin
0
Additional studies demonstrated the entity1_term distribution to be remarkably similar to that of entity2_term, whereas alpha-catenin staining was more diffuse in the cytoplasm of airway epithelial and gland bud cells.
gamma-catenin
beta-catenin
1
Additional studies demonstrated the gamma-catenin distribution to be remarkably similar to that of entity1_term, whereas entity2_term staining was more diffuse in the cytoplasm of airway epithelial and gland bud cells.
beta-catenin
alpha-catenin
0
Additional studies demonstrated the entity1_term distribution to be remarkably similar to that of beta-catenin, whereas entity2_term staining was more diffuse in the cytoplasm of airway epithelial and gland bud cells.
gamma-catenin
alpha-catenin
0
The quantity of the complex is reduced by treatment of Caco-2 cells with the alkylating agent N-ethylmaleimide which also has an inhibitory effect on the ability of entity1_term to associate with entity2_term in vitro.
Munc-18-2
syntaxin 3
1
Interaction of entity1_term with syntaxin 3 controls the association of apical entity2_term in epithelial cells.
Munc-18-2
SNAREs
1
Interaction of Munc-18-2 with entity1_term controls the association of apical entity2_term in epithelial cells.
syntaxin 3
SNAREs
1
Interaction of entity1_term with entity2_term controls the association of apical SNAREs in epithelial cells.
Munc-18-2
syntaxin 3
1
Mechanism of inhibition of proliferating cell nuclear antigen-dependent DNA synthesis by the entity1_term entity2_term.
cyclin-dependent kinase inhibitor
p21
1
Mechanism of inhibition of entity1_term-dependent DNA synthesis by the entity2_term p21.
proliferating cell nuclear antigen
cyclin-dependent kinase inhibitor
0
Mechanism of inhibition of entity1_term-dependent DNA synthesis by the cyclin-dependent kinase inhibitor entity2_term.
proliferating cell nuclear antigen
p21
0
However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the entity1_term cyclin-dependent kinase inhibitor (CKI), and the associated inhibition of entity2_term-CDK2.
p27
cyclin E
1
However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the p27 cyclin-dependent kinase inhibitor (CKI), and the associated inhibition of entity1_term-entity2_term.
cyclin E
CDK2
1
However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the entity1_term entity2_term (CKI), and the associated inhibition of cyclin E-CDK2.
p27
cyclin-dependent kinase inhibitor
1
However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the entity1_term cyclin-dependent kinase inhibitor (CKI), and the associated inhibition of cyclin E-entity2_term.
p27
CDK2
1
However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the entity1_term cyclin-dependent kinase inhibitor (entity2_term), and the associated inhibition of cyclin E-CDK2.
p27
CKI
1
However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the p27 cyclin-dependent kinase inhibitor (entity1_term), and the associated inhibition of cyclin E-entity2_term.
CKI
CDK2
0
However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the p27 entity1_term (CKI), and the associated inhibition of cyclin E-entity2_term.
cyclin-dependent kinase inhibitor
CDK2
0
However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the p27 cyclin-dependent kinase inhibitor (entity1_term), and the associated inhibition of entity2_term-CDK2.
CKI
cyclin E
0
However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the p27 entity1_term (CKI), and the associated inhibition of entity2_term-CDK2.
cyclin-dependent kinase inhibitor
cyclin E
0
However, in non-adherent cells no molecular mechanism has yet been proposed for the cell adhesion-dependent up-regulation of the p27 entity1_term (entity2_term), and the associated inhibition of cyclin E-CDK2.
cyclin-dependent kinase inhibitor
CKI
0
The enzyme showed hardly any activity below 50 degrees C but considerable activity at around 60 degrees C against myofibrils, digesting entity1_term, entity2_term and tropomyosin.
myosin heavy chain
actin
0
The enzyme showed hardly any activity below 50 degrees C but considerable activity at around 60 degrees C against myofibrils, digesting myosin heavy chain, entity1_term and entity2_term.
actin
tropomyosin
0
The enzyme showed hardly any activity below 50 degrees C but considerable activity at around 60 degrees C against myofibrils, digesting entity1_term, actin and entity2_term.
myosin heavy chain
tropomyosin
0
entity1_term mutations completely abolished the ability to generate type II survivors, while entity2_term mutations decreased the growth viability of type II survivors but did not completely eliminate their appearance.
rad59
rad50
0
Deletion of both entity1_term and entity2_term produces a phenotype similar to that produced by deletion of RAD52.
RAD50
RAD51
0
Deletion of both RAD50 and entity1_term produces a phenotype similar to that produced by deletion of entity2_term.
RAD51
RAD52
0
Deletion of both entity1_term and RAD51 produces a phenotype similar to that produced by deletion of entity2_term.
RAD50
RAD52
0
Recently it has been established, through a detailed biochemical analysis, that recombinant Arabidopsis thaliana entity1_term (AtFim1) is a member of the entity2_term family of actin filament bundling or cross-linking proteins [D.R.
fimbrin 1
fimbrin/plastin
1
Recently it has been established, through a detailed biochemical analysis, that recombinant Arabidopsis thaliana fimbrin 1 (entity1_term) is a member of the entity2_term family of actin filament bundling or cross-linking proteins [D.R.
AtFim1
fimbrin/plastin
1
Recently it has been established, through a detailed biochemical analysis, that recombinant Arabidopsis thaliana fimbrin 1 (AtFim1) is a member of the entity1_term family of entity2_term filament bundling or cross-linking proteins [D.R.
fimbrin/plastin
actin
1
Recently it has been established, through a detailed biochemical analysis, that recombinant Arabidopsis thaliana entity1_term (entity2_term) is a member of the fimbrin/plastin family of actin filament bundling or cross-linking proteins [D.R.
fimbrin 1
AtFim1
0
Recently it has been established, through a detailed biochemical analysis, that recombinant Arabidopsis thaliana fimbrin 1 (entity1_term) is a member of the fimbrin/plastin family of entity2_term filament bundling or cross-linking proteins [D.R.
AtFim1
actin
0
Recently it has been established, through a detailed biochemical analysis, that recombinant Arabidopsis thaliana entity1_term (AtFim1) is a member of the fimbrin/plastin family of entity2_term filament bundling or cross-linking proteins [D.R.
fimbrin 1
actin
0
We constructed recombinant viruses based on the herpes simplex virus type 1 mutant tsK which individually were able to express the products of four viral DNA replication genes (entity1_term, UL8, UL9 and entity2_term) in the absence of any of the other proteins required for viral DNA synthesis.
UL5
UL52
0
We constructed recombinant viruses based on the herpes simplex virus type 1 mutant tsK which individually were able to express the products of four viral DNA replication genes (UL5, entity1_term, UL9 and entity2_term) in the absence of any of the other proteins required for viral DNA synthesis.
UL8
UL52
0
We constructed recombinant viruses based on the herpes simplex virus type 1 mutant tsK which individually were able to express the products of four viral DNA replication genes (UL5, UL8, entity1_term and entity2_term) in the absence of any of the other proteins required for viral DNA synthesis.
UL9
UL52
0
We constructed recombinant viruses based on the herpes simplex virus type 1 mutant tsK which individually were able to express the products of four viral DNA replication genes (entity1_term, entity2_term, UL9 and UL52) in the absence of any of the other proteins required for viral DNA synthesis.
UL5
UL8
0
We constructed recombinant viruses based on the herpes simplex virus type 1 mutant tsK which individually were able to express the products of four viral DNA replication genes (entity1_term, UL8, entity2_term and UL52) in the absence of any of the other proteins required for viral DNA synthesis.
UL5
UL9
0
We constructed recombinant viruses based on the herpes simplex virus type 1 mutant tsK which individually were able to express the products of four viral DNA replication genes (UL5, entity1_term, entity2_term and UL52) in the absence of any of the other proteins required for viral DNA synthesis.
UL8
UL9
0
In contrast to the model of entity1_term binding proposed for entity2_term, the utrophin actin-binding domain appears to associate with actin in an extended conformation.
actin
fimbrin
1
In contrast to the model of actin binding proposed for fimbrin, the entity1_term entity2_term-binding domain appears to associate with actin in an extended conformation.
utrophin
actin
1
In contrast to the model of actin binding proposed for fimbrin, the entity1_term actin-binding domain appears to associate with entity2_term in an extended conformation.
utrophin
actin
1
In contrast to the model of entity1_term binding proposed for fimbrin, the entity2_term actin-binding domain appears to associate with actin in an extended conformation.
actin
utrophin
0
In contrast to the model of actin binding proposed for entity1_term, the entity2_term actin-binding domain appears to associate with actin in an extended conformation.
fimbrin
utrophin
0
In contrast to the model of entity1_term binding proposed for fimbrin, the utrophin actin-binding domain appears to associate with entity2_term in an extended conformation.
actin
actin
0
In contrast to the model of entity1_term binding proposed for fimbrin, the utrophin entity2_term-binding domain appears to associate with actin in an extended conformation.
actin
actin
0
In contrast to the model of actin binding proposed for fimbrin, the utrophin entity1_term-binding domain appears to associate with entity2_term in an extended conformation.
actin
actin
0
In contrast to the model of actin binding proposed for entity1_term, the utrophin actin-binding domain appears to associate with entity2_term in an extended conformation.
fimbrin
actin
0
In contrast to the model of actin binding proposed for entity1_term, the utrophin entity2_term-binding domain appears to associate with actin in an extended conformation.
fimbrin
actin
0
Those observations were extended to include a spatiotemporal immunohistochemical analyses of beta-catenin and entity1_term, as well as a more detailed study of entity2_term, during segmentation, compaction, and compartmentalization of the somite.
alpha-catenin
N-cadherin
0
Those observations were extended to include a spatiotemporal immunohistochemical analyses of entity1_term and alpha-catenin, as well as a more detailed study of entity2_term, during segmentation, compaction, and compartmentalization of the somite.
beta-catenin
N-cadherin
0
Those observations were extended to include a spatiotemporal immunohistochemical analyses of entity1_term and entity2_term, as well as a more detailed study of N-cadherin, during segmentation, compaction, and compartmentalization of the somite.
beta-catenin
alpha-catenin
0
MgCl2 strongly inhibits these effects of entity1_term, most likely by binding to the high-affinity divalent cation site on the entity2_term.
profilin
actin
1
Acanthamoeba entity1_term strongly inhibits in a concentration-dependent fashion the rate and extent of Acanthamoeba entity2_term polymerization in 50 mM KCl.
profilin
actin
1
Addition of entity1_term to polymerized entity2_term causes it to depolymerize until a new steady-state, dependent on profilin concentration, is achieved.
profilin
actin
1
Acanthamoeba entity1_term has similar but weaker effects on entity2_term, requiring 5 to 10 times more profilin than with amoeba actin.
profilin
muscle actin
1
Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more entity1_term than with amoeba entity2_term.
profilin
actin
0
Acanthamoeba profilin has similar but weaker effects on entity1_term, requiring 5 to 10 times more entity2_term than with amoeba actin.
muscle actin
profilin
0
Acanthamoeba entity1_term has similar but weaker effects on muscle actin, requiring 5 to 10 times more entity2_term than with amoeba actin.
profilin
profilin
0
Acanthamoeba profilin has similar but weaker effects on entity1_term, requiring 5 to 10 times more profilin than with amoeba entity2_term.
muscle actin
actin
0
Acanthamoeba entity1_term has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba entity2_term.
profilin
actin
0
Addition of entity1_term to polymerized actin causes it to depolymerize until a new steady-state, dependent on entity2_term concentration, is achieved.
profilin
profilin
0
Mechanism of action of Acanthamoeba entity1_term: demonstration of entity2_term species specificity and regulation by micromolar concentrations of MgCl2.
profilin
actin
0
Addition of profilin to polymerized entity1_term causes it to depolymerize until a new steady-state, dependent on entity2_term concentration, is achieved.
actin
profilin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (entity1_term) isoforms, connexin 43 (Cx43), desmin and entity2_term (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
TnI
alpha-smooth muscle actin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, entity1_term (Cx43), desmin and entity2_term (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
connexin 43
alpha-smooth muscle actin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), entity1_term (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and entity2_term (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin light chain
alpha-smooth muscle actin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (entity1_term), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and entity2_term (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MHC
alpha-smooth muscle actin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), entity1_term and entity2_term (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
desmin
alpha-smooth muscle actin
0
METHODS: We have performed a detailed study of the pattern of expression of entity1_term (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and entity2_term (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin heavy chain
alpha-smooth muscle actin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), entity1_term (TnI) isoforms, connexin 43 (Cx43), desmin and entity2_term (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
troponin I
alpha-smooth muscle actin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (entity1_term), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and entity2_term (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MLC
alpha-smooth muscle actin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (entity1_term), desmin and entity2_term (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
Cx43
alpha-smooth muscle actin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and entity1_term (entity2_term), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
alpha-smooth muscle actin
alpha-SMA
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (entity1_term) isoforms, entity2_term (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
TnI
connexin 43
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), entity1_term (MLC), troponin I (entity2_term) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin light chain
TnI
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (entity1_term), myosin light chain (MLC), troponin I (entity2_term) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MHC
TnI
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (entity1_term) isoforms, connexin 43 (Cx43), entity2_term and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
TnI
desmin
0
METHODS: We have performed a detailed study of the pattern of expression of entity1_term (MHC), myosin light chain (MLC), troponin I (entity2_term) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin heavy chain
TnI
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), entity1_term (entity2_term) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
troponin I
TnI
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (entity1_term), troponin I (entity2_term) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MLC
TnI
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (entity1_term) isoforms, connexin 43 (entity2_term), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
TnI
Cx43
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (entity1_term) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (entity2_term), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
TnI
alpha-SMA
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), entity1_term (MLC), troponin I (TnI) isoforms, entity2_term (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin light chain
connexin 43
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (entity1_term), myosin light chain (MLC), troponin I (TnI) isoforms, entity2_term (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MHC
connexin 43
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, entity1_term (Cx43), entity2_term and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
connexin 43
desmin
0
METHODS: We have performed a detailed study of the pattern of expression of entity1_term (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, entity2_term (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin heavy chain
connexin 43
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), entity1_term (TnI) isoforms, entity2_term (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
troponin I
connexin 43
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (entity1_term), troponin I (TnI) isoforms, entity2_term (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MLC
connexin 43
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, entity1_term (entity2_term), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
connexin 43
Cx43
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, entity1_term (Cx43), desmin and alpha-smooth muscle actin (entity2_term), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
connexin 43
alpha-SMA
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (entity1_term), entity2_term (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MHC
myosin light chain
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), entity1_term (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), entity2_term and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin light chain
desmin
0
METHODS: We have performed a detailed study of the pattern of expression of entity1_term (MHC), entity2_term (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin heavy chain
myosin light chain
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), entity1_term (MLC), entity2_term (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin light chain
troponin I
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), entity1_term (entity2_term), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin light chain
MLC
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), entity1_term (MLC), troponin I (TnI) isoforms, connexin 43 (entity2_term), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin light chain
Cx43
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), entity1_term (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (entity2_term), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin light chain
alpha-SMA
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (entity1_term), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), entity2_term and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MHC
desmin
0
METHODS: We have performed a detailed study of the pattern of expression of entity1_term (entity2_term), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin heavy chain
MHC
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (entity1_term), myosin light chain (MLC), entity2_term (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MHC
troponin I
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (entity1_term), myosin light chain (entity2_term), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MHC
MLC
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (entity1_term), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (entity2_term), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MHC
Cx43
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (entity1_term), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (entity2_term), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MHC
alpha-SMA
0
METHODS: We have performed a detailed study of the pattern of expression of entity1_term (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), entity2_term and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin heavy chain
desmin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), entity1_term (TnI) isoforms, connexin 43 (Cx43), entity2_term and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
troponin I
desmin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (entity1_term), troponin I (TnI) isoforms, connexin 43 (Cx43), entity2_term and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MLC
desmin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (entity1_term), entity2_term and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
Cx43
desmin
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), entity1_term and alpha-smooth muscle actin (entity2_term), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
desmin
alpha-SMA
0
METHODS: We have performed a detailed study of the pattern of expression of entity1_term (MHC), myosin light chain (MLC), entity2_term (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin heavy chain
troponin I
0
METHODS: We have performed a detailed study of the pattern of expression of entity1_term (MHC), myosin light chain (entity2_term), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin heavy chain
MLC
0
METHODS: We have performed a detailed study of the pattern of expression of entity1_term (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (entity2_term), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin heavy chain
Cx43
0
METHODS: We have performed a detailed study of the pattern of expression of entity1_term (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (entity2_term), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
myosin heavy chain
alpha-SMA
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (entity1_term), entity2_term (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MLC
troponin I
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), entity1_term (TnI) isoforms, connexin 43 (entity2_term), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
troponin I
Cx43
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), entity1_term (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (entity2_term), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
troponin I
alpha-SMA
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (entity1_term), troponin I (TnI) isoforms, connexin 43 (entity2_term), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MLC
Cx43
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (entity1_term), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (entity2_term), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
MLC
alpha-SMA
0
METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (entity1_term), desmin and alpha-smooth muscle actin (entity2_term), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.
Cx43
alpha-SMA
0
In three of the cell lines with CTNNB1 mutations, complexes of entity1_term with entity2_term and APC were detectable.
beta-catenin
alpha-catenin
1
In three of the cell lines with CTNNB1 mutations, complexes of entity1_term with alpha-catenin and entity2_term were detectable.
beta-catenin
APC
1
In three of the cell lines with entity1_term mutations, complexes of beta-catenin with alpha-catenin and entity2_term were detectable.
CTNNB1
APC
0
In three of the cell lines with entity1_term mutations, complexes of entity2_term with alpha-catenin and APC were detectable.
CTNNB1
beta-catenin
0
In three of the cell lines with entity1_term mutations, complexes of beta-catenin with entity2_term and APC were detectable.
CTNNB1
alpha-catenin
0
In three of the cell lines with CTNNB1 mutations, complexes of beta-catenin with entity1_term and entity2_term were detectable.
alpha-catenin
APC
0
entity1_term expression was reduced by 25-50%, relative to that of entity2_term, in smooth muscle of KO mice, without any change in the relative distribution of the actin isoforms.
Actin
myosin heavy chain
0
entity1_term expression was reduced by 25-50%, relative to that of myosin heavy chain, in smooth muscle of KO mice, without any change in the relative distribution of the entity2_term isoforms.
Actin
actin
0
Actin expression was reduced by 25-50%, relative to that of entity1_term, in smooth muscle of KO mice, without any change in the relative distribution of the entity2_term isoforms.
myosin heavy chain
actin
0
entity1_term stimulates cardiac myosin heavy chain and entity2_term synthesis in the awake rat.
Insulin-like growth factor I
actin
1
entity1_term stimulates entity2_term and actin synthesis in the awake rat.
Insulin-like growth factor I
cardiac myosin heavy chain
1
To determine the effect of entity1_term (IGF-I) on cardiac contractile protein synthesis in vivo, we measured L-[ring-2, 6-3H]phenylalanine incorporation into myosin heavy chain and actin during intravenous infusions (4 h) of either saline or entity2_term (1 microgram.
insulin-like growth factor I
IGF-I
0
To determine the effect of entity1_term (IGF-I) on cardiac contractile protein synthesis in vivo, we measured L-[ring-2, 6-3H]phenylalanine incorporation into myosin heavy chain and entity2_term during intravenous infusions (4 h) of either saline or IGF-I (1 microgram.
insulin-like growth factor I
actin
0
To determine the effect of entity1_term (IGF-I) on cardiac contractile protein synthesis in vivo, we measured L-[ring-2, 6-3H]phenylalanine incorporation into entity2_term and actin during intravenous infusions (4 h) of either saline or IGF-I (1 microgram.
insulin-like growth factor I
myosin heavy chain
0
To determine the effect of entity1_term (entity2_term) on cardiac contractile protein synthesis in vivo, we measured L-[ring-2, 6-3H]phenylalanine incorporation into myosin heavy chain and actin during intravenous infusions (4 h) of either saline or IGF-I (1 microgram.
insulin-like growth factor I
IGF-I
0
To determine the effect of insulin-like growth factor I (IGF-I) on cardiac contractile protein synthesis in vivo, we measured L-[ring-2, 6-3H]phenylalanine incorporation into myosin heavy chain and entity1_term during intravenous infusions (4 h) of either saline or entity2_term (1 microgram.
actin
IGF-I
0
To determine the effect of insulin-like growth factor I (IGF-I) on cardiac contractile protein synthesis in vivo, we measured L-[ring-2, 6-3H]phenylalanine incorporation into entity1_term and actin during intravenous infusions (4 h) of either saline or entity2_term (1 microgram.
myosin heavy chain
IGF-I
0
To determine the effect of insulin-like growth factor I (entity1_term) on cardiac contractile protein synthesis in vivo, we measured L-[ring-2, 6-3H]phenylalanine incorporation into myosin heavy chain and actin during intravenous infusions (4 h) of either saline or entity2_term (1 microgram.
IGF-I
IGF-I
0
To determine the effect of insulin-like growth factor I (IGF-I) on cardiac contractile protein synthesis in vivo, we measured L-[ring-2, 6-3H]phenylalanine incorporation into entity1_term and entity2_term during intravenous infusions (4 h) of either saline or IGF-I (1 microgram.
myosin heavy chain
actin
0
To determine the effect of insulin-like growth factor I (entity1_term) on cardiac contractile protein synthesis in vivo, we measured L-[ring-2, 6-3H]phenylalanine incorporation into myosin heavy chain and entity2_term during intravenous infusions (4 h) of either saline or IGF-I (1 microgram.
IGF-I
actin
0
To determine the effect of insulin-like growth factor I (entity1_term) on cardiac contractile protein synthesis in vivo, we measured L-[ring-2, 6-3H]phenylalanine incorporation into entity2_term and actin during intravenous infusions (4 h) of either saline or IGF-I (1 microgram.
IGF-I
myosin heavy chain
0
Insulin-like growth factor I stimulates entity1_term and entity2_term synthesis in the awake rat.
cardiac myosin heavy chain
actin
0
They had altered adhesive properties as measured by their ability to bind to a fibronectin-coated glass surface, suggesting that the expression of a entity1_term alters the assembly of integrin receptors, entity2_term and cytoskeletal proteins such as vinculin and talin.
rac-1 GAP
actin
1
They had altered adhesive properties as measured by their ability to bind to a fibronectin-coated glass surface, suggesting that the expression of a entity1_term alters the assembly of integrin receptors, actin and cytoskeletal proteins such as vinculin and entity2_term.
rac-1 GAP
talin
1
They had altered adhesive properties as measured by their ability to bind to a fibronectin-coated glass surface, suggesting that the expression of a entity1_term alters the assembly of integrin receptors, actin and cytoskeletal proteins such as entity2_term and talin.
rac-1 GAP
vinculin
1
They had altered adhesive properties as measured by their ability to bind to a fibronectin-coated glass surface, suggesting that the expression of a entity1_term alters the assembly of entity2_term receptors, actin and cytoskeletal proteins such as vinculin and talin.
rac-1 GAP
integrin
1
They had altered adhesive properties as measured by their ability to bind to a entity1_term-coated glass surface, suggesting that the expression of a rac-1 GAP alters the assembly of integrin receptors, entity2_term and cytoskeletal proteins such as vinculin and talin.
fibronectin
actin
0
They had altered adhesive properties as measured by their ability to bind to a fibronectin-coated glass surface, suggesting that the expression of a rac-1 GAP alters the assembly of entity1_term receptors, entity2_term and cytoskeletal proteins such as vinculin and talin.
integrin
actin
0
They had altered adhesive properties as measured by their ability to bind to a fibronectin-coated glass surface, suggesting that the expression of a rac-1 GAP alters the assembly of integrin receptors, entity1_term and cytoskeletal proteins such as entity2_term and talin.
actin
vinculin
0
They had altered adhesive properties as measured by their ability to bind to a fibronectin-coated glass surface, suggesting that the expression of a rac-1 GAP alters the assembly of integrin receptors, entity1_term and cytoskeletal proteins such as vinculin and entity2_term.
actin
talin
0
They had altered adhesive properties as measured by their ability to bind to a entity1_term-coated glass surface, suggesting that the expression of a entity2_term alters the assembly of integrin receptors, actin and cytoskeletal proteins such as vinculin and talin.
fibronectin
rac-1 GAP
0
They had altered adhesive properties as measured by their ability to bind to a entity1_term-coated glass surface, suggesting that the expression of a rac-1 GAP alters the assembly of entity2_term receptors, actin and cytoskeletal proteins such as vinculin and talin.
fibronectin
integrin
0
They had altered adhesive properties as measured by their ability to bind to a entity1_term-coated glass surface, suggesting that the expression of a rac-1 GAP alters the assembly of integrin receptors, actin and cytoskeletal proteins such as entity2_term and talin.
fibronectin
vinculin
0
They had altered adhesive properties as measured by their ability to bind to a entity1_term-coated glass surface, suggesting that the expression of a rac-1 GAP alters the assembly of integrin receptors, actin and cytoskeletal proteins such as vinculin and entity2_term.
fibronectin
talin
0
They had altered adhesive properties as measured by their ability to bind to a fibronectin-coated glass surface, suggesting that the expression of a rac-1 GAP alters the assembly of entity1_term receptors, actin and cytoskeletal proteins such as entity2_term and talin.
integrin
vinculin
0
They had altered adhesive properties as measured by their ability to bind to a fibronectin-coated glass surface, suggesting that the expression of a rac-1 GAP alters the assembly of entity1_term receptors, actin and cytoskeletal proteins such as vinculin and entity2_term.
integrin
talin
0
They had altered adhesive properties as measured by their ability to bind to a fibronectin-coated glass surface, suggesting that the expression of a rac-1 GAP alters the assembly of integrin receptors, actin and cytoskeletal proteins such as entity1_term and entity2_term.
vinculin
talin
0
In this work we report that the Saccharomyces cerevisiae entity1_term, entity2_term, RAD17, MEC1, MEC3 and RAD53 checkpoint genes are required for efficient non-homologous end joining (NHEJ).
RAD9
RAD24
0
In this work we report that the Saccharomyces cerevisiae RAD9, entity1_term, RAD17, MEC1, entity2_term and RAD53 checkpoint genes are required for efficient non-homologous end joining (NHEJ).
RAD24
MEC3
0
In this work we report that the Saccharomyces cerevisiae RAD9, entity1_term, RAD17, MEC1, MEC3 and entity2_term checkpoint genes are required for efficient non-homologous end joining (NHEJ).
RAD24
RAD53
0
In this work we report that the Saccharomyces cerevisiae RAD9, entity1_term, entity2_term, MEC1, MEC3 and RAD53 checkpoint genes are required for efficient non-homologous end joining (NHEJ).
RAD24
RAD17
0
In this work we report that the Saccharomyces cerevisiae RAD9, entity1_term, RAD17, entity2_term, MEC3 and RAD53 checkpoint genes are required for efficient non-homologous end joining (NHEJ).
RAD24
MEC1
0
In this work we report that the Saccharomyces cerevisiae entity1_term, RAD24, RAD17, MEC1, entity2_term and RAD53 checkpoint genes are required for efficient non-homologous end joining (NHEJ).
RAD9
MEC3
0
In this work we report that the Saccharomyces cerevisiae entity1_term, RAD24, RAD17, MEC1, MEC3 and entity2_term checkpoint genes are required for efficient non-homologous end joining (NHEJ).
RAD9
RAD53
0
In this work we report that the Saccharomyces cerevisiae entity1_term, RAD24, entity2_term, MEC1, MEC3 and RAD53 checkpoint genes are required for efficient non-homologous end joining (NHEJ).
RAD9
RAD17
0
In this work we report that the Saccharomyces cerevisiae entity1_term, RAD24, RAD17, entity2_term, MEC3 and RAD53 checkpoint genes are required for efficient non-homologous end joining (NHEJ).
RAD9
MEC1
0
In this work we report that the Saccharomyces cerevisiae RAD9, RAD24, RAD17, MEC1, entity1_term and entity2_term checkpoint genes are required for efficient non-homologous end joining (NHEJ).
MEC3
RAD53
0
In this work we report that the Saccharomyces cerevisiae RAD9, RAD24, entity1_term, MEC1, entity2_term and RAD53 checkpoint genes are required for efficient non-homologous end joining (NHEJ).
RAD17
MEC3
0
In this work we report that the Saccharomyces cerevisiae RAD9, RAD24, RAD17, entity1_term, entity2_term and RAD53 checkpoint genes are required for efficient non-homologous end joining (NHEJ).
MEC1
MEC3
0
In this work we report that the Saccharomyces cerevisiae RAD9, RAD24, entity1_term, MEC1, MEC3 and entity2_term checkpoint genes are required for efficient non-homologous end joining (NHEJ).
RAD17
RAD53
0
In this work we report that the Saccharomyces cerevisiae RAD9, RAD24, RAD17, entity1_term, MEC3 and entity2_term checkpoint genes are required for efficient non-homologous end joining (NHEJ).
MEC1
RAD53
0
In this work we report that the Saccharomyces cerevisiae RAD9, RAD24, entity1_term, entity2_term, MEC3 and RAD53 checkpoint genes are required for efficient non-homologous end joining (NHEJ).
RAD17
MEC1
0
METHODS: We immunohistochemically investigated the expression of E-cadherin (entity1_term), entity2_term (A-Cat) and beta-catenin (B-Cat) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
E-Cad
alpha-catenin
0
METHODS: We immunohistochemically investigated the expression of E-cadherin (entity1_term), alpha-catenin (A-Cat) and beta-catenin (entity2_term) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
E-Cad
B-Cat
0
METHODS: We immunohistochemically investigated the expression of E-cadherin (entity1_term), alpha-catenin (A-Cat) and entity2_term (B-Cat) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
E-Cad
beta-catenin
0
METHODS: We immunohistochemically investigated the expression of E-cadherin (entity1_term), alpha-catenin (entity2_term) and beta-catenin (B-Cat) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
E-Cad
A-Cat
0
METHODS: We immunohistochemically investigated the expression of entity1_term (entity2_term), alpha-catenin (A-Cat) and beta-catenin (B-Cat) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
E-cadherin
E-Cad
0
METHODS: We immunohistochemically investigated the expression of E-cadherin (E-Cad), entity1_term (A-Cat) and beta-catenin (entity2_term) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
alpha-catenin
B-Cat
0
METHODS: We immunohistochemically investigated the expression of E-cadherin (E-Cad), entity1_term (A-Cat) and entity2_term (B-Cat) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
alpha-catenin
beta-catenin
0
METHODS: We immunohistochemically investigated the expression of E-cadherin (E-Cad), entity1_term (entity2_term) and beta-catenin (B-Cat) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
alpha-catenin
A-Cat
0
METHODS: We immunohistochemically investigated the expression of entity1_term (E-Cad), entity2_term (A-Cat) and beta-catenin (B-Cat) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
E-cadherin
alpha-catenin
0
METHODS: We immunohistochemically investigated the expression of E-cadherin (E-Cad), alpha-catenin (A-Cat) and entity1_term (entity2_term) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
beta-catenin
B-Cat
0
METHODS: We immunohistochemically investigated the expression of E-cadherin (E-Cad), alpha-catenin (entity1_term) and beta-catenin (entity2_term) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
A-Cat
B-Cat
0
METHODS: We immunohistochemically investigated the expression of entity1_term (E-Cad), alpha-catenin (A-Cat) and beta-catenin (entity2_term) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
E-cadherin
B-Cat
0
METHODS: We immunohistochemically investigated the expression of E-cadherin (E-Cad), alpha-catenin (entity1_term) and entity2_term (B-Cat) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
A-Cat
beta-catenin
0
METHODS: We immunohistochemically investigated the expression of entity1_term (E-Cad), alpha-catenin (A-Cat) and entity2_term (B-Cat) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
E-cadherin
beta-catenin
0
METHODS: We immunohistochemically investigated the expression of entity1_term (E-Cad), alpha-catenin (entity2_term) and beta-catenin (B-Cat) during human intrahepatic bile duct development, using 31 fetal livers of various gestational ages.
E-cadherin
A-Cat
0
In resting leukocytes, beta2 integrins are constitutively linked to the entity1_term cytoskeleton via the protein entity2_term.
actin
talin
1
In resting leukocytes, entity1_term are constitutively linked to the actin cytoskeleton via the protein entity2_term.
beta2 integrins
talin
1
In resting leukocytes, entity1_term are constitutively linked to the entity2_term cytoskeleton via the protein talin.
beta2 integrins
actin
1
Acidic domain of the phosphoprotein (entity1_term) of vesicular stomatitis virus differentially interacts with homologous and heterologous nucleocapsid protein (entity2_term).
P
N
1
Acidic domain of the phosphoprotein (entity1_term) of vesicular stomatitis virus differentially interacts with homologous and heterologous entity2_term (N).
P
nucleocapsid protein
1
Acidic domain of the entity1_term (P) of vesicular stomatitis virus differentially interacts with homologous and heterologous nucleocapsid protein (entity2_term).
phosphoprotein
N
1
Acidic domain of the entity1_term (P) of vesicular stomatitis virus differentially interacts with homologous and heterologous entity2_term (N).
phosphoprotein
nucleocapsid protein
1
Acidic domain of the phosphoprotein (P) of vesicular stomatitis virus differentially interacts with homologous and heterologous entity1_term (entity2_term).
nucleocapsid protein
N
0
Acidic domain of the entity1_term (entity2_term) of vesicular stomatitis virus differentially interacts with homologous and heterologous nucleocapsid protein (N).
phosphoprotein
P
0
They exhibited strong synergistic increases in entity1_term duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes RAD50, RAD51, and entity2_term for viability.
CAN1
RAD52
0
They exhibited strong synergistic increases in entity1_term duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes RAD50, entity2_term, and RAD52 for viability.
CAN1
RAD51
0
They exhibited strong synergistic increases in entity1_term duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes entity2_term, RAD51, and RAD52 for viability.
CAN1
RAD50
0
They exhibited strong synergistic increases in CAN1 duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes RAD50, entity1_term, and entity2_term for viability.
RAD51
RAD52
0
They exhibited strong synergistic increases in CAN1 duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes entity1_term, RAD51, and entity2_term for viability.
RAD50
RAD52
0
They exhibited strong synergistic increases in CAN1 duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes entity1_term, entity2_term, and RAD52 for viability.
RAD50
RAD51
0
However, some proteins (e.g., entity1_term) and other agents (e.g., cytochalasin D) that bind to entity2_term are affected by the presence of fluorescent labels, making actin intrinsic fluorescence potentially useful in investigating the interaction of these agents with actin, and in validating data obtained using labeled actin.
profilin
actin
1
However, some proteins (e.g., entity1_term) and other agents (e.g., cytochalasin D) that bind to actin are affected by the presence of fluorescent labels, making actin intrinsic fluorescence potentially useful in investigating the interaction of these agents with entity2_term, and in validating data obtained using labeled actin.
profilin
actin
1
However, some proteins (e.g., profilin) and other agents (e.g., cytochalasin D) that bind to entity1_term are affected by the presence of fluorescent labels, making actin intrinsic fluorescence potentially useful in investigating the interaction of these agents with entity2_term, and in validating data obtained using labeled actin.
actin
actin
0
However, some proteins (e.g., profilin) and other agents (e.g., cytochalasin D) that bind to actin are affected by the presence of fluorescent labels, making actin intrinsic fluorescence potentially useful in investigating the interaction of these agents with entity1_term, and in validating data obtained using labeled entity2_term.
actin
actin
0
However, some proteins (e.g., profilin) and other agents (e.g., cytochalasin D) that bind to actin are affected by the presence of fluorescent labels, making entity1_term intrinsic fluorescence potentially useful in investigating the interaction of these agents with entity2_term, and in validating data obtained using labeled actin.
actin
actin
0
However, some proteins (e.g., profilin) and other agents (e.g., cytochalasin D) that bind to entity1_term are affected by the presence of fluorescent labels, making actin intrinsic fluorescence potentially useful in investigating the interaction of these agents with actin, and in validating data obtained using labeled entity2_term.
actin
actin
0
However, some proteins (e.g., profilin) and other agents (e.g., cytochalasin D) that bind to entity1_term are affected by the presence of fluorescent labels, making entity2_term intrinsic fluorescence potentially useful in investigating the interaction of these agents with actin, and in validating data obtained using labeled actin.
actin
actin
0
However, some proteins (e.g., entity1_term) and other agents (e.g., cytochalasin D) that bind to actin are affected by the presence of fluorescent labels, making actin intrinsic fluorescence potentially useful in investigating the interaction of these agents with actin, and in validating data obtained using labeled entity2_term.
profilin
actin
0
However, some proteins (e.g., entity1_term) and other agents (e.g., cytochalasin D) that bind to actin are affected by the presence of fluorescent labels, making entity2_term intrinsic fluorescence potentially useful in investigating the interaction of these agents with actin, and in validating data obtained using labeled actin.
profilin
actin
0
However, some proteins (e.g., profilin) and other agents (e.g., cytochalasin D) that bind to actin are affected by the presence of fluorescent labels, making entity1_term intrinsic fluorescence potentially useful in investigating the interaction of these agents with actin, and in validating data obtained using labeled entity2_term.
actin
actin
0
The head domain of entity1_term thus binds to integrins to form a link to the entity2_term cytoskeleton and can thus regulate integrin function.
talin
actin
1
The head domain of talin thus binds to entity1_term to form a link to the entity2_term cytoskeleton and can thus regulate integrin function.
integrins
actin
1
The head domain of entity1_term thus binds to integrins to form a link to the actin cytoskeleton and can thus regulate entity2_term function.
talin
integrin
1
The head domain of entity1_term thus binds to entity2_term to form a link to the actin cytoskeleton and can thus regulate integrin function.
talin
integrins
1
The head domain of talin thus binds to integrins to form a link to the entity1_term cytoskeleton and can thus regulate entity2_term function.
actin
integrin
0
The head domain of talin thus binds to entity1_term to form a link to the actin cytoskeleton and can thus regulate entity2_term function.
integrins
integrin
0
Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why entity1_term and entity2_term can bind simultaneously to actin.
thymosin beta(4)
profilin
1
Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between entity1_term and entity2_term, and explain why thymosin beta(4) and profilin can bind simultaneously to actin.
actin
thymosin beta(4)
1
Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why entity1_term and profilin can bind simultaneously to entity2_term.
thymosin beta(4)
actin
1
Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why thymosin beta(4) and entity1_term can bind simultaneously to entity2_term.
profilin
actin
1
Data from affinity chromatography, analytical ultracentrifugation, covalent cross-linking, and fluorescence anisotropy show that entity1_term, entity2_term, and actin form a ternary complex.
profilin
thymosin beta(4)
1
Data from affinity chromatography, analytical ultracentrifugation, covalent cross-linking, and fluorescence anisotropy show that entity1_term, thymosin beta(4), and entity2_term form a ternary complex.
profilin
actin
1
Data from affinity chromatography, analytical ultracentrifugation, covalent cross-linking, and fluorescence anisotropy show that profilin, entity1_term, and entity2_term form a ternary complex.
thymosin beta(4)
actin
1
Experiments using a peptide that corresponds to the N-terminus of entity1_term (residues 6-22) confirm the presence of an extensive binding surface between entity2_term and thymosin beta(4), and explain why thymosin beta(4) and profilin can bind simultaneously to actin.
thymosin beta(4)
actin
0
Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between entity1_term and thymosin beta(4), and explain why thymosin beta(4) and profilin can bind simultaneously to entity2_term.
actin
actin
0
Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between entity1_term and thymosin beta(4), and explain why entity2_term and profilin can bind simultaneously to actin.
actin
thymosin beta(4)
0
Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between entity1_term and thymosin beta(4), and explain why thymosin beta(4) and entity2_term can bind simultaneously to actin.
actin
profilin
0
Experiments using a peptide that corresponds to the N-terminus of entity1_term (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why thymosin beta(4) and profilin can bind simultaneously to entity2_term.
thymosin beta(4)
actin
0
Experiments using a peptide that corresponds to the N-terminus of entity1_term (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why entity2_term and profilin can bind simultaneously to actin.
thymosin beta(4)
thymosin beta(4)
0
Experiments using a peptide that corresponds to the N-terminus of entity1_term (residues 6-22) confirm the presence of an extensive binding surface between actin and entity2_term, and explain why thymosin beta(4) and profilin can bind simultaneously to actin.
thymosin beta(4)
thymosin beta(4)
0
Experiments using a peptide that corresponds to the N-terminus of entity1_term (residues 6-22) confirm the presence of an extensive binding surface between actin and thymosin beta(4), and explain why thymosin beta(4) and entity2_term can bind simultaneously to actin.
thymosin beta(4)
profilin
0
Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and entity1_term, and explain why thymosin beta(4) and profilin can bind simultaneously to entity2_term.
thymosin beta(4)
actin
0
Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and entity1_term, and explain why entity2_term and profilin can bind simultaneously to actin.
thymosin beta(4)
thymosin beta(4)
0
Experiments using a peptide that corresponds to the N-terminus of thymosin beta(4) (residues 6-22) confirm the presence of an extensive binding surface between actin and entity1_term, and explain why thymosin beta(4) and entity2_term can bind simultaneously to actin.
thymosin beta(4)
profilin
0
Proteolytic activity was not detected with entity1_term, entity2_term, or myosin heavy-chain substrates.
casein
actin
0
Proteolytic activity was not detected with casein, entity1_term, or entity2_term substrates.
actin
myosin heavy-chain
0
Proteolytic activity was not detected with entity1_term, actin, or entity2_term substrates.
casein
myosin heavy-chain
0
entity1_term and pRb were phosphorylated before the infected myotubes entered S phase, despite the high expression of the cyclin-dependent kinase inhibitor entity2_term, and E2F was released.
p130
p21
1
p130 and entity1_term were phosphorylated before the infected myotubes entered S phase, despite the high expression of the cyclin-dependent kinase inhibitor entity2_term, and E2F was released.
pRb
p21
1
p130 and pRb were phosphorylated before the infected myotubes entered S phase, despite the high expression of the entity1_term entity2_term, and E2F was released.
cyclin-dependent kinase inhibitor
p21
1
p130 and entity1_term were phosphorylated before the infected myotubes entered S phase, despite the high expression of the cyclin-dependent kinase inhibitor p21, and entity2_term was released.
pRb
E2F
0
p130 and pRb were phosphorylated before the infected myotubes entered S phase, despite the high expression of the cyclin-dependent kinase inhibitor entity1_term, and entity2_term was released.
p21
E2F
0
entity1_term and pRb were phosphorylated before the infected myotubes entered S phase, despite the high expression of the cyclin-dependent kinase inhibitor p21, and entity2_term was released.
p130
E2F
0
p130 and pRb were phosphorylated before the infected myotubes entered S phase, despite the high expression of the entity1_term p21, and entity2_term was released.
cyclin-dependent kinase inhibitor
E2F
0
entity1_term and entity2_term were phosphorylated before the infected myotubes entered S phase, despite the high expression of the cyclin-dependent kinase inhibitor p21, and E2F was released.
p130
pRb
0
p130 and entity1_term were phosphorylated before the infected myotubes entered S phase, despite the high expression of the entity2_term p21, and E2F was released.
pRb
cyclin-dependent kinase inhibitor
0
entity1_term and pRb were phosphorylated before the infected myotubes entered S phase, despite the high expression of the entity2_term p21, and E2F was released.
p130
cyclin-dependent kinase inhibitor
0
entity1_term is one of a complex of genes encoding DNA repair proteins that includes MSH2, MLH1, MSH6 and entity2_term.
PMS2
MSH3
0
entity1_term is one of a complex of genes encoding DNA repair proteins that includes entity2_term, MLH1, MSH6 and MSH3.
PMS2
MSH2
0
entity1_term is one of a complex of genes encoding DNA repair proteins that includes MSH2, entity2_term, MSH6 and MSH3.
PMS2
MLH1
0
entity1_term is one of a complex of genes encoding DNA repair proteins that includes MSH2, MLH1, entity2_term and MSH3.
PMS2
MSH6
0
PMS2 is one of a complex of genes encoding DNA repair proteins that includes entity1_term, MLH1, MSH6 and entity2_term.
MSH2
MSH3
0
PMS2 is one of a complex of genes encoding DNA repair proteins that includes MSH2, entity1_term, MSH6 and entity2_term.
MLH1
MSH3
0
PMS2 is one of a complex of genes encoding DNA repair proteins that includes MSH2, MLH1, entity1_term and entity2_term.
MSH6
MSH3
0
PMS2 is one of a complex of genes encoding DNA repair proteins that includes entity1_term, entity2_term, MSH6 and MSH3.
MSH2
MLH1
0
PMS2 is one of a complex of genes encoding DNA repair proteins that includes entity1_term, MLH1, entity2_term and MSH3.
MSH2
MSH6
0
PMS2 is one of a complex of genes encoding DNA repair proteins that includes MSH2, entity1_term, entity2_term and MSH3.
MLH1
MSH6
0
alpha-catenin inhibits entity1_term signaling by preventing formation of a entity2_term*T-cell factor*DNA complex.
beta-catenin
beta-catenin
1
entity1_term inhibits entity2_term signaling by preventing formation of a beta-catenin*T-cell factor*DNA complex.
alpha-catenin
beta-catenin
1
entity1_term inhibits beta-catenin signaling by preventing formation of a entity2_term*T-cell factor*DNA complex.
alpha-catenin
beta-catenin
1
alpha-catenin inhibits entity1_term signaling by preventing formation of a beta-catenin*entity2_term*DNA complex.
beta-catenin
T-cell factor
1
alpha-catenin inhibits beta-catenin signaling by preventing formation of a entity1_term*entity2_term*DNA complex.
beta-catenin
T-cell factor
1
entity1_term inhibits beta-catenin signaling by preventing formation of a beta-catenin*entity2_term*DNA complex.
alpha-catenin
T-cell factor
1
Expression of c-Myc or cyclin D1 was sufficient to activate cyclin E-Cdk2 by promoting the formation of high-molecular-weight complexes lacking the entity1_term entity2_term, as has been described, following estrogen treatment.
cyclin-dependent kinase inhibitor
p21
1
Expression of entity1_term or cyclin D1 was sufficient to activate cyclin E-entity2_term by promoting the formation of high-molecular-weight complexes lacking the cyclin-dependent kinase inhibitor p21, as has been described, following estrogen treatment.
c-Myc
Cdk2
1
Expression of entity1_term or cyclin D1 was sufficient to activate entity2_term-Cdk2 by promoting the formation of high-molecular-weight complexes lacking the cyclin-dependent kinase inhibitor p21, as has been described, following estrogen treatment.
c-Myc
cyclin E
1
Expression of c-Myc or entity1_term was sufficient to activate entity2_term-Cdk2 by promoting the formation of high-molecular-weight complexes lacking the cyclin-dependent kinase inhibitor p21, as has been described, following estrogen treatment.
cyclin D1
cyclin E
1
Expression of c-Myc or cyclin D1 was sufficient to activate entity1_term-entity2_term by promoting the formation of high-molecular-weight complexes lacking the cyclin-dependent kinase inhibitor p21, as has been described, following estrogen treatment.
cyclin E
Cdk2
1
Expression of c-Myc or entity1_term was sufficient to activate cyclin E-entity2_term by promoting the formation of high-molecular-weight complexes lacking the cyclin-dependent kinase inhibitor p21, as has been described, following estrogen treatment.
cyclin D1
Cdk2
1
Expression of entity1_term or cyclin D1 was sufficient to activate cyclin E-Cdk2 by promoting the formation of high-molecular-weight complexes lacking the cyclin-dependent kinase inhibitor entity2_term, as has been described, following estrogen treatment.
c-Myc
p21
0
Expression of c-Myc or entity1_term was sufficient to activate cyclin E-Cdk2 by promoting the formation of high-molecular-weight complexes lacking the cyclin-dependent kinase inhibitor entity2_term, as has been described, following estrogen treatment.
cyclin D1
p21
0
Expression of c-Myc or cyclin D1 was sufficient to activate entity1_term-Cdk2 by promoting the formation of high-molecular-weight complexes lacking the cyclin-dependent kinase inhibitor entity2_term, as has been described, following estrogen treatment.
cyclin E
p21
0
Expression of c-Myc or cyclin D1 was sufficient to activate cyclin E-entity1_term by promoting the formation of high-molecular-weight complexes lacking the cyclin-dependent kinase inhibitor entity2_term, as has been described, following estrogen treatment.
Cdk2
p21
0
Expression of entity1_term or cyclin D1 was sufficient to activate cyclin E-Cdk2 by promoting the formation of high-molecular-weight complexes lacking the entity2_term p21, as has been described, following estrogen treatment.
c-Myc
cyclin-dependent kinase inhibitor
0
Expression of c-Myc or entity1_term was sufficient to activate cyclin E-Cdk2 by promoting the formation of high-molecular-weight complexes lacking the entity2_term p21, as has been described, following estrogen treatment.
cyclin D1
cyclin-dependent kinase inhibitor
0
Expression of c-Myc or cyclin D1 was sufficient to activate entity1_term-Cdk2 by promoting the formation of high-molecular-weight complexes lacking the entity2_term p21, as has been described, following estrogen treatment.
cyclin E
cyclin-dependent kinase inhibitor
0
Expression of c-Myc or cyclin D1 was sufficient to activate cyclin E-entity1_term by promoting the formation of high-molecular-weight complexes lacking the entity2_term p21, as has been described, following estrogen treatment.
Cdk2
cyclin-dependent kinase inhibitor
0
Expression of entity1_term or entity2_term was sufficient to activate cyclin E-Cdk2 by promoting the formation of high-molecular-weight complexes lacking the cyclin-dependent kinase inhibitor p21, as has been described, following estrogen treatment.
c-Myc
cyclin D1
0
The presence, in varying quantities, of entity1_term and entity2_term isoforms of smooth muscle type in the different vessels reflected their degree of differentiation.
myosin heavy chain
actin
0
Both tyrosine phosphorylation and association of entity1_term with entity2_term were inhibited by tyrphostin, a specific inhibitor of the EGFR tyrosine kinase, whereas dissociation of alpha-catenin from E-cadherin was not.
beta-catenin
EGFR
1
Tyrosine phosphorylation of entity1_term was concomitantly induced with association of beta-catenin with entity2_term (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from E-cadherin.
beta-catenin
EGF receptor
1
Tyrosine phosphorylation of entity1_term was concomitantly induced with association of entity2_term with EGF receptor (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from E-cadherin.
beta-catenin
beta-catenin
1
Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of entity1_term with entity2_term (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from E-cadherin.
beta-catenin
EGF receptor
1
Tyrosine phosphorylation of entity1_term was concomitantly induced with association of beta-catenin with EGF receptor (entity2_term) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from E-cadherin.
beta-catenin
EGFR
1
Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of beta-catenin with EGF receptor (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of entity1_term from entity2_term.
alpha-catenin
E-cadherin
1
Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of entity1_term with EGF receptor (entity2_term) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from E-cadherin.
beta-catenin
EGFR
1
The results suggest that tyrosine phosphorylation of entity1_term is achieved by entity2_term upon tryptic digestion of cells and concurrent with but independent of dissociation of alpha-catenin from E-cadherin.
beta-catenin
EGFR
1
The results suggest that tyrosine phosphorylation of entity1_term is achieved by EGFR upon tryptic digestion of cells and concurrent with but independent of dissociation of alpha-catenin from entity2_term.
beta-catenin
E-cadherin
1
The results suggest that tyrosine phosphorylation of entity1_term is achieved by EGFR upon tryptic digestion of cells and concurrent with but independent of dissociation of entity2_term from E-cadherin.
beta-catenin
alpha-catenin
1
The results suggest that tyrosine phosphorylation of beta-catenin is achieved by EGFR upon tryptic digestion of cells and concurrent with but independent of dissociation of entity1_term from entity2_term.
alpha-catenin
E-cadherin
1
Both tyrosine phosphorylation and association of beta-catenin with EGFR were inhibited by tyrphostin, a specific inhibitor of the EGFR tyrosine kinase, whereas dissociation of entity1_term from entity2_term was not.
alpha-catenin
E-cadherin
1
Both tyrosine phosphorylation and association of beta-catenin with EGFR were inhibited by tyrphostin, a specific inhibitor of the entity1_term entity2_term, whereas dissociation of alpha-catenin from E-cadherin was not.
EGFR
tyrosine kinase
1
Both tyrosine phosphorylation and association of beta-catenin with entity1_term were inhibited by tyrphostin, a specific inhibitor of the entity2_term tyrosine kinase, whereas dissociation of alpha-catenin from E-cadherin was not.
EGFR
EGFR
0
Both tyrosine phosphorylation and association of beta-catenin with entity1_term were inhibited by tyrphostin, a specific inhibitor of the EGFR tyrosine kinase, whereas dissociation of alpha-catenin from entity2_term was not.
EGFR
E-cadherin
0
Both tyrosine phosphorylation and association of beta-catenin with entity1_term were inhibited by tyrphostin, a specific inhibitor of the EGFR entity2_term, whereas dissociation of alpha-catenin from E-cadherin was not.
EGFR
tyrosine kinase
0
Both tyrosine phosphorylation and association of beta-catenin with entity1_term were inhibited by tyrphostin, a specific inhibitor of the EGFR tyrosine kinase, whereas dissociation of entity2_term from E-cadherin was not.
EGFR
alpha-catenin
0
Both tyrosine phosphorylation and association of beta-catenin with EGFR were inhibited by tyrphostin, a specific inhibitor of the entity1_term tyrosine kinase, whereas dissociation of alpha-catenin from entity2_term was not.
EGFR
E-cadherin
0
Both tyrosine phosphorylation and association of entity1_term with EGFR were inhibited by tyrphostin, a specific inhibitor of the entity2_term tyrosine kinase, whereas dissociation of alpha-catenin from E-cadherin was not.
beta-catenin
EGFR
0
Both tyrosine phosphorylation and association of beta-catenin with EGFR were inhibited by tyrphostin, a specific inhibitor of the entity1_term tyrosine kinase, whereas dissociation of entity2_term from E-cadherin was not.
EGFR
alpha-catenin
0
Both tyrosine phosphorylation and association of entity1_term with EGFR were inhibited by tyrphostin, a specific inhibitor of the EGFR tyrosine kinase, whereas dissociation of alpha-catenin from entity2_term was not.
beta-catenin
E-cadherin
0
Both tyrosine phosphorylation and association of beta-catenin with EGFR were inhibited by tyrphostin, a specific inhibitor of the EGFR entity1_term, whereas dissociation of alpha-catenin from entity2_term was not.
tyrosine kinase
E-cadherin
0
Both tyrosine phosphorylation and association of entity1_term with EGFR were inhibited by tyrphostin, a specific inhibitor of the EGFR entity2_term, whereas dissociation of alpha-catenin from E-cadherin was not.
beta-catenin
tyrosine kinase
0
Both tyrosine phosphorylation and association of entity1_term with EGFR were inhibited by tyrphostin, a specific inhibitor of the EGFR tyrosine kinase, whereas dissociation of entity2_term from E-cadherin was not.
beta-catenin
alpha-catenin
0
The results suggest that tyrosine phosphorylation of beta-catenin is achieved by entity1_term upon tryptic digestion of cells and concurrent with but independent of dissociation of entity2_term from E-cadherin.
EGFR
alpha-catenin
0
Both tyrosine phosphorylation and association of beta-catenin with EGFR were inhibited by tyrphostin, a specific inhibitor of the EGFR entity1_term, whereas dissociation of entity2_term from E-cadherin was not.
tyrosine kinase
alpha-catenin
0
The results suggest that tyrosine phosphorylation of beta-catenin is achieved by entity1_term upon tryptic digestion of cells and concurrent with but independent of dissociation of alpha-catenin from entity2_term.
EGFR
E-cadherin
0
Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of beta-catenin with EGF receptor (entity1_term) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from entity2_term.
EGFR
E-cadherin
0
Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of entity1_term with EGF receptor (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from entity2_term.
beta-catenin
E-cadherin
0
Tyrosine phosphorylation of entity1_term was concomitantly induced with association of beta-catenin with EGF receptor (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from entity2_term.
beta-catenin
E-cadherin
0
Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of beta-catenin with entity1_term (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from entity2_term.
EGF receptor
E-cadherin
0
Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of beta-catenin with entity1_term (entity2_term) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from E-cadherin.
EGF receptor
EGFR
0
Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of beta-catenin with EGF receptor (entity1_term) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of entity2_term from E-cadherin.
EGFR
alpha-catenin
0
Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of entity1_term with EGF receptor (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of entity2_term from E-cadherin.
beta-catenin
alpha-catenin
0
Tyrosine phosphorylation of entity1_term was concomitantly induced with association of beta-catenin with EGF receptor (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of entity2_term from E-cadherin.
beta-catenin
alpha-catenin
0
Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of beta-catenin with entity1_term (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of entity2_term from E-cadherin.
EGF receptor
alpha-catenin
0
The amino acid composition of the 15-kDa protein was similar to that of mammalian entity1_term and it inhibited the salt-induced polymerization of rabbit entity2_term.
profilin
skeletal muscle actin
0
This suggests that dephosphorylation of cofilin and entity1_term/ADF by TSH could be implicated in the disruption of entity2_term-containing stress fibers and in the reorganization of microfilaments induced by this hormone.
destrin
actin
1
This suggests that dephosphorylation of entity1_term and destrin/ADF by TSH could be implicated in the disruption of entity2_term-containing stress fibers and in the reorganization of microfilaments induced by this hormone.
cofilin
actin
1
This suggests that dephosphorylation of cofilin and entity1_term/ADF by entity2_term could be implicated in the disruption of actin-containing stress fibers and in the reorganization of microfilaments induced by this hormone.
destrin
TSH
1
This suggests that dephosphorylation of entity1_term and destrin/ADF by entity2_term could be implicated in the disruption of actin-containing stress fibers and in the reorganization of microfilaments induced by this hormone.
cofilin
TSH
1
This suggests that dephosphorylation of cofilin and destrin/entity1_term by TSH could be implicated in the disruption of entity2_term-containing stress fibers and in the reorganization of microfilaments induced by this hormone.
ADF
actin
1
This suggests that dephosphorylation of cofilin and destrin/ADF by entity1_term could be implicated in the disruption of entity2_term-containing stress fibers and in the reorganization of microfilaments induced by this hormone.
TSH
actin
1
However, these rod structures were not observed in response to TSH, forskolin, or TPA, suggesting that dephosphorylation of entity1_term correlates with the reorganization of actin microfilaments but not with the nuclear transport of entity2_term.
cofilin
cofilin
1
This suggests that dephosphorylation of cofilin and destrin/entity1_term by entity2_term could be implicated in the disruption of actin-containing stress fibers and in the reorganization of microfilaments induced by this hormone.
ADF
TSH
1
However, these rod structures were not observed in response to TSH, forskolin, or TPA, suggesting that dephosphorylation of entity1_term correlates with the reorganization of entity2_term microfilaments but not with the nuclear transport of cofilin.
cofilin
actin
1
However, these rod structures were not observed in response to entity1_term, forskolin, or TPA, suggesting that dephosphorylation of entity2_term correlates with the reorganization of actin microfilaments but not with the nuclear transport of cofilin.
TSH
cofilin
0
This suggests that dephosphorylation of cofilin and entity1_term/entity2_term by TSH could be implicated in the disruption of actin-containing stress fibers and in the reorganization of microfilaments induced by this hormone.
destrin
ADF
0
This suggests that dephosphorylation of entity1_term and destrin/entity2_term by TSH could be implicated in the disruption of actin-containing stress fibers and in the reorganization of microfilaments induced by this hormone.
cofilin
ADF
0
This suggests that dephosphorylation of entity1_term and entity2_term/ADF by TSH could be implicated in the disruption of actin-containing stress fibers and in the reorganization of microfilaments induced by this hormone.
cofilin
destrin
0
However, these rod structures were not observed in response to entity1_term, forskolin, or TPA, suggesting that dephosphorylation of cofilin correlates with the reorganization of entity2_term microfilaments but not with the nuclear transport of cofilin.
TSH
actin
0
However, these rod structures were not observed in response to TSH, forskolin, or TPA, suggesting that dephosphorylation of cofilin correlates with the reorganization of entity1_term microfilaments but not with the nuclear transport of entity2_term.
actin
cofilin
0
However, these rod structures were not observed in response to entity1_term, forskolin, or TPA, suggesting that dephosphorylation of cofilin correlates with the reorganization of actin microfilaments but not with the nuclear transport of entity2_term.
TSH
cofilin
0
The herpes simplex virus type 1 entity1_term protein influences the intracellular localization of the entity2_term but not the ICP8 or POL replication proteins in virus-infected cells.
UL8
UL52
1
The herpes simplex virus type 1 entity1_term protein influences the intracellular localization of the UL52 but not the ICP8 or entity2_term replication proteins in virus-infected cells.
UL8
POL
1
The herpes simplex virus type 1 entity1_term protein influences the intracellular localization of the UL52 but not the entity2_term or POL replication proteins in virus-infected cells.
UL8
ICP8
1
The herpes simplex virus type 1 UL8 protein influences the intracellular localization of the UL52 but not the entity1_term or entity2_term replication proteins in virus-infected cells.
ICP8
POL
0
The herpes simplex virus type 1 UL8 protein influences the intracellular localization of the entity1_term but not the entity2_term or POL replication proteins in virus-infected cells.
UL52
ICP8
0
The herpes simplex virus type 1 UL8 protein influences the intracellular localization of the entity1_term but not the ICP8 or entity2_term replication proteins in virus-infected cells.
UL52
POL
0
Using these methods, we confirm previous reports that intact entity1_term induces cross-linking as well as filament shortening on entity2_term networks.
talin
actin
1
We studied the roles of entity1_term, an entity2_term-binding phosphoprotein, in superoxide production of neutrophil-like HL-60 cells triggered by opsonized zymosan (OZ).
cofilin
actin
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of oncostatin M (entity1_term) in acting synergistically with interleukin-1alpha (entity2_term) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
OSM
IL-1alpha
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of oncostatin M (entity1_term) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage entity2_term breakdown and collagenase expression, and to determine which receptors mediate these effects.
OSM
collagen
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of oncostatin M (entity1_term) in acting synergistically with entity2_term (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
OSM
interleukin-1alpha
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (entity1_term) to induce cartilage entity2_term breakdown and collagenase expression, and to determine which receptors mediate these effects.
IL-1alpha
collagen
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of entity1_term (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and entity2_term expression, and to determine which receptors mediate these effects.
oncostatin M
collagenase
1
OBJECTIVE: To determine whether other glycoprotein 130 (entity1_term) binding entity2_term can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
gp130
cytokines
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with entity1_term (IL-1alpha) to induce cartilage entity2_term breakdown and collagenase expression, and to determine which receptors mediate these effects.
interleukin-1alpha
collagen
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding entity1_term can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage entity2_term breakdown and collagenase expression, and to determine which receptors mediate these effects.
cytokines
collagen
1
OBJECTIVE: To determine whether other entity1_term (gp130) binding entity2_term can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
glycoprotein 130
cytokines
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding entity1_term can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (entity2_term) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
cytokines
IL-1alpha
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of oncostatin M (entity1_term) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and entity2_term expression, and to determine which receptors mediate these effects.
OSM
collagenase
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding entity1_term can mimic the effects of oncostatin M (OSM) in acting synergistically with entity2_term (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
cytokines
interleukin-1alpha
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with entity1_term (IL-1alpha) to induce cartilage collagen breakdown and entity2_term expression, and to determine which receptors mediate these effects.
interleukin-1alpha
collagenase
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (entity1_term) to induce cartilage collagen breakdown and entity2_term expression, and to determine which receptors mediate these effects.
IL-1alpha
collagenase
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of entity1_term (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage entity2_term breakdown and collagenase expression, and to determine which receptors mediate these effects.
oncostatin M
collagen
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding entity1_term can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and entity2_term expression, and to determine which receptors mediate these effects.
cytokines
collagenase
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of entity1_term (OSM) in acting synergistically with entity2_term (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
oncostatin M
interleukin-1alpha
1
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of entity1_term (OSM) in acting synergistically with interleukin-1alpha (entity2_term) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
oncostatin M
IL-1alpha
1
OBJECTIVE: To determine whether other entity1_term (gp130) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage entity2_term breakdown and collagenase expression, and to determine which receptors mediate these effects.
glycoprotein 130
collagen
0
OBJECTIVE: To determine whether other glycoprotein 130 (entity1_term) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage entity2_term breakdown and collagenase expression, and to determine which receptors mediate these effects.
gp130
collagen
0
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage entity1_term breakdown and entity2_term expression, and to determine which receptors mediate these effects.
collagen
collagenase
0
OBJECTIVE: To determine whether other entity1_term (gp130) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with entity2_term (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
glycoprotein 130
interleukin-1alpha
0
OBJECTIVE: To determine whether other entity1_term (gp130) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (entity2_term) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
glycoprotein 130
IL-1alpha
0
OBJECTIVE: To determine whether other entity1_term (gp130) binding cytokines can mimic the effects of oncostatin M (entity2_term) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
glycoprotein 130
OSM
0
OBJECTIVE: To determine whether other entity1_term (entity2_term) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
glycoprotein 130
gp130
0
OBJECTIVE: To determine whether other entity1_term (gp130) binding cytokines can mimic the effects of entity2_term (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
glycoprotein 130
oncostatin M
0
OBJECTIVE: To determine whether other entity1_term (gp130) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and entity2_term expression, and to determine which receptors mediate these effects.
glycoprotein 130
collagenase
0
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with entity1_term (entity2_term) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
interleukin-1alpha
IL-1alpha
0
OBJECTIVE: To determine whether other glycoprotein 130 (entity1_term) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with entity2_term (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
gp130
interleukin-1alpha
0
OBJECTIVE: To determine whether other glycoprotein 130 (entity1_term) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (entity2_term) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
gp130
IL-1alpha
0
OBJECTIVE: To determine whether other glycoprotein 130 (entity1_term) binding cytokines can mimic the effects of oncostatin M (entity2_term) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
gp130
OSM
0
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding cytokines can mimic the effects of entity1_term (entity2_term) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
oncostatin M
OSM
0
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding entity1_term can mimic the effects of oncostatin M (entity2_term) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
cytokines
OSM
0
OBJECTIVE: To determine whether other glycoprotein 130 (entity1_term) binding cytokines can mimic the effects of entity2_term (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
gp130
oncostatin M
0
OBJECTIVE: To determine whether other glycoprotein 130 (entity1_term) binding cytokines can mimic the effects of oncostatin M (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and entity2_term expression, and to determine which receptors mediate these effects.
gp130
collagenase
0
OBJECTIVE: To determine whether other glycoprotein 130 (gp130) binding entity1_term can mimic the effects of entity2_term (OSM) in acting synergistically with interleukin-1alpha (IL-1alpha) to induce cartilage collagen breakdown and collagenase expression, and to determine which receptors mediate these effects.
cytokines
oncostatin M
0
The herpes simplex virus type 1 (HSV-1) entity1_term, an essential component of the viral DNA replication machinery, is a trimeric complex of the virus-coded UL5, UL8, and entity2_term proteins.
helicase-primase
UL52
1
The herpes simplex virus type 1 (HSV-1) helicase-primase, an essential component of the viral DNA replication machinery, is a trimeric complex of the virus-coded entity1_term, entity2_term, and UL52 proteins.
UL5
UL8
1
The herpes simplex virus type 1 (HSV-1) entity1_term, an essential component of the viral DNA replication machinery, is a trimeric complex of the virus-coded entity2_term, UL8, and UL52 proteins.
helicase-primase
UL5
1
The herpes simplex virus type 1 (HSV-1) entity1_term, an essential component of the viral DNA replication machinery, is a trimeric complex of the virus-coded UL5, entity2_term, and UL52 proteins.
helicase-primase
UL8
1
Deletion mutants of the herpes simplex virus type 1 entity1_term protein: effect on DNA synthesis and ability to interact with and influence the intracellular localization of the UL5 and entity2_term proteins.
UL8
UL52
1
Deletion mutants of the herpes simplex virus type 1 entity1_term protein: effect on DNA synthesis and ability to interact with and influence the intracellular localization of the entity2_term and UL52 proteins.
UL8
UL5
1
An assembly of the UL5 and entity1_term subunits retains both enzymic activities, and the entity2_term protein has been implicated in modulating these functions, facilitating efficient nuclear uptake of the complex and interacting with other viral DNA replication proteins.
UL52
UL8
1
An assembly of the entity1_term and UL52 subunits retains both enzymic activities, and the entity2_term protein has been implicated in modulating these functions, facilitating efficient nuclear uptake of the complex and interacting with other viral DNA replication proteins.
UL5
UL8
1
An assembly of the entity1_term and entity2_term subunits retains both enzymic activities, and the UL8 protein has been implicated in modulating these functions, facilitating efficient nuclear uptake of the complex and interacting with other viral DNA replication proteins.
UL5
UL52
1
The herpes simplex virus type 1 (HSV-1) helicase-primase, an essential component of the viral DNA replication machinery, is a trimeric complex of the virus-coded UL5, entity1_term, and entity2_term proteins.
UL8
UL52
1
The herpes simplex virus type 1 (HSV-1) helicase-primase, an essential component of the viral DNA replication machinery, is a trimeric complex of the virus-coded entity1_term, UL8, and entity2_term proteins.
UL5
UL52
1
Deletion mutants of the herpes simplex virus type 1 UL8 protein: effect on DNA synthesis and ability to interact with and influence the intracellular localization of the entity1_term and entity2_term proteins.
UL5
UL52
0
Phosphorylation of the headpiece domain could regulate the actin binding and bundling properties of entity1_term, or it could regulate the interaction of entity2_term with other proteins.
fimbrin
fimbrin
1
Phosphorylation of the headpiece domain could regulate the entity1_term binding and bundling properties of entity2_term, or it could regulate the interaction of fimbrin with other proteins.
actin
fimbrin
1
Phosphorylation of the headpiece domain could regulate the entity1_term binding and bundling properties of fimbrin, or it could regulate the interaction of entity2_term with other proteins.
actin
fimbrin
0
In the present study we show that brush cells can be identified in tissue sections even at the light microscopic level by immunostaining with antibodies against villin and entity1_term, two proteins that crosslink entity2_term filaments to form bundles.
fimbrin
actin
1
In brush cells, entity1_term and fimbrin are not only present in the entity2_term filament core bundles of apical microvilli and their long rootlets but, in addition, both proteins are also associated with microvilli extending from the basolateral cell surface of the brush cells.
villin
actin
1
In the present study we show that brush cells can be identified in tissue sections even at the light microscopic level by immunostaining with antibodies against entity1_term and fimbrin, two proteins that crosslink entity2_term filaments to form bundles.
villin
actin
1
In brush cells, villin and entity1_term are not only present in the entity2_term filament core bundles of apical microvilli and their long rootlets but, in addition, both proteins are also associated with microvilli extending from the basolateral cell surface of the brush cells.
fimbrin
actin
1
In the present study we show that brush cells can be identified in tissue sections even at the light microscopic level by immunostaining with antibodies against entity1_term and entity2_term, two proteins that crosslink actin filaments to form bundles.
villin
fimbrin
0
In brush cells, entity1_term and entity2_term are not only present in the actin filament core bundles of apical microvilli and their long rootlets but, in addition, both proteins are also associated with microvilli extending from the basolateral cell surface of the brush cells.
villin
fimbrin
0
This is the first report describing the coexistence of entity1_term with entity2_term filaments in the division furrow, implying the possible involvement of profilin in assembly and disassembly of contractile ring microfilaments in the process of cytokinesis.
profilin
actin
1
This is the first report describing the coexistence of profilin with entity1_term filaments in the division furrow, implying the possible involvement of entity2_term in assembly and disassembly of contractile ring microfilaments in the process of cytokinesis.
actin
profilin
0
This is the first report describing the coexistence of entity1_term with actin filaments in the division furrow, implying the possible involvement of entity2_term in assembly and disassembly of contractile ring microfilaments in the process of cytokinesis.
profilin
profilin
0
Demembranated stereociliary cores consisted primarily of protein bands corresponding to entity1_term and entity2_term and several proteins ranging from 43 to 63 kDa.
actin
fimbrin
1
Recombinant human beta-catenin can simultaneously bind to the entity1_term/entity2_term complex but does not bind actin directly.
alpha-catenin
actin
1
Recombinant human entity1_term can simultaneously bind to the alpha-catenin/entity2_term complex but does not bind actin directly.
beta-catenin
actin
1
Recombinant human entity1_term can simultaneously bind to the entity2_term/actin complex but does not bind actin directly.
beta-catenin
alpha-catenin
1
Recombinant human entity1_term can simultaneously bind to the alpha-catenin/actin complex but does not bind entity2_term directly.
beta-catenin
actin
1
Recombinant human beta-catenin can simultaneously bind to the entity1_term/actin complex but does not bind entity2_term directly.
alpha-catenin
actin
0
Recombinant human beta-catenin can simultaneously bind to the alpha-catenin/entity1_term complex but does not bind entity2_term directly.
actin
actin
0
We believe that this complex may mediate the cortical functions of entity1_term at entity2_term patches in S. pombe.
profilin
actin
1
Newly disclosed interactions between gephyrin, exchange factors for G proteins of the Rho and Rac families, the translational regulator RAFT1, and entity1_term like entity2_term might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
actin-binding proteins
profilin
1
Newly disclosed interactions between entity1_term, exchange factors for G proteins of the Rho and Rac families, the translational regulator RAFT1, and entity2_term like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
gephyrin
actin-binding proteins
1
Newly disclosed interactions between gephyrin, exchange factors for G proteins of the Rho and Rac families, the translational regulator entity1_term, and entity2_term like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
RAFT1
actin-binding proteins
1
Newly disclosed interactions between entity1_term, exchange factors for G proteins of the Rho and Rac families, the translational regulator entity2_term, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
gephyrin
RAFT1
1
Newly disclosed interactions between entity1_term, exchange factors for entity2_term of the Rho and Rac families, the translational regulator RAFT1, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
gephyrin
G proteins
1
Newly disclosed interactions between gephyrin, exchange factors for entity1_term of the Rho and entity2_term families, the translational regulator RAFT1, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
G proteins
Rac
1
Newly disclosed interactions between gephyrin, exchange factors for entity1_term of the Rho and Rac families, the translational regulator entity2_term, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
G proteins
RAFT1
1
Newly disclosed interactions between gephyrin, exchange factors for entity1_term of the Rho and Rac families, the translational regulator RAFT1, and entity2_term like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
G proteins
actin-binding proteins
1
Newly disclosed interactions between gephyrin, exchange factors for entity1_term of the entity2_term and Rac families, the translational regulator RAFT1, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
G proteins
Rho
1
Newly disclosed interactions between gephyrin, exchange factors for G proteins of the Rho and entity1_term families, the translational regulator RAFT1, and entity2_term like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
Rac
actin-binding proteins
0
Newly disclosed interactions between gephyrin, exchange factors for G proteins of the entity1_term and Rac families, the translational regulator RAFT1, and entity2_term like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
Rho
actin-binding proteins
0
Newly disclosed interactions between gephyrin, exchange factors for entity1_term of the Rho and Rac families, the translational regulator RAFT1, and entity2_term like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
G proteins
actin-binding proteins
0
Newly disclosed interactions between entity1_term, exchange factors for G proteins of the Rho and Rac families, the translational regulator RAFT1, and actin-binding proteins like entity2_term might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
gephyrin
profilin
0
Newly disclosed interactions between entity1_term, exchange factors for G proteins of the Rho and entity2_term families, the translational regulator RAFT1, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
gephyrin
Rac
0
Newly disclosed interactions between entity1_term, exchange factors for G proteins of the entity2_term and Rac families, the translational regulator RAFT1, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
gephyrin
Rho
0
Newly disclosed interactions between entity1_term, exchange factors for entity2_term of the Rho and Rac families, the translational regulator RAFT1, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
gephyrin
G proteins
0
Newly disclosed interactions between gephyrin, exchange factors for G proteins of the Rho and Rac families, the translational regulator entity1_term, and actin-binding proteins like entity2_term might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
RAFT1
profilin
0
Newly disclosed interactions between gephyrin, exchange factors for G proteins of the Rho and entity1_term families, the translational regulator entity2_term, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
Rac
RAFT1
0
Newly disclosed interactions between gephyrin, exchange factors for G proteins of the entity1_term and Rac families, the translational regulator entity2_term, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
Rho
RAFT1
0
Newly disclosed interactions between gephyrin, exchange factors for entity1_term of the Rho and Rac families, the translational regulator entity2_term, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
G proteins
RAFT1
0
Newly disclosed interactions between gephyrin, exchange factors for G proteins of the Rho and entity1_term families, the translational regulator RAFT1, and actin-binding proteins like entity2_term might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
Rac
profilin
0
Newly disclosed interactions between gephyrin, exchange factors for G proteins of the entity1_term and Rac families, the translational regulator RAFT1, and actin-binding proteins like entity2_term might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
Rho
profilin
0
Newly disclosed interactions between gephyrin, exchange factors for entity1_term of the Rho and Rac families, the translational regulator RAFT1, and actin-binding proteins like entity2_term might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
G proteins
profilin
0
Newly disclosed interactions between gephyrin, exchange factors for entity1_term of the Rho and Rac families, the translational regulator RAFT1, and actin-binding proteins like entity2_term might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
G proteins
profilin
0
Newly disclosed interactions between gephyrin, exchange factors for G proteins of the entity1_term and entity2_term families, the translational regulator RAFT1, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
Rho
Rac
0
Newly disclosed interactions between gephyrin, exchange factors for entity1_term of the Rho and entity2_term families, the translational regulator RAFT1, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
G proteins
Rac
0
Newly disclosed interactions between gephyrin, exchange factors for entity1_term of the entity2_term and Rac families, the translational regulator RAFT1, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
G proteins
Rho
0
Newly disclosed interactions between gephyrin, exchange factors for entity1_termentity2_term of the Rho and Rac families, the translational regulator RAFT1, and actin-binding proteins like profilin might integrate activity-dependent and trophic-factor-mediated signals at developing postsynaptic sites.
G proteins
G proteins
0
Western analysis of gel-purified USF-nucleosome and entity1_term-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone entity2_term relative to acetylated histone H3.
GAL4
H4
1
Western analysis of gel-purified USF-nucleosome and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated entity1_term entity2_term relative to acetylated histone H3.
histone
H4
1
Western analysis of gel-purified entity1_term-nucleosome and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone entity2_term relative to acetylated histone H3.
USF
H4
1
Western analysis of gel-purified USF-nucleosome and GAL4-AH-entity1_term complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone entity2_term.
nucleosome
H3
1
Western analysis of gel-purified USF-nucleosome and entity1_term-entity2_term-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone H3.
GAL4
AH
1
Western analysis of gel-purified USF-nucleosome and GAL4-entity1_term-nucleosome complexes demonstrated the predominant presence of acetylated histone entity2_term relative to acetylated histone H3.
AH
H4
1
Western analysis of gel-purified entity1_term-entity2_term and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone H3.
USF
nucleosome
1
Western analysis of gel-purified USF-entity1_term and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone entity2_term relative to acetylated histone H3.
nucleosome
H4
1
Western analysis of gel-purified USF-nucleosome and GAL4-AH-entity1_term complexes demonstrated the predominant presence of acetylated histone entity2_term relative to acetylated histone H3.
nucleosome
H4
1
Western analysis of gel-purified USF-nucleosome and GAL4-entity1_term-entity2_term complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone H3.
AH
nucleosome
1
Western analysis of gel-purified USF-nucleosome and entity1_term-AH-entity2_term complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone H3.
GAL4
nucleosome
1
Western analysis of gel-purified USF-nucleosome and entity1_term-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone entity2_term.
GAL4
H3
1
Western analysis of gel-purified USF-nucleosome and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone entity1_term relative to acetylated histone entity2_term.
H4
H3
1
Western analysis of gel-purified USF-nucleosome and GAL4-entity1_term-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone entity2_term.
AH
H3
1
Western analysis of gel-purified entity1_term-nucleosome and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone entity2_term.
USF
H3
1
Western analysis of gel-purified USF-nucleosome and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated entity1_term entity2_term.
histone
H3
1
Western analysis of gel-purified USF-entity1_term and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone entity2_term.
nucleosome
H3
1
Western analysis of gel-purified entity1_term-nucleosome and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated entity2_term H4 relative to acetylated histone H3.
USF
histone
0
Western analysis of gel-purified USF-entity1_term and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated entity2_term H4 relative to acetylated histone H3.
nucleosome
histone
0
Western analysis of gel-purified USF-nucleosome and GAL4-entity1_term-nucleosome complexes demonstrated the predominant presence of acetylated entity2_term H4 relative to acetylated histone H3.
AH
histone
0
Western analysis of gel-purified USF-nucleosome and entity1_term-AH-nucleosome complexes demonstrated the predominant presence of acetylated entity2_term H4 relative to acetylated histone H3.
GAL4
histone
0
Western analysis of gel-purified USF-nucleosome and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated entity1_term H4 relative to acetylated histone entity2_term.
histone
H3
0
Western analysis of gel-purified USF-nucleosome and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated entity1_term H4 relative to acetylated entity2_term H3.
histone
histone
0
Western analysis of gel-purified USF-nucleosome and GAL4-AH-entity1_term complexes demonstrated the predominant presence of acetylated entity2_term H4 relative to acetylated histone H3.
nucleosome
histone
0
Western analysis of gel-purified entity1_term-nucleosome and GAL4-entity2_term-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone H3.
USF
AH
0
Western analysis of gel-purified entity1_term-nucleosome and entity2_term-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone H3.
USF
GAL4
0
Western analysis of gel-purified entity1_term-nucleosome and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated entity2_term H3.
USF
histone
0
Western analysis of gel-purified entity1_term-nucleosome and GAL4-AH-entity2_term complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone H3.
USF
nucleosome
0
Western analysis of gel-purified USF-entity1_term and GAL4-entity2_term-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone H3.
nucleosome
AH
0
Western analysis of gel-purified USF-entity1_term and entity2_term-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone H3.
nucleosome
GAL4
0
Western analysis of gel-purified USF-entity1_term and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated entity2_term H3.
nucleosome
histone
0
Western analysis of gel-purified USF-entity1_term and GAL4-AH-entity2_term complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated histone H3.
nucleosome
nucleosome
0
Western analysis of gel-purified USF-nucleosome and GAL4-entity1_term-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated entity2_term H3.
AH
histone
0
Western analysis of gel-purified USF-nucleosome and entity1_term-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated entity2_term H3.
GAL4
histone
0
Western analysis of gel-purified USF-nucleosome and GAL4-AH-nucleosome complexes demonstrated the predominant presence of acetylated histone entity1_term relative to acetylated entity2_term H3.
H4
histone
0
Western analysis of gel-purified USF-nucleosome and GAL4-AH-entity1_term complexes demonstrated the predominant presence of acetylated histone H4 relative to acetylated entity2_term H3.
nucleosome
histone
0
In contrast, the entity1_term and entity2_term genes are essential for homothallic mating-type switching.
RAD51
RAD52
0
Panels of six to 31 MAbs against the haemagglutinin (H), entity1_term (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, entity2_term and P proteins of CDV were employed.
fusion
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (entity1_term), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, entity2_term and P proteins of CDV were employed.
F
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), entity1_term (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, entity2_term and P proteins of CDV were employed.
nucleocapsid protein
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the entity1_term, F, entity2_term and P proteins of CDV were employed.
H
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and entity1_term (M) proteins of MV and the H, F, entity2_term and P proteins of CDV were employed.
matrix
NP
0
Panels of six to 31 MAbs against the entity1_term (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, entity2_term and P proteins of CDV were employed.
haemagglutinin
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, entity1_term, entity2_term and P proteins of CDV were employed.
F
NP
0
Panels of six to 31 MAbs against the haemagglutinin (entity1_term), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, entity2_term and P proteins of CDV were employed.
H
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (entity1_term) and matrix (M) proteins of MV and the H, F, entity2_term and P proteins of CDV were employed.
P
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, entity1_term and entity2_term of CDV were employed.
NP
P proteins
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (entity1_term), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, entity2_term and P proteins of CDV were employed.
NP
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (entity1_term) proteins of MV and the H, F, entity2_term and P proteins of CDV were employed.
M
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), entity1_term (P) and matrix (M) proteins of MV and the H, F, entity2_term and P proteins of CDV were employed.
phosphoprotein
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), entity1_term (entity2_term), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
fusion
F
0
Panels of six to 31 MAbs against the haemagglutinin (H), entity1_term (F), entity2_term (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
fusion
nucleocapsid protein
0
Panels of six to 31 MAbs against the haemagglutinin (H), entity1_term (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the entity2_term, F, NP and P proteins of CDV were employed.
fusion
H
0
Panels of six to 31 MAbs against the haemagglutinin (H), entity1_term (F), nucleocapsid protein (NP), phosphoprotein (P) and entity2_term (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
fusion
matrix
0
Panels of six to 31 MAbs against the entity1_term (H), entity2_term (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
haemagglutinin
fusion
0
Panels of six to 31 MAbs against the haemagglutinin (H), entity1_term (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, entity2_term, NP and P proteins of CDV were employed.
fusion
F
0
Panels of six to 31 MAbs against the haemagglutinin (entity1_term), entity2_term (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
H
fusion
0
Panels of six to 31 MAbs against the haemagglutinin (H), entity1_term (F), nucleocapsid protein (NP), phosphoprotein (entity2_term) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
fusion
P
0
Panels of six to 31 MAbs against the haemagglutinin (H), entity1_term (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and entity2_term of CDV were employed.
fusion
P proteins
0
Panels of six to 31 MAbs against the haemagglutinin (H), entity1_term (F), nucleocapsid protein (entity2_term), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
fusion
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), entity1_term (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (entity2_term) proteins of MV and the H, F, NP and P proteins of CDV were employed.
fusion
M
0
Panels of six to 31 MAbs against the haemagglutinin (H), entity1_term (F), nucleocapsid protein (NP), entity2_term (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
fusion
phosphoprotein
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (entity1_term), entity2_term (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
F
nucleocapsid protein
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (entity1_term), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the entity2_term, F, NP and P proteins of CDV were employed.
F
H
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (entity1_term), nucleocapsid protein (NP), phosphoprotein (P) and entity2_term (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
F
matrix
0
Panels of six to 31 MAbs against the entity1_term (H), fusion (entity2_term), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
haemagglutinin
F
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (entity1_term), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, entity2_term, NP and P proteins of CDV were employed.
F
F
0
Panels of six to 31 MAbs against the haemagglutinin (entity1_term), fusion (entity2_term), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
H
F
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (entity1_term), nucleocapsid protein (NP), phosphoprotein (entity2_term) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
F
P
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (entity1_term), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and entity2_term of CDV were employed.
F
P proteins
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (entity1_term), nucleocapsid protein (entity2_term), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
F
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (entity1_term), nucleocapsid protein (NP), phosphoprotein (P) and matrix (entity2_term) proteins of MV and the H, F, NP and P proteins of CDV were employed.
F
M
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (entity1_term), nucleocapsid protein (NP), entity2_term (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
F
phosphoprotein
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), entity1_term (NP), phosphoprotein (P) and matrix (M) proteins of MV and the entity2_term, F, NP and P proteins of CDV were employed.
nucleocapsid protein
H
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), entity1_term (NP), phosphoprotein (P) and entity2_term (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
nucleocapsid protein
matrix
0
Panels of six to 31 MAbs against the entity1_term (H), fusion (F), entity2_term (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
haemagglutinin
nucleocapsid protein
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), entity1_term (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, entity2_term, NP and P proteins of CDV were employed.
nucleocapsid protein
F
0
Panels of six to 31 MAbs against the haemagglutinin (entity1_term), fusion (F), entity2_term (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
H
nucleocapsid protein
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), entity1_term (NP), phosphoprotein (entity2_term) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
nucleocapsid protein
P
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), entity1_term (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and entity2_term of CDV were employed.
nucleocapsid protein
P proteins
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), entity1_term (entity2_term), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
nucleocapsid protein
NP
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), entity1_term (NP), phosphoprotein (P) and matrix (entity2_term) proteins of MV and the H, F, NP and P proteins of CDV were employed.
nucleocapsid protein
M
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), entity1_term (NP), entity2_term (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
nucleocapsid protein
phosphoprotein
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and entity1_term (M) proteins of MV and the entity2_term, F, NP and P proteins of CDV were employed.
matrix
H
0
Panels of six to 31 MAbs against the entity1_term (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the entity2_term, F, NP and P proteins of CDV were employed.
haemagglutinin
H
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the entity1_term, entity2_term, NP and P proteins of CDV were employed.
H
F
0
Panels of six to 31 MAbs against the haemagglutinin (entity1_term), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the entity2_term, F, NP and P proteins of CDV were employed.
H
H
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (entity1_term) and matrix (M) proteins of MV and the entity2_term, F, NP and P proteins of CDV were employed.
P
H
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the entity1_term, F, NP and entity2_term of CDV were employed.
H
P proteins
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (entity1_term), phosphoprotein (P) and matrix (M) proteins of MV and the entity2_term, F, NP and P proteins of CDV were employed.
NP
H
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (entity1_term) proteins of MV and the entity2_term, F, NP and P proteins of CDV were employed.
M
H
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), entity1_term (P) and matrix (M) proteins of MV and the entity2_term, F, NP and P proteins of CDV were employed.
phosphoprotein
H
0
Panels of six to 31 MAbs against the entity1_term (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and entity2_term (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
haemagglutinin
matrix
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and entity1_term (M) proteins of MV and the H, entity2_term, NP and P proteins of CDV were employed.
matrix
F
0
Panels of six to 31 MAbs against the haemagglutinin (entity1_term), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and entity2_term (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
H
matrix
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (entity1_term) and entity2_term (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
P
matrix
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and entity1_term (M) proteins of MV and the H, F, NP and entity2_term of CDV were employed.
matrix
P proteins
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (entity1_term), phosphoprotein (P) and entity2_term (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
NP
matrix
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and entity1_term (entity2_term) proteins of MV and the H, F, NP and P proteins of CDV were employed.
matrix
M
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), entity1_term (P) and entity2_term (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
phosphoprotein
matrix
0
Panels of six to 31 MAbs against the entity1_term (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, entity2_term, NP and P proteins of CDV were employed.
haemagglutinin
F
0
Panels of six to 31 MAbs against the entity1_term (entity2_term), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
haemagglutinin
H
0
Panels of six to 31 MAbs against the entity1_term (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (entity2_term) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
haemagglutinin
P
0
Panels of six to 31 MAbs against the entity1_term (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and entity2_term of CDV were employed.
haemagglutinin
P proteins
0
Panels of six to 31 MAbs against the entity1_term (H), fusion (F), nucleocapsid protein (entity2_term), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
haemagglutinin
NP
0
Panels of six to 31 MAbs against the entity1_term (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (entity2_term) proteins of MV and the H, F, NP and P proteins of CDV were employed.
haemagglutinin
M
0
Panels of six to 31 MAbs against the entity1_term (H), fusion (F), nucleocapsid protein (NP), entity2_term (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
haemagglutinin
phosphoprotein
0
Panels of six to 31 MAbs against the haemagglutinin (entity1_term), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, entity2_term, NP and P proteins of CDV were employed.
H
F
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (entity1_term) and matrix (M) proteins of MV and the H, entity2_term, NP and P proteins of CDV were employed.
P
F
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, entity1_term, NP and entity2_term of CDV were employed.
F
P proteins
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (entity1_term), phosphoprotein (P) and matrix (M) proteins of MV and the H, entity2_term, NP and P proteins of CDV were employed.
NP
F
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (entity1_term) proteins of MV and the H, entity2_term, NP and P proteins of CDV were employed.
M
F
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), entity1_term (P) and matrix (M) proteins of MV and the H, entity2_term, NP and P proteins of CDV were employed.
phosphoprotein
F
0
Panels of six to 31 MAbs against the haemagglutinin (entity1_term), fusion (F), nucleocapsid protein (NP), phosphoprotein (entity2_term) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
H
P
0
Panels of six to 31 MAbs against the haemagglutinin (entity1_term), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and entity2_term of CDV were employed.
H
P proteins
0
Panels of six to 31 MAbs against the haemagglutinin (entity1_term), fusion (F), nucleocapsid protein (entity2_term), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
H
NP
0
Panels of six to 31 MAbs against the haemagglutinin (entity1_term), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (entity2_term) proteins of MV and the H, F, NP and P proteins of CDV were employed.
H
M
0
Panels of six to 31 MAbs against the haemagglutinin (entity1_term), fusion (F), nucleocapsid protein (NP), entity2_term (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
H
phosphoprotein
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (entity1_term) and matrix (M) proteins of MV and the H, F, NP and entity2_term of CDV were employed.
P
P proteins
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (entity1_term), phosphoprotein (entity2_term) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
NP
P
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (entity1_term) and matrix (entity2_term) proteins of MV and the H, F, NP and P proteins of CDV were employed.
P
M
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), entity1_term (entity2_term) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
phosphoprotein
P
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (entity1_term), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and entity2_term of CDV were employed.
NP
P proteins
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (entity1_term) proteins of MV and the H, F, NP and entity2_term of CDV were employed.
M
P proteins
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), entity1_term (P) and matrix (M) proteins of MV and the H, F, NP and entity2_term of CDV were employed.
phosphoprotein
P proteins
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (entity1_term), phosphoprotein (P) and matrix (entity2_term) proteins of MV and the H, F, NP and P proteins of CDV were employed.
NP
M
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (entity1_term), entity2_term (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.
NP
phosphoprotein
0
Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), entity1_term (P) and matrix (entity2_term) proteins of MV and the H, F, NP and P proteins of CDV were employed.
phosphoprotein
M
0
The cellular tumor antigen entity1_term is bound to the simian virus 40 (SV40) entity2_term in SV40-infected and -transformed cells.
p53
large T-antigen
1
An oligomeric form of simian virus 40 entity1_term is immunologically related to the cellular tumor antigen entity2_term.
large T-antigen
p53
1
This shows that structural changes in the poly(L-proline)-binding region of entity1_term can affect the distantly located entity2_term-binding site.
profilin
actin
1
A chimera consisting of the entity1_term-binding region of entity2_term linked to the amino terminus of alpha-catenin 57-264 behaves as a monomer in solution, as expected, since beta-catenin binding disrupts the alpha-catenin dimer.
alpha-catenin
beta-catenin
1
A chimera consisting of the alpha-catenin-binding region of beta-catenin linked to the amino terminus of alpha-catenin 57-264 behaves as a monomer in solution, as expected, since entity1_term binding disrupts the entity2_term dimer.
beta-catenin
alpha-catenin
1
A chimera consisting of the alpha-catenin-binding region of entity1_term linked to the amino terminus of entity2_term behaves as a monomer in solution, as expected, since beta-catenin binding disrupts the alpha-catenin dimer.
beta-catenin
alpha-catenin 57-264
1
A chimera consisting of the entity1_term-binding region of beta-catenin linked to the amino terminus of alpha-catenin 57-264 behaves as a monomer in solution, as expected, since beta-catenin binding disrupts the entity2_term dimer.
alpha-catenin
alpha-catenin
0
A chimera consisting of the alpha-catenin-binding region of entity1_term linked to the amino terminus of alpha-catenin 57-264 behaves as a monomer in solution, as expected, since beta-catenin binding disrupts the entity2_term dimer.
beta-catenin
alpha-catenin
0
A chimera consisting of the alpha-catenin-binding region of beta-catenin linked to the amino terminus of entity1_term behaves as a monomer in solution, as expected, since beta-catenin binding disrupts the entity2_term dimer.
alpha-catenin 57-264
alpha-catenin
0
A chimera consisting of the entity1_term-binding region of beta-catenin linked to the amino terminus of entity2_term behaves as a monomer in solution, as expected, since beta-catenin binding disrupts the alpha-catenin dimer.
alpha-catenin
alpha-catenin 57-264
0
A chimera consisting of the entity1_term-binding region of beta-catenin linked to the amino terminus of alpha-catenin 57-264 behaves as a monomer in solution, as expected, since entity2_term binding disrupts the alpha-catenin dimer.
alpha-catenin
beta-catenin
0
A chimera consisting of the alpha-catenin-binding region of entity1_term linked to the amino terminus of alpha-catenin 57-264 behaves as a monomer in solution, as expected, since entity2_term binding disrupts the alpha-catenin dimer.
beta-catenin
beta-catenin
0
A chimera consisting of the alpha-catenin-binding region of beta-catenin linked to the amino terminus of entity1_term behaves as a monomer in solution, as expected, since entity2_term binding disrupts the alpha-catenin dimer.
alpha-catenin 57-264
beta-catenin
0
In invasive ductal carcinomas, alpha-catenin was reduced more frequently in diffuse than in solid type tumours, whereas the level of expression of entity1_term and entity2_term was unchanged between them.
beta-catenin
E-CD
0
In invasive ductal carcinomas, entity1_term was reduced more frequently in diffuse than in solid type tumours, whereas the level of expression of beta-catenin and entity2_term was unchanged between them.
alpha-catenin
E-CD
0
In invasive ductal carcinomas, entity1_term was reduced more frequently in diffuse than in solid type tumours, whereas the level of expression of entity2_term and E-CD was unchanged between them.
alpha-catenin
beta-catenin
0
Expression of beta-catenin was investigated in normal breast tissue and 66 breast carcinomas in conjunction with expression of entity1_term (E-CD) and entity2_term.
epithelial cadherin
alpha-catenin
0
Expression of beta-catenin was investigated in normal breast tissue and 66 breast carcinomas in conjunction with expression of entity1_term (entity2_term) and alpha-catenin.
epithelial cadherin
E-CD
0
Expression of entity1_term was investigated in normal breast tissue and 66 breast carcinomas in conjunction with expression of entity2_term (E-CD) and alpha-catenin.
beta-catenin
epithelial cadherin
0
Expression of beta-catenin was investigated in normal breast tissue and 66 breast carcinomas in conjunction with expression of epithelial cadherin (entity1_term) and entity2_term.
E-CD
alpha-catenin
0
Expression of entity1_term was investigated in normal breast tissue and 66 breast carcinomas in conjunction with expression of epithelial cadherin (E-CD) and entity2_term.
beta-catenin
alpha-catenin
0
Expression of entity1_term was investigated in normal breast tissue and 66 breast carcinomas in conjunction with expression of epithelial cadherin (entity2_term) and alpha-catenin.
beta-catenin
E-CD
0
The posttranslational metabolism of entity1_term (MHC) and entity2_term was regulated in parallel with the total contractile protein pool.
myosin heavy chain
actin
0
The posttranslational metabolism of entity1_term (entity2_term) and actin was regulated in parallel with the total contractile protein pool.
myosin heavy chain
MHC
0
The posttranslational metabolism of myosin heavy chain (entity1_term) and entity2_term was regulated in parallel with the total contractile protein pool.
MHC
actin
0
entity1_term or entity2_term recombination-deficient yeast strains stabilize otherwise unstable YACs containing ribosomal DNA or the human color vision locus (Kohno et al., 1994).
RAD52
RAD51
0
Thus, APC forms distinct heteromeric complexes containing combinations of entity1_term, beta-catenin, and entity2_term which are independent from the cadherin-catenin complexes.
alpha-catenin
plakoglobin
1
Thus, entity1_term forms distinct heteromeric complexes containing combinations of alpha-catenin, entity2_term, and plakoglobin which are independent from the cadherin-catenin complexes.
APC
beta-catenin
1
Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, entity1_term, and plakoglobin which are independent from the cadherin-entity2_term complexes.
beta-catenin
catenin
1
Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, entity1_term, and entity2_term which are independent from the cadherin-catenin complexes.
beta-catenin
plakoglobin
1
Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, entity1_term, and plakoglobin which are independent from the entity2_term-catenin complexes.
beta-catenin
cadherin
1
The APC protein and E-cadherin form similar but independent complexes with entity1_term, entity2_term, and plakoglobin.
alpha-catenin
beta-catenin
1
Thus, APC forms distinct heteromeric complexes containing combinations of entity1_term, entity2_term, and plakoglobin which are independent from the cadherin-catenin complexes.
alpha-catenin
beta-catenin
1
The APC protein and E-cadherin form similar but independent complexes with entity1_term, beta-catenin, and entity2_term.
alpha-catenin
plakoglobin
1
The APC protein and E-cadherin form similar but independent complexes with alpha-catenin, entity1_term, and entity2_term.
beta-catenin
plakoglobin
1
The entity1_term protein and E-cadherin form similar but independent complexes with alpha-catenin, entity2_term, and plakoglobin.
APC
beta-catenin
1
Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the entity1_term-entity2_term complexes.
cadherin
catenin
1
The entity1_term protein and E-cadherin form similar but independent complexes with alpha-catenin, beta-catenin, and entity2_term.
APC
plakoglobin
1
Thus, entity1_term forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the entity2_term-catenin complexes.
APC
cadherin
1
The entity1_term protein and E-cadherin form similar but independent complexes with entity2_term, beta-catenin, and plakoglobin.
APC
alpha-catenin
1
The APC protein and entity1_term form similar but independent complexes with entity2_term, beta-catenin, and plakoglobin.
E-cadherin
alpha-catenin
1
Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and entity1_term which are independent from the cadherin-entity2_term complexes.
plakoglobin
catenin
1
The APC protein and entity1_term form similar but independent complexes with alpha-catenin, entity2_term, and plakoglobin.
E-cadherin
beta-catenin
1
Thus, entity1_term forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and entity2_term which are independent from the cadherin-catenin complexes.
APC
plakoglobin
1
The entity1_term protein and entity2_term form similar but independent complexes with alpha-catenin, beta-catenin, and plakoglobin.
APC
E-cadherin
1
Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and entity1_term which are independent from the entity2_term-catenin complexes.
plakoglobin
cadherin
1
The APC protein and entity1_term form similar but independent complexes with alpha-catenin, beta-catenin, and entity2_term.
E-cadherin
plakoglobin
1
Thus, APC forms distinct heteromeric complexes containing combinations of entity1_term, beta-catenin, and plakoglobin which are independent from the cadherin-entity2_term complexes.
alpha-catenin
catenin
1
The APC binding site on beta-catenin may be discontinuous since neither the carboxyl- nor amino-terminal halves of entity1_term will independently associate with APC, although the amino-terminal half independently binds entity2_term.
beta-catenin
alpha-catenin
1
Thus, entity1_term forms distinct heteromeric complexes containing combinations of entity2_term, beta-catenin, and plakoglobin which are independent from the cadherin-catenin complexes.
APC
alpha-catenin
1
The APC binding site on beta-catenin may be discontinuous since neither the carboxyl- nor amino-terminal halves of entity1_term will independently associate with entity2_term, although the amino-terminal half independently binds alpha-catenin.
beta-catenin
APC
1
Thus, APC forms distinct heteromeric complexes containing combinations of entity1_term, beta-catenin, and plakoglobin which are independent from the entity2_term-catenin complexes.
alpha-catenin
cadherin
1
Thus, entity1_term forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the cadherin-entity2_term complexes.
APC
catenin
1
The entity1_term binding site on entity2_term may be discontinuous since neither the carboxyl- nor amino-terminal halves of beta-catenin will independently associate with APC, although the amino-terminal half independently binds alpha-catenin.
APC
beta-catenin
1
The entity1_term binding site on beta-catenin may be discontinuous since neither the carboxyl- nor amino-terminal halves of beta-catenin will independently associate with entity2_term, although the amino-terminal half independently binds alpha-catenin.
APC
APC
0
The entity1_term binding site on beta-catenin may be discontinuous since neither the carboxyl- nor amino-terminal halves of beta-catenin will independently associate with APC, although the amino-terminal half independently binds entity2_term.
APC
alpha-catenin
0
The entity1_term binding site on beta-catenin may be discontinuous since neither the carboxyl- nor amino-terminal halves of entity2_term will independently associate with APC, although the amino-terminal half independently binds alpha-catenin.
APC
beta-catenin
0
The APC binding site on beta-catenin may be discontinuous since neither the carboxyl- nor amino-terminal halves of beta-catenin will independently associate with entity1_term, although the amino-terminal half independently binds entity2_term.
APC
alpha-catenin
0
The APC binding site on entity1_term may be discontinuous since neither the carboxyl- nor amino-terminal halves of beta-catenin will independently associate with entity2_term, although the amino-terminal half independently binds alpha-catenin.
beta-catenin
APC
0
The APC binding site on entity1_term may be discontinuous since neither the carboxyl- nor amino-terminal halves of beta-catenin will independently associate with APC, although the amino-terminal half independently binds entity2_term.
beta-catenin
alpha-catenin
0
The APC binding site on entity1_term may be discontinuous since neither the carboxyl- nor amino-terminal halves of entity2_term will independently associate with APC, although the amino-terminal half independently binds alpha-catenin.
beta-catenin
beta-catenin
0
[Activation induces dephosphorylation of entity1_term (an entity2_term/PIP2-binding protein) and its translocation to plasma membranes in leukocytes].
cofilin
actin
1
